
























A thesis submitted for the degree of Doctor of Philosophy  
University of Otago 

































































General practice has been traditionally considered a low-risk healthcare setting, however 
high patient volumes and high prescribing rates elevate the risk of harm. Māori and Pasifika 
patients are at greater risk of healthcare harm. The extent of medication- related harm, and 
harm by ethnicity, is unknown in New Zealand general practice. 
Determining the nature and extent of these harms is a first step to addressing these 
problems. Strategies to reduce harm increasingly involve patients. Providing risk information 
at an appropriate health literacy level can improve patient engagement. 
Aims 
1) To identify problems associated with medication use in New Zealand general practice 
a) To evaluate the extent of medication-related harm arising from prescribing in NZ 
general practice 
b) To evaluate an automated clinician alert system to see whether there were any  
inequities in clinician action taken based on patient ethnicity or other demographic 
factors 
2) To explore strategies to improve medication safety in New Zealand general practice 
a) To explore what patients and prescribers would like in a decision support and 
communication tool 
b) To explore whether a tailored information package for patients can improve 
iii  
knowledge of NSAIDs and reduce self-reported use of NSAIDs 
Methods 
This thesis used a pragmatic mixed-methods approach in four linked studies. The first two 
studies are analyses of general practice record review data. They outlined problems 
associated with medication use, by estimating the amount of medication-related harm, and 
by determining whether clinician action varies by patient ethnicity when notified of the 
harm. Studies three and four explored strategies to improve medication safety. 
Patients and prescribers were interviewed in the third study to understand what they would 
like from a medication decision support and communication tool. The fourth study 
considered the feasibility of conducting a randomised controlled trial to test whether a 
tailored information package is acceptable and effective in improving knowledge of non- 
steroidal anti-inflammatory drugs (NSAIDs) and reducing self-reported NSAID use in patients 
at risk of renal damage. 
Results 
1. The estimated incidence rate of all medication-related harms in New Zealand general 
practice was 73.9 harms per 1000 patient-years, the estimated incidence of preventable 
or potentially preventable medication-related harms was 15.6 per 1000 patient-years, 
and the estimated hospitalisation rate was 1.1 per 1000 patient-years. Most harms were 
minor (1390/1762, 78.9%), but one in five harms were moderate or severe (373/1762, 
21.1%); three patients died (3/9076, 0.03%). Most medication-related harms were not 
preventable (n=1432, 81.3%); the remainder were considered preventable or potentially 
preventable (n=330, 18.7%). 
iv  
2. Analysis of whether clinicians took action following a risk alert found no evidence of a 
difference in the odds of having action taken by patient ethnicity, however the 
estimated odds for Māori and Pasifika patients were lower compared with Europeans 
(Māori OR 0.88, 95 %CI 0.63–1.22; Pasifika OR 0.88, 95 %CI 0.52–1.49). Females had 
significantly lower odds of having action taken compared with males (OR 0.76, 95 %CI 
0.59–0.96). 
3. Patients want as much information as possible about their medications and risk, but 
doctors find it difficult to communicate that information. Participants were cautiously 
optimistic about a prescribing risk assessment and communication tool, but worried 
about potential harm arising from its use. They also identified requirements for the 
tool and features to avoid. Culturally safe and trustworthy doctor-patient 
relationships are required before successful implementation of any tool. 
4. Patients at risk of renal damage are willing to participate in a study via email 
recruitment, and engage with an interactive learning activity about non-steroidal anti-
inflammatory drugs online. This randomized feasibility trial demonstrated that this 
research method is feasible for the purposes of recruiting patients and testing the 
effects of providing this targeted information package. 
Conclusion 
Medication-related harm in general practice is common. Patient and prescriber perspectives 
are needed to inform harm-reduction strategies. Use of a targeted alert system has potential 
to mitigate risk from medication-related harm. Clinicians typically take action on alerts 
arising from a general practice electronic alert system, but our study suggested that they 
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appear to take less action for women and Māori and Pasifika patients. Recognising clinician 
biases may improve the equitability of health care provision; respectful, culturally safe 
doctor-patient relationships are critical to the successful implementation of any risk-
mitigation tool. Delivering medication-risk information to targeted patients online is feasible, 
and further studies are required to determine determine whether that improves knowledge 
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I was given a jar of pills 
Containing ills of every description 
A prescription I couldn't stomach  
All that's left is Hope inside it 
 
Hope - or deceptive expectation  
Indisposed, with hope deferred  
Referred now to another physician 
Who just writes out another prescription. 
 
(Doctors with egos of minor deities  
contribute to the harms of polypharmacy). 
 
 
   Sharon Leitch 
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Chapter 1 Introduction 
 
1.1. Preface 
This thesis aims to identify problems associated with medication use and to explore 
strategies to improve medication safety in Aotearoa New Zealand (NZ) general practice. This 
chapter introduces the context of medication safety in NZ general practice. The origins of the 
patient safety movement are described and patient safety terminology is defined for 
subsequent use in this thesis. Methods to measure patient safety are discussed, together 
with their limitations. The context of NZ general practice is outlined together with a brief 
history of ethnicity and health equity in NZ. The rationale for concentrating on medication 
safety in general practice is explained. The development and use of current patient safety 
strategies are described, including systems theory, patient safety tools and technologies and 
informed consent and health literacy. The final section describes the development of this 
thesis and presents its aims and methods. 
1.2. The patient safety movement 
The recognition that patients may be harmed by medical care is not new. In the early 1800s, 
Drs Oliver Wendell Holmes and Ignaz Semmelweis independently recognised poor hand 
hygiene was responsible for puerperal fever, although their findings were misunderstood or 
rejected by most of their medical colleagues.1 Frequently misattributed to Hippocrates or 
Galen, it was around this time the phrase “primum non nocere” (Latin: first, do no harm) was 
coined by the French physician Chomel.2 
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In the second half of the twentieth century, the rapidly expanding arsenal of largely untested 
diagnostic procedures and medical treatments were recognised to be causing patient harm.3-
7 It was not until the 1990s that patient safety was considered an important facet of 
healthcare systems, following the publication of the Harvard Medical Practice Study,8,9 and 
the subsequent highly influential report from the United States Institute of Medicine: To Err 
is Human.10,11 The main recommendations arising from that report established a model for 
patient safety across the US health system, from government, to individual healthcare 
organisations, to individual patient encounters (Box 1-1).  
Box 1-1 Key recommendations from To Err is Human10 
 
Following the publication of that report, research and advisory groups dedicated to patient 
safety were established around the globe. At least partially in response to this, in 2001 the 
Agency for Healthcare Research and Quality (AHRQ) was founded in the US,12 and the 
National Patient Safety Agency (NPSA) in the UK.13 The World Alliance for Patient Safety 
was founded in 2002 by the World Health Organization (WHO).14 These groups raise the 
awareness and support quality and safety improvements in smaller healthcare 
 Establish a national group to enhance safety by developing leadership, research, 
tools and protocols 
 Develop mandatory and voluntary reporting systems to identify and learn from 
errors, to continuously improve patient safety 
 Raise safety standards and expectations for safety improvement through 
organisations providing oversight (e.g., funders and professional groups) 
 Implement safe healthcare delivery practices and safety systems in 
healthcare organisations 
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organisations, including guideline development agencies, therapeutic regulatory agencies, 
and professional clinical bodies. 
Healthcare quality and safety is now placed at the forefront of the health systems of all 
developed countries, probably due to the recognition of the cost of patient harm. Fatalities 
and serious harms cause the greatest social and economic burden; serious adverse events 
arising from primary and secondary care have been estimated to account for 3.2% of total 
health loss from all causes in NZ.15 While it is difficult to calculate the exact burden of patient 
harm due to additional health and social costs arising from impaired function and life lost, 
averting even a few preventable fatalities or serious harms is likely to yield significant 
savings, besides any moral imperative for attempting to do so.16 
1.2.1. The patient safety movement in New Zealand 
The NZ government established the Health Quality and Safety Commission (HQSC) in 2010, 
after noting NZ had made only “modest improvements in health quality and safety” 
compared with other similar countries.17 The purpose of the HQSC is to provide a 
coordinated effort on quality related activities. It works with clinicians, providers and 
consumers to improve health and disability support services, aiming to reduce patient harm 
from healthcare associated infections, surgery, medication, and falls.18 
Another strong driver for patient safety in NZ is the Accident Compensation Corporation 
(ACC), which provides NZ’s unique universal no-fault insurance cover for injury. ACC was 
established in 1972 to cover all injuries to employees and motor vehicle injuries.19 ACC cover 
has expanded over time, and since 2005 all treatment injuries have been covered. 
Treatment injury is defined as a personal injury sustained while being treated by a registered 
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health professional.20 ACC spent around $480 million NZD on treatment injury claims in the 
2018/19 financial year and is strongly motivated to reduce its liability in this area.20 ACC 
therefore provides substantial funding for treatment safety programmes, investing $45 
million between 2017 and 2022 to prevent treatment injury, such as its education 
programme for prescribers and patients aiming to prevent Foetal Anticonvulsant Syndrome 
(FACS).20 
1.2.2. Defining patient safety 
Patient safety terminology is confusing. Harm may be described as a patient safety 
incident, or an adverse, serious, or sentinel event. At other times harm is used 
synonymously with error. Patient safety incidents, such as delivering the wrong dose of 
medicine to a patient, do not necessarily result in harm, but are comparatively easy to 
measure in the context of electronic prescribing and dispensing. The lack of shared 
definitions causes challenges in reading and interpreting patient safety literature.21 A 
multidisciplinary approach to developing a shared definition is consistent with current 
recommendations by WHO, and others.22-25 
The World Health Organization has organised patient safety language in the Conceptual 
Framework for the International Classification for Patient Safety.22 This framework was 
primarily derived from hospital-based research. It has been criticised for lack of sensitivity  
for application in general practice settings, particularly in the classification of harm 
severity.26 WHO defines harm as “impairment of structure or function of the body and/or 
any deleterious effect arising there from. Harm includes disease, injury, suffering, disability 
and death.”22 
5  
Box 1-2 The importance of shared patient safety definitions. 
“The importance of being able to classify more consistently the major concepts associated 
with patient safety cannot be underestimated… The consistent use of key patient safety 
concepts with agreed definitions and preferred terms, in conjunction with a 
comprehensive but adaptable classification, paves the way for the systematic collection, 
aggregation and analysis of relevant information. In short, classification must be deeply 
integrated in all work on patient safety around the world” 
Sir Liam Donaldson23          
 
Patients typically define harm more broadly than clinicians.27 A comprehensive 
understanding of harm should include both physical and emotional harms, delays in 
treatment associated with extension or worsening of poor health, inconvenience, and 
additional financial costs to patients.28 The WHO definition can be expanded to include 
those features (Box 1-3). This broad definition of harm will be used throughout this thesis. 




Patients and their families are the primary victims of healthcare-related harm. The term 
“second victim” has been used to describe healthcare workers, rightly recognising the 
“Patient harm is physical or emotional negative consequences to patients directly 
arising from health care, beyond the usual consequences of care and not 
attributable to the patient’s health condition.” 
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emotional impact of patient harm on clinicians.29 Despite widespread understanding and 
use of “second victim,” this term has been criticised as it distracts attention from the 
primary victims, may reduce the impetus for patient safety research, and may subtly help 
clinicians and organisations avoid responsibility.30,31 However, a truly holistic definition of 
healthcare-related harm would include primary and secondary victims, as well as factors 
such as environmental contamination from chemical leakage and the ethical dilemmas 
associated with pharmaceutical funding decisions. An holistic approach is congruent with a 
Māori worldview and perspective of health, which acknowledges a far greater degree of 
interrelatedness between all things than non-Māori perspectives.32 For example, Western 
thinking values health mainly in terms of personal wellbeing and socio-economic output, 
while Māori concepts of health include physical, mental and spiritual dimensions as well as 
whānau (family) and community wellbeing.32 Such a definition of health-care related harm 
is beyond the scope of the thesis, but should be held in mind when considering healthcare 
harms in NZ. 
1.2.3. Measuring patient safety 
In addition to difficulties associated with a paucity of defined patient safety terms, 
measuring patient safety is challenging. Adverse events are seldom directly observed in 
general practice settings, because patient contact in general practice is brief and medication 
is typically administered off-site. Harm in general practice settings is typically recorded if a 
patient complains to a clinician about it, and if that clinician considers it worthy of 
documentation.33 Additionally, patients face barriers to accessing healthcare and to 
reporting harm.34-36 Despite these limitations, attempting to measure patient safety in some 
form is a laudable aim. Traditional methods of measuring patient safety include incident 
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reporting, use of trigger tools, and use of routinely collected data.21,37,38 
Incident reporting relies on clinicians recording events in some type of organisational 
database for review and evaluation. Use of incident reporting systems depends on multiple 
factors, including ease of use of the reporting system (including accessible technology), 
clinician time and motivation. The patient safety culture of the organisation, namely, the 
shared values, staff attitudes and behaviour play an important role in incident reporting.39,40 
Incident reporting systems vary greatly depending on healthcare setting; they are typically 
underdeveloped in general practice settings where use depends on practice safety culture.41 
They are prone to underreporting, and report analysis and subsequent learning is 
hindered.33,42 
Medical record audits aim to detect patient harm in a systematic way. The Global Trigger 
Tool was developed by expert consensus in 2003 by the American Institute for Healthcare 
Improvement (IHI), for hospital use as a rapid retrospective record audit tool.38 Medical 
records are checked by trained reviewers for “triggers”: factors that increase the likelihood 
of harm being present. Examples of triggers include INR>6.0,a glucose <3.5mmol/L,b and 
falls.38 Charts with triggers are systematically reviewed for patient harms.38 Trigger tools 
help both detect and monitor patient harm rates throughout the health system. They may 
be used to compare harm rates over time and between organisations, and can help prioritise 
safety improvement measures and resource allocation.38 Trigger tools have now been 
                                                          
a INR = International Normalised Ratio, a standardised measure of how long it takes blood to clot. It is used to 
measure the effect of anticoagulants (particularly warfarin). The therapeutic range is usually around 2.0- 3.5, 
depending on the condition. An INR of 6.0 or more indicates a higher risk of bleeding. 
 
b Blood glucose levels should be above 4.0mmol/L. Low blood glucose levels (hypoglycaemia) may cause 
confusion, coma and death. Hypoglycaemia is usually caused by medication, especially insulin. 
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adapted for use in other countries and healthcare settings, including NZ general 
practice.18,43-45 Trigger tools are becoming increasingly sophisticated as they incorporate 
technological advances, such as improving automating and electronic record scanning using 
natural language processing.46,47 The trigger tool is an important first step in developing a 
tool to measure patient safety in general practice, although this method is incapable of 
measuring harms which are not “flagged” by the trigger review method. Trigger tools 
monitor harm rates and may enhance patient safety culture, but unless used prospectively, 
they are unable to prevent harms from occurring. 
Data collected for other purposes also provide insight into adverse events.37 Record review 
studies involve in-depth examination of clinical records, scouring these for evidence of 
patient harm, or other patient safety issues (e.g., inappropriate prescribing). Record review 
studies are time and personnel intensive.48 They can provide unique insight into a patient’s 
journey of care and in-depth analysis of causal factors,49 but the quality of the review 
depends on the quality of the records.33 Evaluation of this method has found it typically lacks 
rigor and reproducibility,50,51 and yet it remains the main way  of assessing national adverse 
event rates.52 Evaluation of third party data, such as insurance claims, is another method of 
evaluating patient safety.53,54 This method provides some information, but is further 
removed from the source data, is skewed towards more severe patient harms, and all the 
limitations of the above methods are compounded.54,55 
Composite measures of the above methods, as well as using automated evaluation methods 
proposed by technological advances are likely to provide a more comprehensive evaluation 
of patient safety over time.52,56 Until there is wider acceptance of shared definitions and 
validated methodologies, the ability to measure and compare patient safety parameters 
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remains severely limited. In the meantime, researchers must acknowledge the limitations of 
their chosen methodology to assess patient harm across the health system. 
 
1.2.4. New Zealand general practice - worthy of patient safety attention 
General practice is the usual first point of contact for patients seeking healthcare and 
provides a gateway to accessing the rest of the NZ health system.57 Care is delivered 
predominantly in community general practice clinics by health professionals including 
general practitioners (GPs), practice nurses, nurse practitioners, pharmacists and other 
health professionals. General practice provides diagnostic and treatment services, health 
education, disease prevention and screening. Clinicians routinely use electronic health 
records to facilitate patient care. Patients increasingly can access at least some of their 
records and interact with their clinicians online via secure patient portals (e.g., view test 
results, book appointments and request repeat prescriptions). There are some linkages 
between primary and secondary care IT services; it is anticipated these will improve over 
time as the government has committed over $515 million in the 2021 budget to develop  
effective health infrastructure, including a national health information platform.58,59 NZ 
general practice faces similar issues to other developed nations – increasing longevity is 
increasing the complexity of our patients, who have increasing multimorbidity and 
polypharmacy.60-63 
NZ has a dual public-private health system. NZ general practices are typically run as small 
businesses, usually owned and operated by general practitioners.64 Most general practice 
healthcare is partly subsidised by the government on a capitation basis (i.e., practices 
receive annual funding per enrolled patient, calculated quarterly). Accident care is partly 
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funded by the national ACC scheme. A patchwork of targeted funds is administered 
regionally at present and is applied to some patients and conditions on a variable basis 
(e.g., extra funding for high-needs patients, free cervical smears for Māori and Pasifika 
women, free maternity care for women in the first trimester, removal of some complex 
skin lesions, etc.). Around 33% of New Zealanders have private health insurance.65 Those 
who do usually only have cover for hospital care for elective surgery (e.g., cataracts, joint 
replacements etc.), which paradoxically places additional strain on the public health care 
system.66 Patients 14 years and older have to pay an out-of-pocket co-payment to receive 
general practice care and medication. These co-payments limit access to care, and 
exacerbate inequity.64,67 Patients can apply for a Community Services Card from the 
government, which reduces medical and prescription fees. 
Most patient safety efforts concentrate on hospital care, rightly recognising that hospitals 
are places where patients are typically sicker, where more invasive investigations occur 
and more risky treatments are administered. However, more healthcare in NZ is delivered 
in general practice than any other healthcare setting. Each year, nearly 80% of New 
Zealanders visit their GP at least once; the population average is 2.9 visits per year.68 In 
comparison, only around 24% of the population are hospitalised per year (latest figures are 
available only for the 2017-18 year: age-standardised publicly-funded hospitalisation rate 
of 224 discharges per 1000 patients, privately-funded hospitalisation rate is 17 per 
1000).69,70 
General practice has traditionally been regarded as a low-risk environment for patient 
harm,71 although the patient safety data available to date indicate that harm arising from 
general practice has probably been underestimated.72 While few dangerous investigations or 
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treatments are administered in general practice, prescribing rates are high. During the 2015-
16 year, nearly 80% of enrolled general practice patients received at least one prescription 
item, and NZ GPs prescribed more than 42.4 million prescription items, or 9,715 items per 
1000 patients.73 High patient volumes and high prescribing rates in general practice 
consequently represent a high risk of causing harm, although the risk of harm per individual 
patient is likely to be low.72 
Improving patient safety in general practice is a priority for international and local health 
systems. Patient safety in general practice is increasingly important as more healthcare 
services are transferred from secondary to primary healthcare settings.74 The most common 
services transferred to primary healthcare to date include lower risk activities such as minor 
surgery, intra-uterine device insertion, diabetes care, and sleep apnoea care.75 This transfer 
of services to primary care presents both new clinical risks and also organizational safety 
risks, such as increased workload and administration-related safety issues. Should this trend 
continue, patient safety in general practice will require increased attention. 
Without a clinical perspective, it is probably hard to understand why addressing patient 
safety in general practice is so difficult. Box 1-4 aims to provide some insight into the work of 
a general practitioner, inspired by Aneez Esmail.76 
Box 1-4 Grassroots general practice in New Zealand 
I work in a small suburban clinic, in a poor part of town. Many of my patients can’t 
afford to see me, even though it’s only $19.50 NZD with a Community Services Card (or 
$25-$43 without one). They can’t afford the $5 per item prescription charge per item 
either. We’re all grateful for the new mega-chemists that somehow operate without 
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charging a prescription fee, but they are in town, and it’s a $5 return trip on the bus. 
Naturally my patients save up their problems before they come and see me, so each 15 
minute appointment is bursting with problems. Sometimes their presentation is so 
delayed that they are extremely unwell and require urgent secondary care, or they are 
just a lot sicker than they need to be. Some people I’ve referred months ago but they 
are getting worse waiting for their hospital appointment. My day is frequently 
interrupted with phone calls and stymied by technological issues limiting my ability to 
access critical patient information or complete paperwork. Around 10% of my patients 
don’t speak much English, but instead rely on interpreters or family to communicate. 
My patients are usually kind, respectful, and in good humour. Other patients are 
hostile and aggressive, demanding tests I can’t order, and medication they don’t need. 
In this time-pressured and resource-limited setting I need to carefully listen, examine, 
test, refer, diagnose, and treat my patients with care and compassion.  
I also advise people about what they have read on the internet, encourage the 
reluctant to have invasive screening tests or vaccinations, navigate the tensions 
between estranged parents bringing their shared-care child for review, respond to 
criticisms about my colleagues, tell people they are unfit to drive, write insurance 
reports, keep abreast of medical developments, never miss anything, and never make 
a mistake. My prescribing is entirely “evidence based” from current clinical guidelines. I 
calculate the risks and benefits of each medication for each patient. My patients are 
fully informed about their medications, and have the capacity to actively participate in 
shared decision-making discussions about their treatment...  
Of course, most of the time my GP colleagues and I just do the best we can. The 
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concept of “satisficing” – “settling for… management that that is satisfactory and 
sufficient” while relying on relational continuity to address long-term problems over 
time, seems apt.60 In short, life at the grassroots is muddy. I keep my boots on.  
The complexity of prescribing in the real world is highlighted in the following vignettes 
by NZ GPs. 
“On Sunday I get a call from an elderly patient. Her husband is dying of bowel cancer. 
He cannot sleep. I started him on a sleeping pill to help a month ago. Recently she has 
seen a programme on television about how people who take sleeping pills die earlier 
than those that don’t and so she has stopped it and her husband is up half the night 
again which means she is as well. I promise to visit but I wonder why I am, ‘Heck, he’s 
dying. Why not sleep well?’ When I get to the door I knock three times but no one hears 
me. I go back to the car and call my patient to say I am there. She lets me in and we 
talk for a long time about randomised controlled trials and what can be inferred and 
the inevitability of her husband’s illness. She encourages and nods and nods and 
encourages until I remember she is deaf on the side I am talking to. She is not sure 
what I am saying but she thinks it is her husband’s own fault he doesn’t sleep because 
he stays up to watch rugby and she says to lie down and close his eyes and think of God 
and what do I think? I smile and say it is ok to take the pill. She says that’s good then.” 
Dr Glenn Colquhoun77  
“Beside his bed there is a small china egg cup containing two pills and two capsules. 
‘They are my wake-up ones, before breakfast,’ he informs me. ‘And where are your 
night ones?’ I ask. I am relieved to see a plastic pack with a compartment for each day 
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of the week. But when I open it, Monday has Thyroxine, Tuesday Omeprazole, 
Wednesday Zopiclone, Thursday and Friday Laxsol, but Saturday and Sunday are 
unidentified. ‘What are these ones?” I ask. He replied: ‘I think they are spares. I like a 
few spares… I’ve got my own system and it works.’” Dr Lucy O’Hagan78 
 
1.3. A brief history of ethnicity and health equity in New Zealand 
NZ’s history and colonial legacy has a huge impact on the health of New Zealanders. The 
following synopsis explains why evaluating equity by ethnicity is a vital component of health 
research in this country. 
Aotearoa NZ, home to the indigenous population of Māori, was colonised by Britain from the 
mid-19th century. The founding constitutional document, Te Tiriti O Waitangi (The Treaty of 
Waitangi), was signed in 1840 by representatives of the British Crown and Māori leaders. It 
enshrines the ideals of equity and protection of Māori.79 Te Tiriti O Waitangi was not 
honoured by the early British colonists. Similar to other indigenous peoples, Māori land was 
confiscated, Māori children were taken from their families, and Māori culture and language 
were suppressed. The Māori population was further decimated through warfare, disease, 
urban drift and cultural disassociation.80 
Early settlers envisaged NZ as a “better Britain” where an egalitarian society could flourish 
(unless you were Māori or a woman).81,82 British and Irish people could freely immigrate to 
NZ until the 1960s. Traditional social and economic ties with Britain were greatly weakened 
when Britain joined the European Economic Community in 1973. This generated interest in 
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establishing a NZ national identity and a renewed commitment to  the Principles of the 
Treaty, still articulated by most public institutions today.80 NZ has a legislative commitment 
to biculturalism, but in reality it is a multi-ethnic country, which practices “de facto 
multiculturalism.”80,83 The main ethnic groupings used in NZ health research are European, 
Māori, Pasifika (Pacific peoples), Asian, MELAA (Middle Eastern / Latin American / African) 
and “Other ethnicity” (all other ethnicities not previously specified). 
NZ in 2021 has a population of 4.9 million people. The majority are descendants of those 
original British and Irish settlers, with 70.2% of the population identifying as European.84 
Europeans have better health and socioeconomic advantages than other ethnic groups. This 
is most starkly evident in life expectancy; Europeans live for approximately 7.5 years more 
than Māori and 5.5 years more than Pasifika.85 In the 2018 Census 16.5% of the population 
identified as Māori.86 Māori are over-represented in nearly every adverse statistic, 
experiencing worse health and more deprivation than other ethnic groups in NZ.86,87 
Pasifika refers to people living in NZ who identify with the Pacific islands because of ancestry 
or cultural heritage; the term represents more than 40 different ethnic groups including 
Samoan, Tongan, Cook Islands Māori, Niuean, Fijian, Tokelauan and others. People from the 
Pacific Islands have been travelling to NZ for employment and education opportunities for 
the past 150 years. In boom times, Pasifika were recruited to work in NZ, but in economic 
downturns they have been harshly and unfairly treated.88 In 2018 Pasifika made up 8.1% of 
the population.89 Like Māori, Pasifika are also over-represented in adverse health and 
socioeconomic statistics.90 
The first Asian immigrants to NZ were Chinese gold-miners who arrived in the 1860s. 
Government legislation actively discriminated against Chinese immigrants from 1881- 1986; 
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Chinese were ineligible for naturalisation (citizenship) until 1951.91 Since the 1990s  NZ has 
had a policy of competitive migration and actively sought skilled Asian migrants.83 On the 
other hand, waves of xenophobia and racism have disproportionately targeted people of 
Asian descent and influenced NZ policy.83,92,93 In the 2018 Census 15.1% of the population 
identified as Asian.84 People of Asian ethnicity generally experience good health and life 
expectancy, with new immigrants experiencing better health than those born in NZ.94 A lack 
of attention to Asian health in the health sector is of concern as this population group grows; 
recognising the ethnic diversity within this group may clarify health issues for sub- 
groups.94,95   
MELAA people make up only 1.5% of the population, and Other ethnicity 1.2%.84 People 
from the Middle East are the largest subgroup, with nearly 28,000 people as at the 2018 
Census.84 Many recent immigrants in this group are refugees, who have a unique set of 
complex health needs.96 The terrorist attack on March 15 2019 brought decades of anti- 
Muslim and anti-Arab prejudice to light.97 People of MELAA and Other ethnic groups are 
largely ignored in the health literature due to their statistically marginal contribution to the 
data. 
Equal opportunity for all New Zealanders is enshrined in NZ law and health policy.98 
Addressing the nefarious legacy of colonisation, assimilation, and pervasive structural racism 
in health is beyond the scope of this thesis. NZ researchers have an obligation to evaluate 
healthcare interventions in terms of ethnicity, in order to ensure they do not exacerbate 
health inequity.99,100 New Zealanders can identify with multiple ethnicities, but prioritised 
ethnicity is used in the health sector and in this thesis.101 
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Box 1-6 Equity defined 
“In Aotearoa New Zealand, people have difference in health that are not only avoidable 
but unfair and unjust. Equity recognises different people with different levels of 
advantage require different approaches and resources to get equitable health 
outcomes.”                                                                                        Ministry of Health98 
 
1.4. Medication safety in general practice 
The rationale for considering patient safety in general practice was addressed above. 
Prescribed medications comprises the bulk of treatment administered in general practice, so 
medication safety should be a priority for patient safety efforts in this area. High prescribing 
rates in general practice increase the risk of patient harm from medication. One way to 
measure the extent of serious medication harm in general practice is by examining hospital 
admissions. Up to half of all hospital admissions in one international meta-analysis were 
attributed to adverse medication events; higher rates were observed in studies focusing on 
older people.102,103 A European review of publications from 2000-2014 found 3.5% of all 
admissions on average were caused by an adverse drug  reaction.104 A review of Australian 
literature from 2008-13 found 2-3% of all hospitalisations were medication- related.105 In 
NZ, a 2014 study found nearly a third of acute medical hospital admissions were related to 
adverse medication events.106  
Hospital admissions reflect only the most serious medication-related harms. Measuring the 
true extent of medication-related harm in general practice is difficult. Firstly, the harm will 
be recorded in the patient records only if the patient complains to their healthcare provider 
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about a problem, and if the provider then considers the patient complaint sufficiently 
serious to do something about it. Secondly, the provider may record a medication harm in 
several ways; for example, nausea with antibiotics may be considered a minor side-effect 
and hence may not be recorded, more serious adverse reactions may be recorded in the 
general notes or as “medication warnings”, and unusual reactions or those involving new 
medications may be reported to Centre for Adverse Reactions Monitoring (CARM). Thirdly, 
non-physical medication harms are unlikely to be recorded at all; for example, the hassle, 
expense and time wasted in obtaining a correct prescription in the case of a prescribing or 
dispensing error is all borne by the patient, yet is seldom acknowledged. 
Estimating medication-related harm in general practice is therefore fraught with difficulty; 
comparisons between studies are hampered by methodological variability and paucity of 
shared definitions. A comprehensive meta-analysis of published and unpublished 
international studies from 1980-2014 found up to 24 safety incidents per 100 consultations 
(the median incident rate for each study was 2-3 per 100 consultations); diagnostic and 
medication-related incidents were most likely to be associated with patient harm, with 8-
11% of medication-related incidents resulting in patient harm.107 A systematic review of 
published international literature estimated the incidence of preventable adverse drug 
events as 15/1000 person-years.108 
Similarly, comparisons of country-specific data are difficult due to the broad range of 
outcome measures. For example, a survey of Australian general practice patients over 45 
years old found 11.6% patients reported an adverse drug event in the preceding six 
months.109 The incidence of avoidable significant harm in general practice in England is 35.6 
(95% CI 23.3 to 48.0) per 100 000 patient- years; medication-related problems accounted for 
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a quarter of these harms.110 In a cross-sectional mixed methods analysis of patient safety 
incidents in England and Wales, medication-related incidents accounted for the greatest 
proportion of incidents (31%, and 15% of serious harms).111 In a retrospective general 
practice record review study in the Netherlands 5.8% of patients experienced harm; 14.7% 
of adverse events detected related to medication.71 And a Swedish study examining both 
primary and secondary care records found a prevalence of adverse drug events of 12% 
(95%CI 11.1-12.9%).112 
1.4.1. Epidemiology of harm in New Zealand general practice 
To improve knowledge of patient harm arising from general practice in NZ a general practice 
record review study was undertaken (Patient harms in NZ general practices: Records Review 
Study). The general practice records of 9076 randomly selected general practice patients 
from 2011 to 2013 inclusive were examined.28,113 These records provide a window on the 
whole health system; as well as detailed accounts of general practice care, they provide 
information about patients’ key hospital experiences. 
Using the definition of harm outlined above, it was found that 1505 patients (16.6%) 
experienced at least one harm in the three year study period; when study results were 
weighted to the NZ population this is equivalent to 18.0% of all NZ general practice 
patients experiencing harm.113 The estimated incidence of harm was 123 per 1000 patient-
years. Some patients experienced multiple harms during the study period. While most 
harms were minor, one in four harms were considered moderate or severe. Harms 
included medication reactions, wound infections, falls, hospitalisation, intracerebral 
bleeding and death. Harm from medication prescribed in general practice accounted for 
most of the harm (1762/2972, 59.2% of all harms). I used the data from that study to 
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independently conduct a detailed analysis of the medication-related harms identified. 
Results are presented in Chapter 2. 
1.5. Strategies to improve medication safety 
Since 2004, WHO has initiated three Global Patient Safety Challenges. Recognising the harm 
arising from medication, the Third Global Patient Safety Challenge was launched in 2017 - 
Medication Without Harm.114,115 The overall goal of this Challenge is “improving medication 
safety by strengthening the systems for reducing medication errors and avoidable 
medication-related harm.”115 WHO aims to reduce the amount of severe, avoidable 
medication-related harm across the world by 50% over 5 years.115 So far WHO has identified 
priority areas for improving medication safety, and has developed medication safety 
resources for patients and clinicians. 
WHO has laid out a five-point strategic framework for addressing the Global Patient Safety 
Challenge on Medication Safety at international, national, and local levels. Of particular 
relevance to this thesis is their final strategic objective, which is to “empower patients, 
families and their carers to become actively involved and engaged in treatment or care 
decisions, ask questions, spot errors and effectively manage their medications.”115 They aim 
to do this by putting “mechanisms in place, including the use of tools and technologies, to 
enhance patient awareness and knowledge about medicines and medication use process, 
and patients’ role in managing their own medications safely.”115 
1.5.1. Systems theory 
Other industries have successfully improved safety by taking a systems perspective. As early 
as 1960 the psychologist Alphonse Chapanis, famous for redesigning cockpit controls and 
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improving aviation safety, concentrated on medication-related errors in hospital care.116 
Chapanis identified four areas which required attention, namely communication, medication 
procedures, the working environment, and training and education.116 Much of the learnings 
from his research remain relevant today, yet many of the issues that were identified sixty 
years ago remain unaddressed, and patient harm from medication still occurs worldwide.114 
The systems theory of healthcare safety acknowledges “most healthcare problems and 
solutions belong to the system.”117 The health system is complex, interrelated, and context-
specific.118,119 Complex systems consist of multiple interactive relationships between people, 
work, technology, organizational structures, and internal and external environmental 
factors.120 Healthcare provision is susceptible to both variability in demand and resource 
constraints, which increases the complexity of creating and maintaining safe systems. This 
variability also exacerbates the intrinsic goal conflict associated with healthcare provision.120 
Goal conflict refers to the idea that being efficient (tasks should be completed using the 
minimum of resources required) and being thorough (tasks should only be attempted if 
sufficient resources are available to complete them safely) are irreconcilable goals.121 Goal 
conflicts in a variable complex system inevitably result in adaptation of work processes, 
leading to a difference between “work-as-imagined” (what is in the procedure manual) and 
“work-as-done” (what we actually do around here to get the job done, which may include 
procedural violation).120,122 If “work-as-done” is normalised without adequate safety 
considerations, then over time an organization will migrate towards an accident-prone 
system.122 In short, understanding safety requires examination of not just the system 
components and outcomes (both good and bad), but also interactions within the system and 
the adaptations required to undertake everyday work.120  
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Resilience Engineering for safer systems requires the tensions between efficiency and 
thoroughness be balanced in order to both anticipate and respond to patient safety 
threats.121 Resilience Engineering defines success as the capacity to anticipate and plan for 
changing risk parameters before harm occurs.122 A systems approach to healthcare safety 
incorporates the following five principles: first, multiple perspectives are required to 
understand the system; second, working conditions (i.e., requirements, demands, supply, 
constraints) are acknowledged; third, interactions and workflow are analysed; fourth, 
professional decisions are reviewed to understand why they made sense within the context 
of the system; fifth, successful system change is analysed to recognise what was actually 
required to achieve success.117 
The Systems Engineering Initiative for Patient Safety (SEIPS) model is a human 
factors/ergonomics (HFE) framework for studying and improving health and healthcare, 
underpinned by three principles: systems orientation, person centeredness, and design-
driven improvements.123 Traditional patient safety efforts rely heavily on education and 
subsequent behaviour change, probably overestimating the capacity of individuals to 
change, while underestimating organisational factors. HFE addresses problems by 
redesigning the system so it is resilient to unanticipated events, so the most intuitive and 
logical decision is the correct action to take for end-users. HFE strategies attend to factors 
ranging from the individual to the organisational level.124 Figure 1-1 provides a model of a 
SEIPS approach to describing the pathway of an elderly patient obtaining a repeat 
prescription by phone for antihypertensive medication during a Covid lockdown.125 (As it 
happens, this hypothetical patient was overdue a blood-pressure assessment and had not 
been taking her medication for a few months due to cost, and because her pills make her 
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feel dizzy. Her daughter found out and was concerned; she encouraged her mother to ring 
up for a repeat prescription. This patient was advised to come in for a blood-pressure check, 
but declined as she was afraid of catching Covid in the practice). Consideration of all these 
factors helps explain why the suboptimal prescribing occurred, resulting in patient harm. 
Figure 1-1 depicts multiple components and multiple points of interaction. Any one 
component or action in that model could be examined and potentially improved to attempt 
to reduce the medication-related harm. 
Systems theory research involves building and using explicit models to explain cause-and- 
effect.122 These models can be tested and calibrated with data and repeated by others.126 
System-level decisions also affect whether new innovations are adopted, spread, or are 
implemented.127 Examples of systems factor thinking relating to medication include 
developing and testing computerised prescribing systems, patient controlled analgesia (PCA) 
pump review, and emergency medication draw redesign.128,129 
Implementation science is related to systems theory research. Implementation science aims 
to improve healthcare quality by examining the methods of promoting the uptake of 
evidence-based practices into routine use.130 Implementation science is particularly useful 
when considering how to best embed use of a new tool into routine workflow by taking a 
systems approach to assess all aspects of the tool and workflow. One implementation 
science theory, Normalisation Process Theory, is further discussed in Study 3 (Chapter 4), in 
which general practitioners and patients were interviewed on their opinions about a patient 
safety tool. 
1.5.2. Patient safety tools and technologies 
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Many methods of improving patient safety have been trialed, including audit, best practice 
guidelines, electronic alerts and reminders, clinician education, and addressing patient 
safety culture, but it is unclear which of these are the most effective.131-133 Electronic 
prescribing is now well-recognised to improve the quality of prescribing and reduce 
prescribing errors.134 Simple automated alert systems for electronic prescribing show 
warning messages of interactions between concurrently prescribed and long-term 
medications, as well as known drug allergies. Typically, potential interactions are over- 
reported, so some alerts are clinically meaningless and the frequency and volume of warning 
messages can be overwhelming - leading to “alert fatigue.”135-138 Prescribing software 
vendors limit alert modification because of concerns of potential liability should a 





Figure 1-1 SEIPS model of a socio-technical systems approach for a patient obtaining a repeat prescription for anti-hypertensive medication 
during a Covid lockdown 
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There are a range of computerised decision support systems available to improve safe 
prescribing.140 The most sophisticated systems are completely integrated with the electronic 
health record and automatically pre-populate with patient data. They are highly relevant to 
the task at hand (e.g., checking the renal function and INR of someone transitioning from 
warfarin to dabigatran). They automatically pop up at the time of prescribing, rather than 
relying on clinician motivation and time to use, and they may require manual input before 
the clinician can proceed and generate the prescription (e.g., check-box ticks required for 
the following statement: “I have checked the patient is using reliable contraception, and 
have counselled them about the risks of pregnancy while taking isotretinoin (a highly 
teratogenic medicine)”). A systematic meta-review of decision support software found only 
weak and inconsistent evidence of improvements in safer prescribing.135 Evidence regarding 
patient outcomes is inconsistent, suggesting only modest benefits at best.135,141,142 Decision 
support technology can be evaluated from a human factors perspective, such as by using the 
Instrument for Evaluating Human Factors Principles in Medication Related Decision Support 
Alerts (I-MeDeSA), which has some limitations in its design and scoring system.143,144 
The most useful tools will become increasingly tailored to recognise individual patient risk 
(e.g., by including parameters such as renal function to estimate risk more accurately), or 
recognise the complexity of multimorbidity and polypharmacy, and provide meaningful 
feedback in terms of suggested medications for deprescribing trials. They will build on the 
evidence of successful clinical decision support tools.145 
One such tailored alert system has been developed by the NZ health informatics company 
Conporto Health. The Conporto Event Detection and Mitigation alert system (Conporto 
EDM) is a warning system to alert clinicians when their patients are at higher risk of 
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experiencing harm from medication.146 Their proof-of-concept trial demonstrated that 
clinicians do note these warnings and take remedial action, but there was concern that there 
was inequity in action taken when evaluated by patient ethnicity.147 Detailed evaluation of 
the Conporto EDM proof-of-concept trial is reported in Study 2. Conporto Health also 
participated in the randomised feasibility trial discussed in Study 4. 
 
1.5.3. Informed consent and health literacy 
All prescribing is a tension between risks and benefits. Prescribers have a moral and legal 
obligation to ensure patients are fully informed about those risks and benefits (Box 1-7 
contains selected points from the Medical Council of New Zealand’s Statement on good 
prescribing).148-150 Despite specific training, clinicians generally have poor understanding 
and low confidence in their ability to interpret statistics.151,152 
While there is a good body of evidence outlining specific steps to improving shared decision 
making between clinicians and patients,153-155 this process can still be challenging due to 
language and low health literacy. Health literacy is the ability to obtain, process and 
understand health information in order to make informed and appropriate health-related 
decisions.156 Health literacy has been identified as a cause of health disparities,157 and 
decision support tools can help address deficits in health literacy.158 
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Box 1-7 MCNZ Statement on good prescribing practice (selected points)150 
 
New Zealanders typically have low levels of health literacy – over half of adults surveyed 
had skills “insufficient to cope with the health literacy demands they typically face.”159 
When these results were broken down by ethnicity, 75-80% of Māori and 90% of Pasifika 
had low health literacy levels.159 Māori and people who are socioeconomically 
disadvantaged are disproportionately affected by adverse events and by harms arising 
from healthcare, including mortality, injury, and disability.15,160-162  Māori and socially 
disadvantaged patients were found to be at higher risk of polypharmacy in a study of older 
New Zealanders.62 To fully engage in patient-centred care, patients need to understand 
“Ensure that the patient (or other lawful authority) is fully informed and consents to 
the proposed treatment and that he or she receives appropriate information, in a way 
they can understand, about the options available; including an assessment of the 
expected risks, adverse effects, benefits and costs of each option.” 
“Satisfy yourself that the patient understands how to take or use any 
medicine prescribed and is able to take it or use it.” 
“Periodically review the effect (benefits and harms) of the treatment and any new 
information about the patient’s condition and health if the treatment is being 
prescribed for an extended period of time. Continuation or modification of 
treatment should depend on your evaluation of progress towards the objectives 
outlined in a treatment plan.” 
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their health information and risks. This will enable patients and their whānau to 
meaningfully participate in shared decision making. 
 
1.6. Rationale for research 
 
In order to address some of these issues, the following research question was proposed: 
How can medication safety in NZ general practice be improved? To answer that question, we 
need to understand how much medication-related harm is occurring, and whether any of 
that harm is preventable. Ethnicity is associated with inequitable health outcomes in general 
– but we do not know if this is true in general practice too. Once the extent of medication-
related harm is known, potential solutions could be considered and trialed. 
1.6.1. Aims 
3) To identify problems associated with medication use in New Zealand general practice 
a) To evaluate the extent of medication-related harm arising from prescribing in NZ 
general practice 
b) To evaluate an automated clinician alert system to see whether there were any  
inequities in clinician action taken based on patient ethnicity or other demographic 
factors 
4) To explore strategies to improve medication safety in New Zealand general practice 
a) To explore what patients and prescribers would like in a decision support and 
communication tool 
b) To explore whether a tailored information package for patients can improve 
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knowledge of NSAIDs and reduce self-reported use of NSAIDs 
1.6.2. Objectives 
1) To identify problems associated with medication use in New Zealand general  practice, 
two projects were carried out: 
a) A large retrospective records review was undertaken to describe an epidemiology 
of harm in New Zealand general practice. Sub-analysis of the harms data relating to 
medication has determined the incidence of medication-related harm arising from 
general practice prescribing. 
b) Preliminary evaluation of an automated clinician alert system showed that clinicians 
took actions on the alerts, but there was concern that there was inequity in action 
taken by ethnicity. Those data have been analysed to determine whether the 
automated clinician alert system exacerbates ethnic inequity. 
2) To explore potential strategies to improve safe medication use in New Zealand general 
practice, two more projects were undertaken: 
a) Patients and prescribers were interviewed to understand what they would like in a 
decision support and communication tool. 
b) Findings from the preceding projects were used to develop a tailored information 
package for patients at higher risk from Non-Steroidal Anti-Inflammatory Drugs 
(NSAIDs). A randomised control trial (RCT) is required to assess the impact of an 
information package in improving knowledge of NSAIDs and reducing self-reported 
use of NSAIDs. To ensure best use of resources for the full RCT, a randomised 
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feasibility trial was conducted. 
1.7. Overview of Methods 
This thesis is the work of a general practitioner: general practice is the medical specialty 
which probably most embodies pragmatism. Pragmatism was introduced to modern 
philosophy in 1898, borrowed from the work of Immanuel Kant.163 Pragmatism understands 
phenomena in relation to their practical consequences, concentrating on “what works” 
rather than aiming to understand higher truth or reality.164 Instead, reality is understood 
through action.164 Pragmatic responses call for creative ideas, focused problem solving, 
opportunity to choose and democratic process.163 
Pragmatic philosophy has found a home in many practical fields such as law, engineering, 
social work and medicine. By the mid-1990s clinical pragmatism was seen as an important 
tool in evaluating ethical and moral problems associated with medicine.165 This approach 
was subsequently extended to qualitative research methods, described as pragmatic 
inquiry.166 Research should be tested for pragmatic validity – research should be both 
grounded in and useful for clinical practice.166 
Research aligned with pragmatism obviously uses methods that will best solve the problem 
at hand. Mixed methods combines quantitative and qualitative methods in a single 
programme of research.167 Mixed methods helps answer more complex and nuanced 
questions than can be answered with quantitative or qualitative methodology alone. It has 
gained popularity over the past decade, particularly in health research.168,169  The two main 
types of mixed method design are described as convergent, where the methods are 
combined throughout the research, or sequential, where one method informs the next 
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phase of the research.169 This thesis uses a sequential mixed methods design to explore 





An example of pragmatism is the evolution of this thesis. The original plan was to build a 
tailored alert system for this doctoral research project. That work would have used the main 
learnings from the record review study (described in Study 1), combined with contemporary 
epidemiological information and medical decision support technology to try to improve 
medication safety in general practice by averting preventable patient harm. It was to be 
designed as a communication tool for discussing risks and benefits of medications with 
patients and their whānau, thereby supporting health education and patient-centered care. 
Figure 1-2 Pictorial representation of mixed methods used in this thesis 
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Stakeholder engagement with patients and clinicians was undertaken to ensure the tool was 
designed to best meet the needs of end-users (Study 3). 
 
In 2018 Conporto Health completed a successful proof-of-concept study for a similar tool, so 
it was considered unfeasible to continue with the proposed doctoral project. Instead, 
Conporto Health was willing to collaborate to conduct further patient safety research, 
leading to two projects. The first project analysed their data to check for health equity issues 
(Study 2). The second Conporto Health project is closely aligned with my original plan and 
combines aspects of an alert system with that of patient information and education. Using 
the knowledge gleaned from the stakeholder interviews a patient education package was 
developed based on one of the Conporto EDM alerts. A randomised feasibility trial was 
conducted to determine whether the proposed method is suitable to investigate the impact 
of providing the information package to patients at risk of renal damage (Study 4). 
1.8. Overview of the thesis structure 
The thesis takes the form of a series of four linked studies, book-ended by Introduction and 





1.9. Summary of Introduction 
 
This chapter has introduced the patient safety movement from international and NZ 
perspectives, concentrating on medication-related safety issues in general practice. Patient 
safety terms were defined. The context of NZ general practice was discussed. Strategies to 
improve patient safety were outlined, as well as barriers to achieving those strategies. 
Finally, the aims of this thesis were articulated, together with a brief discussion on 
pragmatism and mixed methods research. 




Chapter 2  Medication-related harms in general practice 
 
2.1. Preface 
This chapter contains a published original manuscript titled “Medication-related harm in 
New Zealand general practice: a retrospective records review”. This manuscript was 
published in the British Journal of General Practice in 2021: Leitch S, Dovey S, Cunningham 
W, et al. Medication-related harm in New Zealand general practice: a retrospective records 
review. Br J Gen Pract. 2021;71(709):e626-e633. doi: 10.3399/BJGP.2020.1126. The 
manuscript is presented here as published, but has been reformatted to fit the overall thesis 
style and referencing. 
As discussed in the Introduction, while medication safety is considered a priority and has 
been extensively studied in hospital settings, medication safety in general practice is 
relatively unexamined. Evaluating patient safety in general practice is difficult due to the 
intermittent nature of the care provided, and the fact most healthcare is administered off-
site (i.e., patients are prescribed medication which they take at home, limiting the capacity 
to observe and record adverse events). One method of evaluating patient safety in general 
practice is to review patient records for evidence of patient harm. This method is far from 
perfect, and has been particularly criticized because results from record review studies are 
difficult to reproduce.50,51 However, it is probably the most feasible method we have 
available to obtain a general (if imperfect) assessment of patient harm in general practice.  
This chapter explores data from a large record review study for medication-related harm. 
The Safety, Harms and Risk Reduction Project (SHARP) is a large retrospective review of NZ 
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general practice records.28,113 It aimed to determine the epidemiology of healthcare harm 
observable in general practice records. SHARP obtained and reviewed the records of over 
9000 patients from 44 different practices; at that time the NZ enrolled patient population 
was 4,092,647 and there were 988 general practices.170 Reviewers identified 2972 harms of 
any nature experienced by 1505 patients. The estimated incidence of harm was 123 per 
1000 patient-years, and the incidence rate of preventable or potentially preventable harm 
was 26 harms per 1000 patient-years.113 This current work is a sub-analysis of those data, 
examining the medication-related harms that were identified in the SHARP study. 
2.1.1. Chapter Aim 
To examine the extent of medication-related harm arising from prescribing in NZ 
general practice – what is the prevalence of harm, and what are the risk factors for 
experiencing harm? 
2.1.2 Candidate Contribution statement 
PhD candidate Sharon Leitch was the clinical coordinator for the SHARP study. She recruited 
the study practices, reviewed general practice records, coded harms, identified medication-
related harms arising from general practice prescribing, conducted the statistical analyses, 
and wrote this manuscript. The full author contributor statement is found at the end of the 
paper. 
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The extent of medication-related harm in general practice is unknown. 
2.1.2. Aim 
To identify and describe all medication-related harm in electronic general practice records. 
The secondary aim was to investigate factors potentially associated with medication-related 
harm. 
2.1.3. Design and Setting 
Retrospective cohort records review study in 44 randomly selected New Zealand general 
practices for the three years 2011-2013. 
2.1.4. Methods 
Eight general practitioners reviewed 9076 randomly selected patient records. Medication- 
related harms were identified when the causal agent was prescribed in general practice. 
Harms were coded by type, preventability, and severity. The number and proportion of 
patients who experienced medication-related harm was calculated. Weighted logistic 
regression was used to identify factors associated with harm. 
2.1.5. Results 
976/9076 study patients (10.8%) experienced 1,762 medication-related harms over three 
years. After weighting, the incidence rate of all medication-related harms was 73.9 harms 
per 1000 patient-years, and the incidence of preventable or potentially preventable 
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medication-related harms was 15.6 per 1000 patient-years. Most harms were minor 
(1385/1762, 78.6%), but one in five harms were moderate or severe (373/1762, 21.2%); 
three patients died. Eighteen study patients were hospitalised; after weighting this 
correlates to a hospitalisation rate of 1.1 per 1000 patient-years. Increasing age, number of 
consultations, and number of medications were associated with increased risk of 
medication-related harm. Cardiovascular medications, antineoplastic and 
immunomodulatory agents, and anticoagulants caused most harm by frequency and 
severity. 
2.1.6. Conclusion 
Medication-related harm in general practice is common. This study adds to the evidence 
about the risk posed by medication in the real world. Findings can be used to inform 
decision-making in general practice. 
How this fits in 
 
The extent of medication-related harm in general practice is unknown. This 
retrospective records review found that medication-related harm in general practice 
is common, and is typically minor and arising from standard care. Patients who are 
older, who have more consultations and who take more medication are at greatest 
risk of harm. The risk of patient harm increased with age. Patients aged 60–74 years 
had nearly double the risk of harm compared with the reference group (patients 
aged 15– 59 years), and patients aged >75 years had triple the risk. This knowledge 
can inform shared-decision making about treatment options. 
42  
2.1.7. Keywords 
general practice; New Zealand; patient harm; primary health care; retrospective studies. 
2.2. Background 
Reducing medication-related harm is a top priority for improving patient safety.114,171 
Primary healthcare settings remain relatively unexamined for patient harm.172 It is possible 
patient harm in general practice has been underestimated.72 Medication-related harm 
accounts for around 3% of all hospital admissions on average, with higher rates observed in 
older people.103-106  
Clinical trials, event reporting, and compensation claims provide a limited perspective on 
medication-related harm in the real world, producing data not typically generalisable to 
general practice populations. Population-based records review research can identify harms 
experienced in the course of routine clinical care, and identify patients at increased risk of 
harm to improve patient safety.49 
This study examined medication-related harm in general practice using a subset of data from 
a nation-wide retrospective cohort review of general practice electronic health records that 
looked at all harms.28,170 The primary aim of this paper was to estimate the incidence, 
preventability and severity of all harms attributable to medication prescribed in general 
practice in New Zealand. The secondary aim was to investigate factors potentially associated 
with medication-related harm, including age, sex, ethnicity, social deprivation, number of 





All New Zealand general practices were stratified by size and location.28,170 Practice size was 
defined by the number of enrolled patients, divided into tertiles to form three groups 
consisting of large, medium and small practices. Location was defined as rural or urban 
based by practice address.28,170 Practice size and location defined six strata. Twelve practices 
were randomly selected by from each strata and invited to participate; 44 study practices 
consented to participate (71.0% of the 62 eligible randomly selected practices with 
compatible practice software).170 
2.3.2. Participants 
Patients enrolled in recruited practices were randomly selected for participation at the mid-
point of the study period; in total 9076 patients were randomly selected (based on prior 
power calculations).170 The general practice records of the randomly selected patients for 
the 3 year study period (1 January 2011 to 31 December 2013, inclusive) were  anonymised 
at time of electronic data extraction. The extracted records contained everything that is 
normally available in patient records, including demographic data, consultation notes, 
screening data, laboratory and radiology results, referral letters, alerts, and prescriptions. 
Secondary care referrals, discharge summaries and clinic letters were available where these 
had been stored electronically in the record. 
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Consent and data access were granted by each practice rather than from individual 
patients.173 This research was approved by the University of Otago ethics committee, and 
reviewed by the Ngāi Tahu Research Consultation Committee. 
2.3.3. Reviewers 
Each patient’s file was examined by at least 1 of 8 clinically active GPs with a minimum of 10 
years’ experience. Reviewers participated in training sessions at the commencement of the 
study. Feedback from double-reviewed files (n=948, 10.4%) was used to further improve 
reviewer consistency. The range of agreement between pairs of reviewers was 66.7-100.0%; 
overall kappa = 0.344, P<0.001. 
2.3.4. Covariates 
Patient demographic data including age at 1 July 2012, sex, self-identified ethnicity,174 and 
socioeconomic deprivation were obtained. Māori are the indigenous people of New Zealand. 
Pasifika refers to the people of the Pacific islands (for example, Samoa, Tonga, etc.) who are 
now living in New Zealand. Participants were sorted into one of five socio- economic 
categories ranging from 1 (least deprived) to 5 (most deprived) based on their home address 
and census-derived data for each area meshblock.175 Information on the number of unique 
medications prescribed, and number of consultations were also obtained within the 
specified period. Practice size and location are defined above. 
2.3.5. Outcomes 
Harm was defined as: “physical, emotional or financial negative consequences to patients 
directly arising from health care, beyond the usual consequences of care, and not 
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attributable to patients’ health conditions”.176 Reviewers identified episodes where patients 
experienced harm, as documented in their records. Other patient safety measures, such as 
“near-misses”, “safety incidents”, “inappropriate prescribing” and “errors,” were not 
recorded unless they resulted in patient harm. Each patient record was recorded in binary 
terms: harm or no harm. 
Harm was rated minor, moderate, severe or death.28 Short-lived and relatively trivial harms 
were coded as minor (for example, rashes, vomiting, and inconvenience to patients, such as 
being given the wrong prescription). Moderate harm was defined as having increased or 
persistent morbidity (for example, fractures, untreated anaemia, and poor diabetic control). 
Severe harms included renal failure, pulmonary embolism, myocardial infarction, and 
morphine overdose. Reviewers used their clinical expertise to assess preventability from 
fivec categories.28,177 Following discussion and consensus these options were aggregated in 
analysis to “preventable or potentially preventable” (original codes: “preventable and 
originated in primary care” and “potentially preventable and originated in primary care”) 
and “not preventable” (“not preventable, standard treatment,” “not preventable and 
originated in primary care,” “not preventable and originated in secondary care,” and 
“preventable and originated in secondary care OR not preventable and originated in primary 
care”). 
Harms were documented in descriptive form, then coded using Medical Dictionary for 
Regulatory Activities 18.0 codes.178 Data extraction is depicted in Figure 2-1. Medications 
were coded by drug type using the Anatomical Therapeutic Chemical (ATC) classification 
system.179 
                                                          
c Erratum. Reviewers used their clinical expertise to assess preventability from six categories. 
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Figure 2-1 Selection of medication-related harms from SHARP data 
2.3.6. Statistical Analysis 
The number and proportion of medication-related harms was calculated by patient 
demography (age, sex, ethnicity, and deprivation), clinical information (number of consults 
and number of unique medications prescribed during the study period), and practice 
characteristics (practice size and practice location). Incidence rates were calculated as the 
number of events divided by the total number of person-years of follow-up (for example, 
3*9076 years, 3 years per person). In order to obtain an estimate of the incidence of 
medication-related harm in New Zealand, sampling weights were applied to the incidence 
rates allowing for the probability of each practice being selected per strata, and each patient 
being selected per practice. Harms were examined by ATC classification. Individual 
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medications were examined by rate of prescribing and percentage of patients harmed. 
Logistic regression with robust standard error was used to explore associations between 
medication-related harm and patient demographics, clinical information and practice 
characteristics. The final model included all covariates listed above. Estimates were then 
adjusted using appropriate sampling weights. 
Stata (version 15.1) was used for all statistical analyses. The Stata svy package was used for 
applying sample weights. Data were missing for ethnicity (139, 1.5%) and deprivation (894, 
9.9%). Complete data analyses were carried out on 8053 patients. 
2.4. Results 
From 2011-2013 inclusive, 7308 of 9076 (80.5%) patients received 175 657 prescriptions for 
846 different medications from their general practices; 1770 (19.5%) patients were not 
prescribed any medications. Patients were prescribed 0-53 different medications each, 
(median 4 [IQR 1-9]). Reviewers identified 1762 medication-related harms in 976 (10.8%) 
patient records over the 3-year study period: 255 different medications were associated 
with harm. Medication-related harm accounted for 59.0% of all 2972 harms observed in the 
record review study. After applying weighting, the incidence rate of medication-related harm 
in New Zealand general practice was 73.9 harms per 1000 patient-years, and the incidence 
rate of preventable or potentially preventable medication-related harm was 15.6 harms per 
1000 patient-years (Table 2-1). Table 2-1 outlines the relationship between medication-
related harms, patient demographics, clinical variables (numbers of consultations and 
medications) and practice characteristics as unweighted data and weighted estimates. Table 
2-2 presents the logistic regression models of study variables in relation to medication-
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related harm. 
Table 2-1 Demographic data of study patients, clinical exposure and practices in relation to 
medication-related harm related to GP prescribing 






  Unweighted study data, n (%) Weighted data, n (%)a 
Total  8100 (89.2) 976 (10.8) 3,737,889 (88.2) 502,404 (11.8) 
PATIENTS      
Age  
 
0-4 years 296 (94.6) 17 (5.4) 146,698 (93.0) 11,114 (7.0) 
5-14 years 1283 (97.6) 32 (2.4) 599,128 (96.5) 21,511 (3.5) 
15-59 years 4765 (93.3) 345 (6.8) 2,274,914 (92.1) 195,620 (7.9) 
60-74 years 1217 (80.0) 305 (20.0) 504,945 (76.7) 153,736 (23.3) 
75+ years 539 (66.1) 277 (34.0) 212,204 (63.8) 120,424 (36.2) 
Sex  Female 4189 (87.8) 583 (12.2) 1,972,810 (86.9) 298,012(13.1) 
Male 3911 (90.9) 393 (9.1)  1,765,079 (89.6) 204,392 (10.4) 
Ethnicityb 
 
European 6092 (88.4) 797 (11.6)  2,901,377 (87.1) 428,700 (12.9) 
Māori 1207 (91.0) 119 (9.0) 385,728 (90.2)  42,081 (9.8) 
Pasifika 298 (94.3) 18 (5.7)  102,189 (95.0) 5,322 (5.0) 
Other 384 (94.6) 22 (5.4) 306,709 (93.7) 20,675(6.3) 
Deprivationc 
 
1 1762 (89.6) 204 (10.4)  1,165,530 (88.5) 150,861(11.5) 
2 1655 (88.9) 207 (11.1) 829,358 (87.4) 119,827 (12.6) 
3 1525 (89.7) 176 (10.3) 663,132 (89.2)  79,880 (10.8) 
4 1202 (88.8) 152 (11.2) 469,926 (87.0) 70,324 (13.0) 




0-3 2466 (99.7) 8 (0.3) 1,081,613 (99.5) 5,567 (0.5) 
4-12 3096 (95.9) 132 (4.1) 1,476,184 (94.5) 86,466 (5.5) 




0-4 4601 (98.6) 64 (1.4) 2,115,238 (98.0) 43,101 (2.0) 
5-9 2099 (89.1) 257 (10.9) 956,015 (87.3) 139,267 (12.7) 
10+ 1400 (68.1) 655 (31.9) 666,636 (67.6) 320,036 (32.4) 
PRACTICES      
Practice size 
 
Large 2650 (88.2) 353 (11.8)  2,409,416 (87.0) 358,999 (13.0) 
Medium 2729 (88.6) 351 (11.4) 927,812 (89.6) 107,132 (10.4) 
Small 2721 (90.9) 272 (9.1) 400,661 (91.7) 36,273 (8.3) 
Location 
 
Urban 4082 (89.8) 462 (10.2) 3,050,365 (88.0) 416,372 (12.0) 
Rural 4018 (88.7)  514 (11.3) 687,524 (88.9) 86,032 (11.1) 
a. Weighting was applied based on the relative probability of each practice being selected per strata, and each 
person being selected to participate per practice, due to the complex sampling design of the study. Weighting 
means these results are nationally generalisable to the New Zealand population. 
b. Missing data = 139 
c. Missing data = 894. Deprivation is based on NZDep index of socioeconomic deprivation, where 1=least deprived, 
5=most deprived.175 
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Table 2-2 Logistic regression of study variables in relation to harms arising from medication 
prescribed in general practice (binary outcome variables medication-related harm: harm or 
no harm) 
 Unadjusteda  Adjustedb  Adjusted & 
Weightedc 
 
Variable OR (95% CI) P Value OR (95% CI) P value OR (95% CI) P value 
PATIENTS       
Age       
0-4 years 0.79 (0.48-1.31) 0.365 0.56 (0.31-1.00) 0.049 0.75 (0.42-1.33) 0.308 
5-14 years 0.34 (0.24-0.50) <0.001 0.60 (0.41-0.88) 0.010 0.58 (0.31-1.10) 0.095 
15-59 years 1 [Reference] - 1 [Reference] - 1 [Reference] - 
60-74 years 3.46 (2.93-4.09) <0.001 1.81 (1.49-2.19) <0.001 1.98 (1.50-2.61) <0.001 
75+ years 7.10 (5.92-8.51) <0.001 2.86 (2.30-3.56) <0.001 3.08 (2.15-4.41) <0.001 
Gender       
Male 1 [Reference] - 1 [Reference] - 1 [Reference] - 
Female 1.39 (1.21-1.59) <0.001 1.07 (0.91-1.26) 0.397 0.98 (0.68-1.43) 0.931 
Ethnicity       
European 1 [Reference] - 1 [Reference] - 1 [Reference] - 
Māori 0.75 (0.62-0.92) 0.006 1.03 (0.81-1.32) 0.790 1.01 (0.81-1.27) 0.924 
Pasifika 0.46 (0.29-0.75) 0.002 0.57 (0.33-0.96) 0.036 0.43 (0.19-0.98) 0.045 
Other 0.44 (0.29-0.69) <0.001 0.86 (0.52-1.42) 0.554 0.68 (0.41-1.15) 0.145 
Deprivationd       
1 1 [Reference] - 1 [Reference] - 1 [Reference] - 
2 1.08 (0.88-1.33) 0.459 1.00 (0.80-1.27) 0.969 1.04 (0.79-1.37) 0.783 
3 1.00 (0.81-1.23) 0.977 0.92 (0.72-1.18) 0.528 0.86 (0.58-1.29) 0.457 
4 1.09 (0.87-1.36) 0.437 1.05 (0.82-1.36) 0.685 1.15 (0.80-1.65) 0.443 
5 1.13 (0.90-1.41) 0.292 1.14 (0.87-1.49) 0.360 1.05 (0.58-1.90) 0.871 
Consultations       
0-3 1 [Reference] - 1 [Reference] - 1 [Reference] - 





<0.001 11.83 (4.27-32.80) <0.001 
Medications       
0-4 1 [Reference] - 1 [Reference] - 1 [Reference] - 
5-9 8.80 (6.66-11.63) <0.001 3.41 (2.45-4.74) <0.001 3.05 (2.10-4.44) <0.001 
10+ 33.63 (25.84-43.78) <0.001 7.25 (5.19-10.11) <0.001 5.71 (3.83-8.50) <0.001 
PRACTICES       
Practice size       
Large 1 [Reference] - 1 [Reference] -  1 [Reference] - 
Medium 0.97 (0.83-1.13) 0.662 0.91 (0.75-1.10) 0.336 0.72 (0.46-1.11) 0.134 
Small 0.75 (0.64-0.89) <0.001 0.75 (0.61-0.93) 0.008 0.65 (0.44-0.95) 0.027 
Location       
Urban 1 [Reference] - 1 [Reference] - 1 [Reference] - 
Rural 1.13 (0.99-1.29) 0.071 0.92 (0.78-1.08) 0.203 0.78 (0.55-1.09) 0.145 
a. Unadjusted: Unweighted univariate logistic regression  
b. Adjusted: Unweighted multiple logistic regression to adjust for potential confounders – all other variables were 
considered potential confounders 
c. Adjusted and Weighted: Multiple logistic regression weighted for the relative probability of each person being 
selected as a study participant 




Older patients were more likely to experience medication-related harm. In the final model 
(adjusted and weighted) patients aged 60-74 years had double the odds of experiencing 
medication-related harm (odds ratio [OR] 1.98, 95% confidence interval [CI] 1.50-2.61), and 
patients 75 years and older had triple the odds (OR 3.08, 95%CI 2.15- 4.41), compared to 
patients aged 15-59 years. 
Women appeared to be at increased risk of medication-related harms in the unadjusted 
model, however after adjustment for the other variables there was no difference in risk by 
sex. The smallest ethnic group was Pasifika ethnicity (n=316, 3.5%), which had a lower risk of 
experiencing harm than Europeans (OR 0.43, 95%CI 0.19-0.98) (Table 2-2). There was no 
evidence that social deprivation was associated with medication-related harm. 
2.4.2. Clinical exposure 
Increasing number of consultations and medications were correlated with increased risk of 
medication-related harm. Compared to patients who had 0-3 consultations over the study 
period, the odds of experiencing medication-related harm for patients that had 4-12 
consultations over the three year study period was 5.38 (95%CI 1.55-18.67) times greater; 
for patients with >13 consultations over 3 years the odds were 11.83 (95%CI 4.27-32.80) 
times greater (Table 2-2). Similarly, when compared with patients prescribed 0-4 unique 
medications in the study period, being prescribed 5-9 medications was associated with an 
increased OR of medication-related harm of 3.05 (95%CI 2.10-4.44). Being prescribed >10 




Practice size was associated with risk of medication-related harm, but practice location was 
not. Patients attending small practices had a lower OR of experiencing medication-related 
harm compared to patients attending large practices (OR for patients attending small-sized 
practices 0.65, 95%CI 0.44-0.95; OR for patients attending medium-sized practices 0.72, 
95%CI 0.46-1.11) (Table 2-2). 
2.4.4. Harms 
Most medication-related harm was directly related to the medication (1673/1762, 94.9%), 
but 5.1% was attributable to indirect causes such as access, communication (for example, 
asthma deteriorated as patient did not understand fluticasone needed to be taken 
regularly), or procedures (for example, local pain and swelling following administration of 
vaccine). Gastroenterological effects were the most common harm type by body system 
(n=387, 22.0%) (Table 2-3). Medication-related harms were mainly of minor severity 
(n=1385, 78.6%) (for example, angiotensin-converting enzyme inhibitor cough). Most 
medication-related harms were not preventable (n=1432, 81.3%) (for example, weight gain 
with oral contraceptive); the remainder were considered preventable or potentially 
preventable (n=330, 18.7%) (for example, cardiac arrest following co-prescription of 
medications which increased the QT interval). One in five medication-related harms were 
moderately severe (n=373/1762, 21.1%) (for example, developed type 2 diabetes following 
long-term course of prednisone) or severe (n=44, 2.5%) (for example, ventricular tachycardia 
and cardiac arrest attributed to amiodarone causing prolongation of the QT interval), and 
four harms were associated with the death of 3 patients (n=4, 0.2%). Eighteen patients were 
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hospitalised as a result of medication- related harm, representing 0.2% (n=18/9076) of all 
study patients and corresponding to a weighted hospitalisation rate of 1.1 per 1000 patient-
years. 
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Generally unwell  63 (33.9) 75 year old female felt dizzy and sleepy after taking donepezil. 
Mild severity, not preventable. 
 
10 year old male experienced anorexia and poor weight gain on 
methylphenidate. Mild severity, potentially preventable.  
Fatigue  47 (25.3) 
Weight change  24 (12.9) 
Exacerbation of 
existing condition  
20 (10.8) 





diarrhoea 213 (55.0) 
2 year old female developed diarrhoea after taking amoxycillin. 
Mild severity, not preventable.  
 
81 year old male developed severe constipation from codeine 
requiring hospitalisation. Severe harm, potentially preventable. 
Constipation 53 (13.7) 
Dyspepsia 48 (12.4) 
Bleeding 28 (7.2) 
Pain 12 (3.1) 
Other 33 (8.5) 
Cardiology 
217 (12.3) 
Hypotension 136 (62.7) 93 year old male experienced recurrent falls secondary to 
hypotension while taking cilazapril, metoprolol, frusemide and 
isosorbide mononitrate. Moderate severity. Potentially 
preventable. 
Heart failure  39 (18.0) 
Arrhythmias 27 (12.4) 
Other 15 (6.9) 
Neurology 
192 (10.9) 
Cognition 61 (31.8) 83 year old woman experinced a haemorrhagic cerebrovascular 
accident after commencing aspirin and clopidogrel, resulting in 
death. Not preventable. 
 
79 year old man developed postural hypotension while taking 
metoprolol and cilazapril. Fell and developed a subdural 
haemaotoma, died during hospitalisation for this. Potentially 
preventable. 
Sensory 41 (21.4) 
Headache 35 (18.2) 
Balance 32 (16.7) 











69 year old male with severe chronic renal failure died within two 
weeks of an increased dose of metformin and allopurinol. Death. 





Pain 75 (70.1) 81 year old male experienced repeated episodes of gout while 
taking bendrofluazide. Mild severity. Potentially preventable. Gout 18 (16.8) 




Rash 50 (48.1) 8 year old female developed scalp irritation and discomfort after 
using malathion shampoo. Mild severity, not preventable.  Itch 23 (22.1) 








 66 (65.3) 
53 year old male experienced vivid dreams and sleep disturbance 
while taking varenicline. Mild severity. Not preventable. 
 
43 year old female described as abusing prescribed codeine. 
Moderate severity. Potentially preventable.  
Sleep disturbance 
 26 (25.7) 
Addiction 
 9 (8.9) 
Haematology 
81 (4.6) 
Haematology 77 (95.1) 49 year old male developed thrombocytopenia while taking 





Diabetes related 48 (67.6) 71 year old female taking glipizide and insulin experienced 
recurrent hypoglycamic episodes. Moderate severity. Potentially 
preventable. 
Sweating and 
flushing 10 (14.1) 





Bleeding 34 (56.7) 51 year old female on dabigatran experienced menorrhagia 
requiring a blood transfusion. Moderate severity. Not 
preventable. 
Infection/discharge 18 (30.0) 
Pregnancy 8 (13.3) 
Respiratory  
57 (3.2) 
Cough & wheeze  57 (100.0) 71 year old male developed acute pneumonitis while taking 





38 (100.0) 32 year old male required hospitalisation and time off work for a 
GI bleed while taking diclofenac and no proton-pump inhibitor. 




Table 2-4 shows harm by ATC classification group. Harms from cardiovascular medications 
(ATC Group C), predominantly antihypertensives and statins, affected the most patients; 517 
patients were harmed of 5965 patients prescribed those medications (8.7%); 2.1% 
(n=11/517) of those harms were severe. Antineoplastic and immunomodulatory agents (ATC 
Group L) had the highest rate of harm (n=21/131, 16.0%) but none of the harms were 
severe, and these agents were taken by only 1.4% (n=131/9076) of patients. 
Medication relating to blood and blood forming organs (ATC Group B) were the third most 
harmful agents affecting 6.0% (n=102/1688) of study patients taking those medications, the 
most harmful being dabigatran (B01AE07), warfarin (B01AA03) and dipyridamole (B01AC07). 
This group had the highest proportion of severe harms (6.9%, n=7/102). Analgesia, 
antibiotics and asthma medications were among the most commonly prescribed medication 
types. Of these commonly prescribed medications, diclofenac and amoxicillin with clavulanic 
acid were associated with the most harm (n=27/1016, 2.7% and n=21/926, 2.3% 
respectively). 
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Table 2-4 Medication-related harm by Anatomical Therapeutic Chemical (ATC) classification 
group 
  Patients harmed/ Patients 
prescribed unique 
medicine, n (%) 
N=1,433/55,340 (2.6)a 
Percentage of patients 
harmed as a proportion of 
medication-related harm by 
ATC class 
1,433/1,433 (100) 
A Alimentary tract and metabolism 124/6,174 (2.0) 8.7 
B Blood and blood forming organs 102/1,688 (6.0) 7.1 
C Cardiovascular system 517/5,956 (8.7) 36.1 
D Dermatologicals 25/6,385 (0.4) 1.7 
G 
Genitourinary system and sex 
hormones 
52/1,482 (3.5) 3.6 
H Systemic hormonal preparations 30/1,653 (1.8) 2.1 




21/131 (16.0) 1.5 
M Musculoskeletal system 91/4,600 (2.0) 6.4 
N Nervous system 291/9,178 (3.2) 20.3 
P 
Antiparasitics, insecticides and 
repellents 
4/377 (1.1) 0.3 
R Respiratory system 16/5,612 (0.3) 1.1 
S Sensory organs 7/1,330 (0.5) 0.5 
V Various 1/98 (1.0) 0.1 
a. Each unique medicine was counted once per patient. Some patients were prescribed more than one medicine in each ATC 
code. ATC = Anatomical Therapeutic Chemical.  
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2.5 Discussion 
The incidence rate of medication-related harm in New Zealand general practice after 
weighting was 73.9 harms per 1000 patient-years; the incidence rate of potentially 
preventable medication-related harm was 15.6 harms per 1000 patient-years. Most 
medication-related harms were of minor severity, but three patients died. The 
hospitalisation rate was 1.1 per 1000 patient-years. Factors strongly associated with 
medication-related harm were increasing age and clinical exposure. Pasifika ethnicity and 
attending a small practice were protective. Cardiovascular medications caused the most 
harm. 
2.5.1. Strengths and Limitations 
General practice records are a rich data source permitting comprehensive review of 
medication-related harms.49 The authors believe this large, detailed, retrospective review of 
a nationally representative sample of general practice records is likely to provide the closest 
possible estimate of medication-related harm in the real-world. Harm rates are generalisable 
to the entire country. There have been few appreciable changes in New Zealand general 
practice prescribing since the study period, although medication use and polypharmacy have 
increased slightly.180,181 
Harm rates presented should be considered a conservative estimate. Only recorded harms 
are included; it is unknown how many additional harms occurred but were not recorded. The 
authors assume all patient participants selected at the mid-point of the study period 
remained enrolled for the three year study period. Medication-related harms were only 
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included if there was a prescription for the corresponding agent in the electronic medical 
record. Therefore, harms arising from medications administered or dispensed in general 
practice without a prescription (for example, some contraceptives, practitioner supply 
medications182 etc.) were not included. Additionally, controlled drugs such as morphine and 
methylphenidate required a hand-written prescription during the study period, but a 
concurrent electronic prescription may not have been generated. Harms were recorded 
verbatim – for example, it is not possible to know whether someone would have 
experienced haematemesis regardless of whether they had been taking diclofenac. 
Harm estimates are not easily comparable between studies due to variations in terminology 
and methodology.23,26,108 Critics of the record review method point to this and object to low 
rates of reproducibility.50,51 However, the records review method is comprehensive and 
provides unique insight into the patient experience of medication- related harm.49 Reviewer 
training and feedback was used to improve reviewer concordance. 
2.5.2. Comparison with existing literature 
The authors’ research found medication-related harm was common, for several reasons. 
Records were examined for all medication-related harm and not just preventable adverse 
events or patient-safety incidents; the patient-focused definition of harm is comprehensive; 
and the authors examined all patient records (not just those considered high risk or 
identified by a trigger tool). The figures are therefore higher than published figures, although 
comparisons between these types of studies is difficult. The most comparable systematic 
review estimated the incidence of preventable adverse drug events as 15 per 1000 person-
years,108 which is equivalent to our incidence rate for preventable or potentially preventable 
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medication-related harm. Other studies indicate medication-related harm is a substantial 
problem, but are less comparable with our findings. One meta-analysis found up to 24 
patient safety incidents per 100 primary care consultations, with up to 11% of medication-
related incidents resulting in patient harm,107 a literature review found up to 2.3% of deaths 
followed adverse events attributable to primary care treatment, with up to 42% of serious 
medication-related harms in primary care considered preventable,183 while a record review 
study found 25.7% of preventable harms attributable to medication.110 
2.5.3. Implications for research and practice 
General practice has been considered a relatively safe health care setting. This study found 
medication-related harm is common in general practice, mostly minor and not preventable, 
often arising from standard care. However, sometimes harms resulted in severe outcomes 
including hospitalisation and death; one in four harms were considered at least potentially 
preventable.d These findings reinforce the need for vigilance and care in even routine 
medication use. 
This research adds to the field’s knowledge of which patients are at highest risk of 
medication-related harm; namely, patients who are older, who have more consultations and 
who take more medications. Identifying these patients may help inform shared decision-
making at the time of prescribing and target risk monitoring. Further research is required to 
determine how best to address and reduce the risk of medication-related harm in the 
context of routine general-practice prescribing.  
Medication-related harm in general practice is common. This study builds on the evidence 
                                                          
d Erratum: One in five harms were considered at least potentially preventable.  
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base about the risk posed by medication in the real world. Findings can be used to inform 
decision-making in general practice and to target patient safety initiatives towards patients 
at higher risk of harm. 
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2.8 Chapter Summary 
This chapter has examined the extent of medication-related harm arising from prescribing in 
NZ general practice. Medication harm is relatively common. Most medication-related harms 
were considered not preventable, but approximately 1 in 5 harms were considered 
potentially preventable. People at higher risk of harm are those who are older, take more 
medication, and those who attend their general practice clinic more frequently. These data 





Chapter 3 Evaluation of equity in use of an automated 
clinician alert system 
 
3.1. Preface 
The following chapter contains a published original manuscript titled “Medication risk 
management and health equity in New Zealand general practice: a retrospective cross- 
sectional study.” It was published in the International Journal for Equity in Health in 2021: 
Leitch S, Zeng J, Smith A, Stokes T. Medication risk management and health equity in New 
Zealand general practice: a retrospective cross-sectional study. Int J Equity Health. 
2021;20(119):1-8. doi:10.1186/s12939-021-01461-y. The manuscript is presented here as 
published, but has been reformatted to fit the overall thesis style and referencing. 
As discussed in the Introduction, health equity is a major concern of the NZ health system. 
Historic injustices and racism have resulted in poor health outcomes for Māori and Pasifika 
patients. NZ law and health policy recognise the rights of all citizens to fair and equitable 
treatment. Using the record review method, we found a medication-related harm rate of 
73.9 per 1000 patient-years in NZ general practice (Chapter 2). Although no differences were 
detected in harm rates by ethnicity, these likely still exist. This finding may represent 
inequitable access to healthcare; however, that study was not powered to detect differences 
in consultation rates or harm rates by ethnicity.  
Various patient safety tools and technologies have been developed to try and prevent or 
mitigate harm arising from medication for all patients. Conporto Health has developed an 
Event Detection and Mitigation alert system (Conporto EDM) to alert clinicians when their 
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patients are at higher risk of experiencing harm from medication.184 In this system, an 
automatic electronic record scan is triggered by the patient making an appointment or 
requesting a prescription, or by presenting to the emergency department (ED), as shown in 
Figure 3-1. If the scan detects a pre-specified alert, then a warning alert is sent to the clinician, 
as depicted in Figure 3-2. Conporto EDM was trialled in 2018 in 66 general practices located 
throughout New Zealand. In their proof-of-concept data review Conporto Health found GPs 
were not taking action to remedy the potential harm for patients of Māori and Pasifika 
ethnicity in the same way they were taking action for patients of European ethnicity. To ensure 
their tool was not worsening inequities in health, Conporto were keen to investigate this 
preliminary finding further. The aim of this project was therefore to further evaluate data from 
the Conporto Health automated clinician alert system to see whether there were differences 
in whether clinicians took action depending on the ethnicity of the patient. 




Figure 3-2 Screenshot of the Conporto PMS inbox message event notification 
 
3.1.2. Chapter Aim 
To evaluate an automated clinician alert system to see whether there were any inequities in 
clinician action taken based on patient ethnicity or other demographic factors. 
3.1.3. Candidate Contribution statement 
PhD candidate Sharon Leitch designed the study, analysed the data and wrote the 
manuscript. The full author contributor statement is found at the end of the paper. 
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3.2. Medication risk management and health equity in New Zealand general 
practice: a retrospective cross-sectional study 
Sharon Leitch sharon.leitch@otago.ac.nz (Corresponding author) Department of General 
Practice and Rural Health, Otago Medical School – Dunedin Campus, University of Otago 
Jiaxu Zeng jimmy.zeng@otago.ac.nz Department of Preventive and Social Medicine, Otago 
Medical School – Dunedin Campus, University of Otago 
Alesha Smith alesha.smith@otago.ac.nz School of Pharmacy, University of Otago 
Tim Stokes tim.stokes@otago.ac.nz Department of General Practice and Rural Health, Otago 
Medical School – Dunedin Campus, University of Otago 
3.3. Abstract 
3.3.1. Background 
Despite an overt commitment to equity, health inequities are evident throughout Aotearoa 
New Zealand. A general practice electronic alert system was developed to notify clinicians 
about their patient’s risk of harm due to their pre-existing medical conditions or current 
medication. We aimed to determine whether there were any disparities in clinician action 
taken on the alert based on patient ethnicity or other demographic factors. 
3.3.2. Methods 
Sixty-six New Zealand general practices from throughout New Zealand participated. Data 
were available for 1611 alerts detected for 1582 patients between 1 Jan 2018 and 1 July 
2019. The primary outcome was whether action was taken following an alert or not. Logistic 
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regression was used to assess if patients of one ethnicity group were more or less likely to 
have action taken. Potential confounders considered in the analyses include patient age, 
gender, ethnicity, socio-economic deprivation, number of long term diagnoses and number 
of long term medications. 
3.3.3. Results 
No evidence of a difference was found in the odds of having action taken amongst ethnicity 
groups, however the estimated odds for Māori and Pasifika patients were lower compared 
to the European group (Māori OR 0.88, 95%CI 0.63-1.22; Pasifika OR 0.88, 95%CI 0.52-1.49). 
Females had significantly lower odds of having action taken compared to males (OR 0.76, 
95%CI 0.59-0.96). 
3.3.4. Conclusion 
This analysis of data arising from a general practice electronic alert system in New Zealand 
found clinicians typically took action on those alerts. However, clinicians appear to take less 
action for women and Māori and Pasifika patients. Use of a targeted alert system has the 
potential to mitigate risk from medication-related harm. Recognising clinician biases may 
improve the equitability of health care provision. 
3.3.5. Keywords 
Ethnicity, equity, decision support, general practice, harm 
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3.4. Background 
Health inequities are defined as differences in health outcomes or risks to health between 
peoples of different social advantage.185 Te Tiriti O Waitangi (The Treaty of Waitangi), the 
founding constitutional document of Aotearoa New Zealand (NZ), upholds the ideals of 
equity and protection of Māori (the Indigenous people).79,186,187 
New Zealand provides universal cover for most health services, including hospital-based 
inpatient and outpatient care.65 Primary healthcare is delivered in community-based general 
practices. General practice services and medication for children under the age of 14 years 
are fully subsidised. However, most other patients co-pay for primary healthcare (typically 
$13 -$35 USD) and pay a small prescription charge per medication ($3.50 USD). Annual out-
of-pocket health spending per capita is $520 USD, accounting for around 12% of New 
Zealand total health spending.188 In comparison, the median weekly income is $455 USD; 
Māori and Pasifika (people living in NZ who identify as Pacific peoples) have lower median 
weekly incomes than people of other ethnicities.189 
Systemic racism is widespread in the New Zealand health system.190 Despite ambitious 
national goals to “improve, promote and protect the health and wellbeing of New 
Zealanders,”191 healthcare inequity persists for Māori and Pasifika.67 People of Māori and 
Pasifika ethnicity and people who experience socioeconomic deprivation, have excessively 
high adverse event rates, including premature mortality, injury, disability, and healthcare-
related harms.15,67,160-162,192 These groups experience under-prescribing of appropriate 
medications, higher prescribing of inappropriate medications,193 and higher rates of 
polypharmacy.36,62 
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Computerised decision support tools can help improve the quality and safety of prescribing 
by identifying and alerting clinicians to potentially dangerous prescribing actions.134,140,142,194 
Conporto Health Event Detection & Mitigation (Conporto EDM) is an automated alert system 
that detects whether general practice patients are at high risk of medical harm due to their 
medical conditions, medications, or for want of mitigating preventative action.147 Events in 
this system consist of 10 pre-specified conditions (Table 3-1). The system is triggered by 
activities such as making an appointment, or a prescription request. Clinicians are informed 
at the start of each session which of their patients to be seen are at increased risk of harm 
via secure email, with detailed information sent to the electronic health record “Inbox”. The 
“Inbox” is a portal containing all messages relevant to that patient, including laboratory 
results, radiology results, correspondence from secondary care, and Conporto EDM alerts. 
Clinicians have full discretion as to whether they act on the Conporto EDM alerts. Patients 
are not advised of the alerts unless informed by their clinician. In an attempt to avoid alert 
fatigue, clinicians are only notified of each triggered Conporto EDM alert once every three 
months. Therefore, if a Conporto EDM alert is triggered by the patient making an 
appointment or requesting more medication within three months since the last alert, the 
clinician will not be notified of those alerts. 
 




Allopurinol prescribed at a dose of >200mg/day to a patient with 
chronic renal insufficiency (eGFR <30 mL/min/1.73 m2)a 
Macrolide & simvastatin Prescription for an macrolide antibiotic, with a co-prescription 
for simvastatin 
Bupropion epilepsy Bupropion (Zyban) prescribed to a patient with epilepsy 
Metformin eGFR<30 Metformin prescribed to a patient with renal insufficiency where 
the eGFR is < 30 mL/min/1.73 m2 
MTX no Folic acid Prescription of methotrexate, without a co-prescription for folic 
acid 
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NSAID eGFR<45 Prescription of a NSAIDb, in a patient with chronic renal 
insufficiency (eGFR < 45 mL/min/1.73 m2) 
NSAID, Ulcer, no PPI Prescription of a NSAID, without co-prescription for an proton-
pump inhibitor to a patient with a history of peptic ulceration 
PDEi & Nitrite Prescription of a phosphodiesterase type-5 inhibitor, with a co-
prescription for a nitrate 
Valproate F epilepsy Prescription of sodium valproate to a female aged 10-59 years 
with a diagnosis of epilepsy, without history of hysterectomy 
Valproate F Prescription of sodium valproate to a female aged 10-59 years, 
without history of hysterectomy OR epilepsy 
aeGFR = estimated glomerular filtration rate, specified here as having been calculated with the Cockcroft-Gault equation 
bNSAID = Non-steroidal anti-inflammatory drug, e.g. aspirin, ibuprofen, diclofenac, etc. 
 
Preliminary analysis of Conporto EDM data from 1 March – 31 October 2018 was undertaken 
by Conporto Health.147 This suggested that although general practitioners did generally take 
action following an event alert notification, when analysed by individual harm event they 
appeared less likely to take action for Māori and Pasifika patients.147 However, important 
confounders were not adjusted for in those analyses. Also, action rates were evaluated by 
individual event, even though four of the event groups were too small to make statistical 
inferences when broken down by ethnicity. We therefore re-examined the association 
between the actions clinicians took after receiving an event alert and patient ethnicity to 
determinate robustness of the earlier findings. We did this by grouping all alerts to look at 
action taken as a whole rather than by individual event, and adjusting for a set of important 
confounders. The aim of this study is to determine whether there were any disparities in 
clinician action taken (versus no action) following an alert based on patient ethnicity or other 
demographic factors. 
3.5. Methods 
General practices were recruited from all regions of New Zealand, from those participating 
in the Conporto Health Look-Up programme (an online platform presenting an integrated 
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summary patient record between healthcare providers). Sixty-six practices signed a 
consent form to participate in the Conporto EDM proof-of-concept trial. Study participants 
were patients attending those clinics; individual patient consent was not obtained. Ethical 
approval for this secondary data review was obtained from the University of Otago Human 
Ethics Committee (HD19/061). The project was also reviewed by the Ngāi Tahu research 
consultation committee. 
3.5.1. Derivation of study alerts 
During the proof-of-concept trial, patient clinical notes were retrospectively reviewed to 
see whether clinicians took action or not after receiving an alert. The review was 
undertaken initially by a computer programme which scanned the notes and could 
determine if action was taken depending on the text, e.g. “stop metformin”; further review 
was undertaken by a GP and a pharmacist if the results from the computer review were 
ambiguous. 
Conporto Health provided information for all alerts recorded in Conporto EDM between 1 
Jan 2018 and 1 July 2019, with patient information retrieved from the general practice 
records secondary to event data. Figure 3-3 illustrates the steps for the identification of the 
study alerts. 2499 event alerts were detected within the study period. We excluded 852 
alerts where there was no action data recorded; i.e. the medical records had not been 
reviewed to determine whether action was taken or not. A further 36 events were excluded 
which had been coded as “false positive” during the proof-of-concept trial, i.e., after 
checking the medical records, the initial alert was found to be incorrect. Alert data was 
linked with patient general practice information held by Conporto, extracted from study 
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general practices using the electronic health record. 
 
3.5.2. Primary outcome 
The primary outcome measure was whether clinicians took action or not after receiving a 
Conporto EDM alert. All alert types were analysed as one group. Alert consequences were 
categorised into “action” or “no action taken,” as determined by Conporto reviewers during 
the preliminary analysis period. 
3.5.3. Covariates 
Ethnicity is self-identified in New Zealand, and people can identify with more than one 
ethnic group.101 Prioritised ethnicity was used in concordance with standard New Zealand 
Figure 3-3 Derivation of study data 
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health and disability sector use.101 Patients were categorised to one of the following five 
categories: European, Māori, Pasifika, Asian and Other. “Other” ethnicity in this dataset 
includes people of Middle Eastern, Latin American and African ethnicities. Deprivation in 
New Zealand is assessed by geographical meshblock, by combining census data parameters 
including income, home ownership, and employment (NZDep13).195 Patients were assigned 
to the deprivation groups according to their NZDep13 score, in which deprivation increases 
by group number. Group 1 (scores 1 and 2) represents the least deprived area; groups 2 
(score 3 and 4), 3 (5 and 6), and 4 (7 and 8) are increasingly deprived, while group 5 (9 and 
10) represents the most deprived. 
In New Zealand, clinicians highlight long-term diagnoses and long-term medications in their 
patient’s electronic health record in order to provide best practice care and facilitate 
communication between healthcare providers. Typically, long-term diagnoses refer to 
conditions that the patient receives active treatment for, and serious historic diagnoses. 
Long-term medications are those which the patient is prescribed regularly (e.g., every three 
months). 
Demographic data (age at the time of the GP appointment, gender, ethnicity and 
socioeconomic deprivation) and clinical data (number of long-term diagnoses and number of 
long-term medications) were extracted from the electronic health records. Age, number of 
long-term diagnoses and long-term medications were treated as categorical variables. Age 
was divided into three clinically meaningful groups – those aged 1-49 years, 50-74 years and 
75 years and older. Numbers of diagnoses and medications are grouped into three clinically 
meaningful groups; 1-5 long-term diagnoses or long-term medications, 6-10, and 11 or more. 
3.5.4. Missing data 
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Complete data was available for 1235/1611 (76.7%) events. Information on covariates was 
missing if it was absent in the general practice records. The covariate with the most missing 
data was long-term medications (301/1611 events, 18.7%), followed by socio- economic 
deprivation (181/1611, 11.3%) and long-term diagnoses (144/1611, 8.9%). 
3.5.5. Statistical analyses 
Logistic regression with robust standard error was used to investigate if the actions taken 
differed across ethnicity groups. Robust standard error allows correlations between the 
events reported from the same patient. We considered potential confounding by age, 
gender, socio-economic deprivation, number of long-term diagnoses, and number of long-
term prescriptions. Each covariate was initially fitted separately, then with ethnicity. The 
final model included all covariates. 
Unadjusted and adjusted odd ratios along with 95% CI were reported for each covariate. 
Finally, the EDM alerts were analysed by event type. The number and proportion of notified 
alerts were reported and of those alerted events, those of actioned events were also 
reported. Complete-case analysis was used for handling missing data and was performed 
based on 1235 events. All statistical analyses were performed using Stata software version 
15.1.196 
3.6. Results 
Table 3-2 shows events by patient demographic and clinical covariates, by action (whether 
action was taken or not). 
Around half of the alerts resulted in an action (791/1611, 49.1%). Most alerts occurred in 
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patients aged at least 50 years old (1313/1611, 81.5%) and female (1004/1611, 62.3%). 
There was no clear pattern of action taken by age group. Females had proportionally less 
action taken than males (female action taken 458/1004, 45.6%; male 333/607, 54.9%). 
NZ European ethnicity constituted 70.6% of the sample (1137/1611), Māori 241 (15.0%), 
Pasifika 82 (5.1%), Asian 101 (6.3%) and Other 50 (3.1%). Patients of Asian ethnicity were 
proportionally most likely to have action taken (59/101, 58.4%), and patients of Other 
ethnicity were least likely to have action taken (17/50, 34.0%). More than 40% of the sample 
lived in areas of high deprivation (NZDep13 quintile 4 or 5 = 692/1611, 43.0%). There was no 
clear pattern in the proportion of action taken by deprivation. 
The median number of long term diagnoses was 6 (IQR 3-8), and the median number of long-
term medication 7 (IQR 4-10). There appeared to be a positive trend towards more action 
taken with increasing number of both long-term diagnoses and long-term medications. 
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Table 3-2 Table of events by patient demographic and clinical covariates 
Variable  No Action 
n=820 (50.9%)a 
Action  
n=791 (49.1%) a         
Total 
n=1611 (100%) b 
Age in years    
1-49 166 (55.7) 132 (44.3) 298 (18.5) 
50-74 351 (47.4) 389 (52.6) 740 (45.9) 
75 or more 303 (52.9) 270 (47.1) 573 (35.6) 
Missing 0 0  0 
    
Gender      
Male  274 (45.1) 333 (54.9) 607 (37.7) 
Female  546 (54.4) 458 (45.6) 1004 (62.3) 
Missing 0 0 0 
       
Prioritised Ethnicity    
European 577 (50.8) 560 (49.3) 1137 (70.6) 
Māori 128 (53.1) 113 (46.9) 241 (15.0) 
Pasifika 40 (48.8) 42 (51.2) 82 (5.1) 
Asian 42 (41.6) 59 (58.4) 101 (6.3) 
Other  33 (66.0) 17 (34.0) 50 (3.1) 
Missing 0 0 0 
    
Deprivationc    
   1    103 (48.6) 109 (51.4) 212 (13.2) 
   2    119 (52.2) 109 (47.8) 228 (14.2) 
   3    159 (53.4) 139 (46.6) 298 (18.5) 
   4    172 (49.7) 174 (50.3) 346 (21.5) 
   5    167 (48.3) 179 (51.7) 346 (21.5) 
Missing 100 (55.3) 81 (44.8) 181 (11.3) 
    
Long-term diagnoses      
1-5 376 (52.5) 340 (47.5) 716 (44.5) 
6-10 287 (49.9) 288 (50.1) 575 (35.7) 
11 or more 75 (42.6) 101 (57.4) 176 (10.9) 
Missing 82 (56.9) 62 (43.1) 144 (8.9) 
    
Long-term medications     
1-5 281 (53.3) 246 (46.7) 527 (32.7) 
6-10 244 (47.0) 275 (53.0) 519 (32.2) 
11 or more 112 (42.4) 152 (57.6) 264 (16.4) 
Missing 183 (60.8) 118 (39.2) 301 (18.7) 
 a Action Columns show number, row percentage 
 b Total Column shows number, column percentage for each section 
 c Deprivation: 1 represents the least socioeconomically deprived, 5 the most deprived. 
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Table 3-3 shows that the adjusted odds of having action taken for Māori patients was 0.88 
(95%CI 0.63-1.22) times that of European patients. Similarly, Pasifika ethnicity was 
associated with a reduced adjusted odds of receiving actions (OR=0.88, 95%CI 0.52-1.49) 
compared to Europeans. Although the estimated odds suggest that Māori and Pasifika 
patients were less likely to be treated, the results are not statistically significant. In addition, 
patients of Asian ethnicity had increased odds of having action taken (OR 1.39, 95% CI 0.86-
2.23), however the association was not statistically significant. 
Women had reduced odds of having action taken compared to men in both the unadjusted 
and adjusted models. After adjusting for confounding, the odds ratio for women having 
action taken for an alert was 0.76 (95%CI 0.59-0.96). There was no association found 
between action taken and age, social deprivation, number of long-term diagnoses, or 
number of long-term medications. 
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Table 3-3 The unadjusted and adjusted odds ratios of action for all events taken, by patient 
characteristics and clinical covariates 
Variable  No Action 
n=820 (50.9%)a 
Action  
n=791 (49.1%) a         
Total 
n=1611 (100%) b 
Age in years    
1-49 166 (55.7) 132 (44.3) 298 (18.5) 
50-74 351 (47.4) 389 (52.6) 740 (45.9) 
75 or more 303 (52.9) 270 (47.1) 573 (35.6) 
Missing 0 0  0 
    
Gender      
Male  274 (45.1) 333 (54.9) 607 (37.7) 
Female  546 (54.4) 458 (45.6) 1004 (62.3) 
Missing 0 0 0 
       
Prioritised Ethnicity    
European 577 (50.8) 560 (49.3) 1137 (70.6) 
Māori 128 (53.1) 113 (46.9) 241 (15.0) 
Pasifika 40 (48.8) 42 (51.2) 82 (5.1) 
Asian 42 (41.6) 59 (58.4) 101 (6.3) 
Other  33 (66.0) 17 (34.0) 50 (3.1) 
Missing 0 0 0 
    
Deprivationc    
   1    103 (48.6) 109 (51.4) 212 (13.2) 
   2    119 (52.2) 109 (47.8) 228 (14.2) 
   3    159 (53.4) 139 (46.6) 298 (18.5) 
   4    172 (49.7) 174 (50.3) 346 (21.5) 
   5    167 (48.3) 179 (51.7) 346 (21.5) 
Missing 100 (55.3) 81 (44.8) 181 (11.3) 
    
Long-term diagnoses      
1-5 376 (52.5) 340 (47.5) 716 (44.5) 
6-10 287 (49.9) 288 (50.1) 575 (35.7) 
11 or more 75 (42.6) 101 (57.4) 176 (10.9) 
Missing 82 (56.9) 62 (43.1) 144 (8.9) 
    
Long-term medications     
1-5 281 (53.3) 246 (46.7) 527 (32.7) 
6-10 244 (47.0) 275 (53.0) 519 (32.2) 
11 or more 112 (42.4) 152 (57.6) 264 (16.4) 
Missing 183 (60.8) 118 (39.2) 301 (18.7) 
 a Action Columns show number, row percentage 
 b Total Column shows number, column percentage for each section 
 c Deprivation: 1 represents the least socioeconomically deprived, 5 the most deprived. 
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Table 3-4 shows that just under half of the events were actioned overall (791/1611, 49.1%). 
The majority of events were notified (1358/1611, 84.3%). Of those notified, 58.2% 
(791/1358) were actioned. The most common event detected was co-prescription of a 
macrolide antibiotic and simvastatin. This accounted for more than one quarter of events 
(425/1611, 26.4%). The least common event was a prescription for buproprion in a patient 
diagnosed with epilepsy (4/1611, 0.3%). Excluding buproprion, notification rates ranged 
from 98.2% (160/163 females of childbearing age prescribed sodium valporate for epilepsy) 
to 55.8% (24/43 patients with low renal function who were prescribed a high dose of 
allopurinol). Clinicians proportionally took the most action for patients who were taking 
methotrexate but not folic acid (98/155, 63.2%), and (excluding buproprion) the least action 
for females of childbearing age taking sodium valproate for epilepsy (48/163, 29.5%). 
Individual event action rates (excluding buproprion) following notification ranged from 
30.0% - 87.5%. 
 
Table 3-4 All Conporto EDM Alerts 
Alert N  
(% of all events) 
Notified      
(%  of event) 
Actioned  
(% of notified) 
Macrolide & Simvastatin 425 (26.4) 363 (85.4) 239 (65.8) 
NSAID eGFR<45 372 (23.1) 302 (81.2) 165 (54.6) 
Meformin eGFR<30 187 (11.6) 161 (86.1) 113 (70.2) 
Valproate F 178 (11.1) 157 (88.2) 63 (40.1) 
Valproate F epilepsy 163 (10.1) 160 (98.2) 48 (30.0) 
MTX no folic acid 155 (9.6) 118 (76.1) 98 (83.1) 
PDEi & Nitrite 51 (3.2) 44 (86.3) 29 (65.9) 
Allopurinol >200mg eGFR<30 43 (2.7) 24 (55.8) 21 (87.5) 
NSAID, ulcer, no PPI 33 (2.1) 25 (75.8) 15 (60.0) 
Buproprion epilepsy 4 (0.3) 4 (100) 0 (0) 
80  
3.7. Discussion 
3.7.1. Summary of findings 
We found no evidence supporting the assertion that Māori or Pasifika ethnicity groups are 
associated with lower odds of clinicians taking action after an alert based on the reported 
confidence intervals. However, the estimated odds ratios do suggest that Māori or Pasifika 
ethnicity is associated with lower odds of clinicians taking action after an alert. Women had 
nearly double the number of alerts compared to men, which is consistent with the fact 
women see their GPs more frequently than men, even after excluding consultations relating 
to gynaecological and obstetric conditions.197 Our study suggests that females were less 
likely to have action taken compared to males following an alert. Women have a long history 
of experiencing inequitable health care compared to men, such as receiving less pain relief 
for similar levels of acute and chronic pain.198,199 This may be attributable to the status of 
women in society; addressing gender equality is considered an important factor in improving 
women’s health.200 
3.7.2. Strengths and limitations 
This paper provides a snapshot of high-needs general practice patients in New Zealand, as 
well as some of the risks they are exposed to while receiving routine healthcare. This study 
had a wide geographical spread of patients, and an ethnic distribution profile similar to the 
New Zealand population, although the study had a lower proportion of Asian patients and a 
higher proportion of Other ethnicities.201 A weakness of this study is that it could be 
underpowered to detect differences by ethnicity. Also, one quarter of participants had at 
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least one missing covariate, and thus were not included in the analysis. 
3.7.3. Comparison with existing literature 
The underlying premise of this work was a rich literature demonstrating increased risk of 
harm and unfair treatment of people based on ethnicity. This is well documented for Māori 
and Pasifika patients.67,190 Migrants and people who don’t speak English face additional 
challenges in a healthcare setting due to cultural and language barriers.202,203 In  addition, 
preliminary review of these data led us to anticipate differences in clinician action based on 
ethnicity. 
Our findings suggest patient gender is associated with whether general practice clinicians 
take action after receiving an alert. It is possible that patient ethnicity also has some effect, 
although our results are not statistically significant. While other factors may be at play, 
implicit associations of gender and ethnicity can play a role in medical judgement and result 
in biased provision of care.204-207 
3.7.4. Implications for health policy 
As the proportion of older patients increases in New Zealand general practice, so too do 
their numbers of long-term conditions and long-term medications.62,181 The burden of 
multimorbidity is known to be particularly high for Māori and Pasifika patients.61 These 
factors add to the complexity of general practice consultations.60 Targeted alert systems can 
help busy general practitioners identify patients at greatest risk of experiencing medication-
related harm, and take actions to mitigate those risks.142,208 Clinicians in this study took 
action following receipt of targeted event alerts more often than not. Promoting use of such 
a system has the potential to reduce medication-related harm in general practice. 
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Inequitable care is evident throughout the New Zealand health system.67,187 The causes for 
this are multifactorial; no doubt racism and sexism contribute to health inequities, adverse 
patient experiences and negative health outcomes.209,210 While addressing these issues at a 
system level is important,67 this paper focused on the action of individual clinicians. Training 
clinicians to speak up against racism and sexism, as well as recognise their own implicit 
biases, may help reduce inequities based on those characteristics.204,211-213 
3.8. Conclusion 
This analysis of data arising from a general practice electronic alert system in New Zealand 
assessed whether clinicians took action on those alerts. Clinicians typically did take action. 
Our study has found no evidence to support the assertion that Māori and Pasifika ethnicity 
are associated with lower odds of having action taken on an alert, although the adjusted 
odds ratios suggest these ethnicity groups are associated with a lower odds, and therefore 
future studies would benefit from larger samples to investigate this research question 
further. Female sex is also associated with lower odds of having action taken. Recognising 
clinician biases may improve the equitability of health care provision. 
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3.9. List of abbreviations 
Conporto EDM – Conporto Health Event Detection & Mitigation system 
GP – general practitioner  
NZ – New Zealand 
EHR – Electronic Health Record 
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3.11. Chapter Summary 
This chapter has explored an existing data set to determine whether there were inequities 
by ethnicity in the action taken by GPs following an a patient alert. It is an example of the 
type of work that could be routinely undertaken to evaluate equity of health service 
provision. This chapter has highlighted the inherent systemic and clinician biases present in 
NZ health care delivery - taking a patient-centered approach may help address these biases. 
Chapter 4 takes this approach; patients and GPs are interviewed about a proposed tool to 
reduce harm from medication. 
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Chapter 4 Patient and prescriber perspectives on a 
decision support and communication tool 
 
4.1. Preface 
The following chapter contains a published original manuscript titled “The views of doctors 
and patients on a proposed risk assessment and communication tool: a qualitative study 
using Normalisation Process theory.” It was published in Implementation Science 
Communications in 2020: Leitch S, Smith A, Crengle S, Stokes T. The views of doctors and 
patients on a proposed risk assessment and communication tool: a qualitative study using 
Normalisation Process theory. Implement Sci Commun. 2021;2(16)1-12. doi: 
10.1186/s43058-021-00120-1. The manuscript is presented here as published, but has been 
reformatted to fit the overall thesis style and referencing. 
As discussed in the first half of this thesis, medication use in NZ general practice is associated 
with patient harm. Chapter 2 described an epidemiology of medication-related harm, finding 
an incidence of 73.9 harms per 1000 patient-years. Chapter 3 presented analysis of an alert 
system that aimed to mitigate that medication-related harm, which suggested the 
effectiveness of alerts may be affected by clinician biases. The second half of this thesis is 
informed by those data, and suggests strategies to reduce medication- related harm. 
Systems theory as applied to health care delivery was discussed in the Introduction, in 
particular the Systems Engineering Initiative for Patient Safety (SEIPS) model was introduced 
as an example of a human factors/ergonomics (HFE) framework for better understanding 
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work systems and related interactions and outcomes in healthcare. Systems theory is useful 
for analysing complex systems to help understand failure and success in the context of the 
whole system. Implementation science is related to systems theory, but has a stronger focus 
on the methods used to promote the uptake of evidence-based practices into routine use to 
improve the efficacy and quality of healthcare services. One implementation science theory 
is Normalisation Process Theory (NPT), which was chosen for use in this project as it was a 
good fit and has been widely used in this area – further details about this theoretical 
framework are elaborated on below. 
The Introduction also discussed how shared decision making can improve medication- 
safety, but poor health literacy is a common limiting factor to participating in shared 
decision-making. One potential solution is to provide patients with specific, tailored 
information about their medications at an appropriate health-literacy level. Therefore 
development of a risk assessment and communication tool was planned. In preparation, the 
work presented in this chapter was undertaken. It aimed to explore what patients and 
prescribers want in a decision support and communication tool. Ultimately, the tool was not 
developed, as a similar tool was released onto the NZ market in 2018 (Conporto Health 
EDM), and it was considered unfeasible to progress in developing the proposed tool. 
Nonetheless, the information contained in this chapter is useful to understand what the key 
stakeholders in a clinical consultation want from such a tool. 
4.1.1. Chapter Aim 
To explore what patients and prescribers would like in a decision support and 
communication tool 
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4.2. The views of New Zealand general practitioners and patients on a proposed 
risk assessment and communication tool: a qualitative study using 
Normalisation Process Theory 
 
Sharon LEITCH. Dunedin School of Medicine, University of Otago. Corresponding Author. 
Alesha SMITH. School of Pharmacy, University of Otago. 
Sue CRENGLE. Dunedin School of Medicine, University of Otago.  
Tim STOKES. Dunedin School of Medicine, University of Otago. 
4.3. Abstract 
4.3.1. Background 
Communicating risks of medication harm and obtaining informed consent is difficult due to 
structural barriers, language and cultural practices, bias, and a lack of resources 
appropriately tailored for the health literacy of most patients. A decision support tool was 
proposed to alert prescribers of risk and provide tailored information for patients to 
facilitate informed decision-making with patients and their whānau (family) around 
medication use. Patient and prescriber co-design was used to ensure the tool was designed 
to best meet the needs of end-users and avoid increasing health inequity. This paper 
describes the first stage of the co-design process. 
4.3.2. Method 
Normalisation Process Theory (NPT) was used to prospectively evaluate the tool. Semi-
structured interviews were held with fifteen patients (five Māori, five Pasifika and five NZ 
European) and nine general practitioners (two Māori and seven European). 
90  
4.3.3. Results 
Three themes were identified, which related to the three NPT concepts most relevant to 
developing the tool. Theme 1 (coherence: meaning and sense making by participants) 
explored participants’ understanding of prescribing safety, medication harm and risk, which 
is based on experience. Patients want as much information as possible about their 
medications and risk, but doctors find it difficult to communicate that information. 
Theme 2 related to the NPT concept of cognitive participation (commitment and 
engagement by participants) explored what participants thought about a prescribing 
decision support tool. Participants were cautiously optimistic, but worried about potential 
harm arising from its use. They also identified requirements for the tool and features to 
avoid. Theme 3 describes the collective action required for successful implementation of the 
tool; namely, culturally safe and trustworthy doctor-patient relationships. 
4.3.4. Conclusion 
Patients and general practitioners provided different perspectives when prospectively 
evaluating the proposed risk assessment and communication tool. This co-design research 
identified important pre-requisites for the tool and features to avoid, and novel ideas for the 
proposed tool. Overall participants supported the development of the proposed risk 
assessment and communication tool, but identified the important role that doctor-patient 
relationships would play to ensure successful implementation. Use of Māori and Pacific 
languages in the proposed tool may enhance engagement and understanding. 
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4.3.5. Keywords 
Normalisation Process Theory, Communication, Risk, Medication Harm, General Practice, 
Equity 
4.4. Contributions to the literature 
 A novel electronic decision support tool for use in New Zealand general practice aims to 
assess patient risk of medication harm, and improve risk communication and shared 
decision-making.
 Patient and general practitioner co-design aims to anticipate implementation issues, 
improve the tool’s utility, and mitigate health inequities arising from its use.
 This paper describes the use of Normalisation Process Theory as a way to aid the 
prospective evaluation of the proposed tool by general practitioners and patients.
 Normalisation Process Theory enabled exploration of the concepts of safe prescribing, 
medical autonomy, and cultural safety in the context of New Zealand general practice.
4.5. Background 
Prescribing medication presents a tension between risks and benefits. Prescribers have a 
legal and moral obligation to ensure patients are fully informed about those risks and 
benefits.148,149,214,215 Obtaining truly informed consent can be challenging due to structural 
barriers, language, differing cultural practices and expectations, bias, and a lack of resources 
appropriately tailored for the health literacy of most patients.159,192,216 
Health inequities are potentially avoidable differences in health between peoples of 
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different social groups.185 The founding document of Aotearoa New Zealand (NZ), is Te Tiriti 
O Waitangi (The Treaty of Waitangi), which, among other things, enshrines the concepts of 
equity and protection of Māori (the Indigenous people).79,186,187 Health inequity in NZ arises 
from the corrosive effects of colonisation and racism.192,217-220 Aspirational goals to 
“improve, promote and protect the health and wellbeing of New Zealanders,”191 have done 
little to address the inequity experienced by Māori and Pasifika (people living in NZ who 
identify as Pacific peoples, including Samoan, Cook Islands Māori, Tongan, etc.).67   
Māori, Pasifika, and people who experience socioeconomic deprivation bear a greater 
burden of disease and have worse health outcomes across a broad range of health 
conditions in NZ, including birth outcomes, rheumatic fever, meningococcal disease, long 
term conditions, multimorbidity and cancer.61,221-226 These populations experience 
disproportionately high adverse event rates, including premature mortality, injury, disability, 
and harms arising from healthcare.15,67,160-162,192 They paradoxically experience both under-
prescribing of appropriate medications, higher prescribing of inappropriate medications,193 
and higher rates of polypharmacy.36,62 
Primary health services provide the majority of healthcare in NZ,187 typically requiring out-of-
pocket co-payments, as do prescription medications.227 The 2018-19 NZ Health Survey found 
that similar proportions of Māori, Pasifika and NZ European had attended a general 
practitioner (GP) in the previous 12 months and that the mean number of visits was higher in 
Māori (age sex standardised rate ratio 1.22).228 However, a higher proportion of the Māori 
and Pasifika populations reported unmet need for primary health care due to the cost of 
primary health care over the same period (21.9% of Māori and 19.4% of Pasifika vs 12.7% of 
European/Other).228 A higher proportion of Māori and Pasifika (11.8% of Māori and 14.0% of 
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Pasifika vs. 4.2% of European/Other) reported not having a prescription filled because of the 
cost.228 Overrepresentation of Māori and Pasifika in lower socio-economic groups 
compounds inequity.35,217 
Health literacy is the ability to obtain, process and understand health information in order to 
make informed and appropriate health-related decisions.156 Low levels of health literacy are 
associated with worse healthcare outcomes.157 New Zealanders typically have low levels of 
health literacy – over half of adults surveyed had skills “insufficient to cope with the health 
literacy demands they typically face.”159 The proportion of the Māori population with low 
health literacy levels is higher with 80% of Māori men and about 75% of Māori women 
experiencing low levels of health literacy.159 While policy and public programmes may 
address health literacy at the national level, clinicians are responsible for communicating 
health information so patients can understand, whatever their health literacy level.229 
Decision support tools can improve patient knowledge of their options and expectations of 
outcomes, support patient participation in shared decision making, and improve 
communication between patients and clinicians.158 Decision support tools available in NZ 
primary care either focus solely on medication interactions or algorithms for specific 
medication use. A novel tool which integrates these concepts would potentially address 
some of the above issues. The development of such a tool was proposed. The tool would 
alert prescribers to medication risk based on potential interactions and patient factors (e.g., 
renal function), and provide both clinician decision support and patient information, thus 
facilitating communication and supporting informed decision-making. The aim of this study 
is to determine what potential users of the tool (patients and GPs) think about the proposed 
tool. It is hoped this process will help identify unforeseen issues, such design features that 
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could exacerbate health inequities or be culturally unsafe.230 
4.5.1. Theoretical Framework 
This research utilises an implementation science approach. Implementation science has the 
capacity to increase the impact of health disparity research and mitigate inequities due to its 
broad focus on all aspects of implementation, from health policy to bedside.231-233 Further, 
implementation science theories can provide a framework for the collection and analysis of 
data and help explain the findings.234 We have chosen to use one particular implementation 
science theory: Normalisation Process Theory (NPT). NPT bridges the translational gap 
between research evidence and practical implementation, and is comprehensive, flexible 
and has a strong focus on participatory co-design.234-237 NPT has been used for research 
involving ethnic minority populations and to explore issues of equity. 238-241 NPT provides a 
useful framework for researchers to anticipate implementation issues while designing a 
complex intervention and its evaluation.235-237,242  Early use of NPT was initially in eHealth 











Table 4-1 Normalisation process theory (NPT) concepts in developing an e-tool 
 
*Appendix 2 contains the complete interview guide 
NPT Concept243  Example interview questions* 
Coherence 
Is the intervention meaningful for 
participants? Establish shared 
definitions and understanding of 
both the problem and the potential 
intervention 
Patient questions: 
What does harm from medicine mean to you? What does 
risk from medicine harm mean? 
When do you think it’s important to know about your risk 
from medication?  
Do you think it’s important to discuss medication risk with 
your GP?  
 
GP questions: 
What prompts you to consider assessing a patient’s risk 
from their medication?  
How confident do you feel explaining medication risk to 
patients? 
Cognitive Participation 
Do participants think the 
intervention is a good idea? 
Establish whether patients and 
doctors are committed to engage 
with this tool 
Patient questions: 
Do you think the proposed MedKōrero tool, to assess risk 
and improve communication about that risk, will help 
you/your whanau make decisions about treatment? 
What kind of impact would a tool like this have for 




Do you think the proposed MedKōrero tool, to assess risk 
and communicate that risk to patients, will promote shared 
decision making? Would it be helpful to your day-to-day 
work?  
Collective Action 
What work needs to be done to 
implement this new intervention? 
Ascertain the likely work 
participants will need to do to in 
relation to the tool, in order to learn 
what features the tool requires in 
order to minimise additional work. 
Patient questions: 




What kind of impact would a tool like this have in your 
clinical setting?  
What would promote its use? What would be a barrier to 
its use? 
Reflexive Monitoring 
Ascertain the likely impact of the 
tool, in order to develop the tool to 
enhance positive impact and 
minimise negative impact. 
Patients and GPs:  
Can you think of potential system-wide effects of using this 
tool? 
What would be the intended and unintended 
consequences 
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NPT considers implementation as a social process which requires ongoing work by the 
parties involved and is divided into four domains, outlined in Table 4-1: Coherence, Cognitive 
Participation, Collective Action and Reflexive Monitoring. Minimising the amount of work 
required to use the tool and any potential disruption to workflow will help ensure that the 
tool is actually used.129 
4.6. Method 
The consolidated criteria for reporting qualitative research guidelines (COREQ) were used to 
prepare this article (see Appendix 1 for full methodological details).244 
Stakeholder co-design was planned to ensure the tool was designed to best meet the needs 
of end-users.245 Semi-structured interviews were conducted using a topic guide (Appendix 
2), which was informed by the domains of NPT most relevant to prospectively evaluating a 
tool: Coherence, Cognitive Participation and Collective Action. Participants were essentially 
co-opted to participate in the cognitive work of developing ideas around the tool during the 
course of the interview. Participants were advised of the broad overview of the tool in the 
advertising material, the participant information sheet, the consent form, and verbally at the 
start of the interview as follows. “We want to develop and trial a tool, to alert primary care 
prescribers when patients are at increased risk of harm from medication. We hope this tool 
will facilitate communication about medication risks and empower shared decision-making 
about medication use between patients and prescribers. We want to talk to patients and 
prescribers about their opinions about a tool like this, to help develop a tool that is going to 
best help both patients and prescribers.” No prototype was presented as it was considered 
that may overly influence participants’ comments. 
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The prescriber (GP) interview framework was pilot tested with a GP prescriber by SL and TS 
observing, who then provided feedback on further iterations of the topic guide. No changes 
were made as a result of the pilot interview and it was not included in the analysis. The topic 
guides were used flexibly to allow participants to construct their accounts in their own 
terms. 
4.6.1. Recruitment 
A purposive sampling approach was taken for recruitment of both doctors and patients, 
with the aim of recruiting ethnically diverse samples, particularly of patients. Participants 
were recruited by personal contact and Facebook group pages. The study team anticipated 
that we would not need any more than 15 patient or GP interviews to reach data 
saturation in each group. See Appendix 1 for further details of the recruitment strategy. 
SL was identified as a GP and a PhD candidate and recruited all participants. Participants 
received information about the study and signed a consent form prior to their interview. 
4.6.2. Data collection 
SL interviewed all participants once, either in person, by phone or videoconference between 
8 April and 2 July, 2019. Face-to-face interviews were conducted in a place of the 
participants choosing; either in a University office, a café, the patient’s workplace or home. 
All interviews were conducted in English. Interviews were recorded and transcribed. 
Interview field notes were taken during phone and videoconference interviews only. One 
prescriber phone interview could not be recorded; this interview was written up from 
detailed interview notes. Two prescriber participants supplemented their interview by 
emailing further information or background documents after the interview. 
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Nine doctor and 15 patient interviews were undertaken. Data was transcribed and 
preliminary analysis occurred concurrently with the interviewing process. Data saturation 
was reached before the conclusion of these interviews with no new ideas being discussed by 
participants. 
4.6.3. Data analysis 
A deductive thematic analysis was conducted using the framework method.246 Interviews 
were coded by SL, assisted by NVivo 11 software, into the three relevant NPT domains. 
Interpretation of the data was an iterative process which was led by SL, with review of the 
codes, subcategories, categories and themes by TS. 
4.7. Results 
Fifteen patients (five Māori, five Pasifika and five European patients) and nine doctors (two 
Māori and seven European general practitioners) were interviewed (Table 4-2).  
Table 4-2 Demographic details of study participants 
  Patients Doctors 
Gender Male 4 6 
Female 11 3 
Age <50 8 4 
≥50 7 5 
Ethnicity European 5 7 
Māori 5 2 
Pasifika 5 0 
Location Rural 0 2 




Figure 4-1 outlines the Normalisation Process Theory (NPT) framework together with the 
categories and subcategories developed from the interview data, and how the coding frame 




Figure 4-1 Relationship between NPT framework, coding categories and themes 
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4.7.1. Theme 1 – “Prescribing is a risky business” [Coherence] 
Recognising the tension between the risks and benefits of medication was critical for 
understanding the rationale for the project, and both doctors and patients expressed 
cognisance of this, drawing on their experience of medication harm. Doctors based their 
understanding of risks and benefits on their clinical experience: 
“Medications are always a balance of gain or whatever you're trying to treat balanced 
against risks of potential side effects.” Doctor 9 (European female) 
Patients, on the other hand, referenced their personal or whānau (family) experiences: 
“With the preventer I take, you do have a chance of getting oral thrush in your mouth. So 
that has happened to me a couple of times. Yeah. And it's a pain in the butt, but it's better 
than having an asthma attack so I knew that it might happen. And when it did, I was like, 
well, this is the trade-off. I prefer not to have an asthma attack.” Patient 1 (Māori female) 
“I think the more medication you take the more risk of things interacting. I mean, some of 
the things I take, it says if your kidney function’s going down don’t give it, and I think, I’m 
already on it. They know I’m on it. And, you know, I accept that there are just risks you’ve 
got to take.” Patient 6 (European female)  
The doctors reported tailoring the amount and type of information to share with their 
patients depending on their perception as to what the patient would like to know. Doctors 
relied on their knowledge of their patients to determine what level of shared decision-
making was attempted: 
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“I make a rough assessment depending on how well I know them, I suppose, about how 
much they understand. It’s a dynamic thing with all those things as I go through thinking 
about it and discussing what we do, depending on how they respond, I can go a little bit 
differently. It’s not a static thing.” Doctor 7 (European male) 
Doctors found communicating information about medication and medication risks difficult. 
Barriers to communication reported included time, the challenge of presenting information 
at an appropriate health literacy level, and a perception that some patients are not 
interested in this information. Doctors typically focused on communicating the important 
risks: 
“It takes a long time to explain small risks of harms so I tend to filter out the important 
ones, or the ones I feel are important.” Doctor 3 (European male) 
“Our perception of risk is always very different to theirs. And also trying to communicate 
percentages, or you know, numbers needed to treat, all those sorts of concepts are very 
difficult for people to take on board.” Doctor 9 (European female) 
“Health literacy is a real skill I think in connecting with people and communicating on their 
level... you don’t always get that right. So it’s as much for the aggressive, in a rush person 
who is frustrated at waiting thirty minutes and just wants to pick their pills up and get out 
of there, as much as it is for the person who can’t read and write, and has difficulty in 
conceptualising how medications work, and what we mean by risk.” Doctor 5 (European 
male) 
In contrast, patient participants were keen to have as much knowledge about their 
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medications as possible. Patients frequently wanted more information than their doctor or 
pharmacist provided. They were happy to find their own information, but were concerned 
about the quality of the information they found on the internet: 
“I have admit that after five years I’ve only got a vague idea what my drugs actually do... I 
want to be more informed as to what my medication is…. I would like to be more 
empowered. To know what it is I'm taking and why I’m taking it.” Patient 2 (Māori male) 
“You can research a lot, but authenticating what's genuine and what isn't as well can also 
be huge.” Patient 9 (Māori female) 
4.7.2. Theme 2 - “Giving people the mana over their experience, their information and 
their decisions” [Cognitive Participation] 
The idea of the proposed tool was met with qualified enthusiasm from both patients and 
clinicians. Patients and clinicians wanted to include various elements as part of a risk 
assessment and communication tool (Table 4-3). Participants, both doctors and patients, 
were cautiously optimistic that the proposed tool would be beneficial. Doctors felt the tool 
had potential to reduce their workload, as having tailored risk information readily accessible 
could save time and be a useful resource for both patients and clinicians. 
Conversely, they were frank to admit they would reject anything perceived to impact 
negatively on their workflow or on the doctor-patient relationship. Doctors thought that if 
the tool worked well, it could actually prevent medication related harm, reducing patient 
morbidity and pressure on the health system: 
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“I guess you'd hope the hospital presentations would be lessened because of it, given the 
number of hospital admissions that are related to medication harm.” Doctor 3 (European 
female) 
“Realistically the consequences could be enormous if harm was prevented, and hospital 
admissions were saved.” Doctor 6 (European male) 
Patients were more positive than doctors about the concept of the tool. Patients envisaged 
the tool would provide them with trustworthy medical information that they could access 
both during their general practice consult and also later, independently of their doctor. They 
felt this would facilitate information sharing and decision-making with whānau. Patients 
equated medical knowledge with improved understanding and control of their health: 
“I'm surprised that doesn't already exist... I think what is really important is giving people 
the mana or the authority over their experience and their information and their decisions. 
I think everything else stems from that.” Patient 1 (Māori female) 
“So in terms of that decision making, some sort of tool that would allow me to know what 
it was I was taking and why would be helpful… And I suppose this is a more difficult one, I 
suppose red flags in terms of there are things that you should be keeping an eye on with 
this medication.” Patient 2 (Māori male) 
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Table 4-3 Summary of what participants want in a prescribing and communication tool 
Doctors and patients want 
 A trustworthy, endorsed tool 
 A user-friendly tool that is intuitive 
 The capacity to use on different platforms (mobile, desktop) 
Doctors want 
 A tool embedded within the patient management system 
 A tool that is fast 
 The capacity to turn on/turn off/ignore tool or parts of the tool 
 A simplified interactions checker (so prescriber doesn’t need to check each 
medication individually) 
 A tool targeted to reduce polypharmacy 
 Age and renal function integrated into any calculations 
 Children’s weight integrated into prescribing calculations (and printed on label) 
 Pregnancy or pregnancy risk factored into recommendations 
 Ethnicity (and earlier onset of disease) factored into risk weightings 
 A simple risk severity grading system (e.g. traffic light system) 
 Other risk assessment tools integrated within the one tool (e.g. CHA2DS2-VASc) 
 Patient access to empower shared decision-making 
 Streamlined monitoring for medications 
 An audit function to the tool 
 Alerts which are highly clinically relevant 
 Alternative medication suggestions (e.g. current first line agents based on 
updated prescribing or antimicrobial guidelines) 
Patients want 
 Access to the tool independent of their doctor 
 A tool that is culturally sensitive (and perhaps the potential to change language) 
 Something that is free to use and will help them understand their medications 
 “Just right” amount of information: not too much nor too little 
 Risk information presented simply (e.g. traffic light system) 
107  
However both doctors and patients were concerned there was potential for the tool to 
exacerbate harm. Too much information could put people off taking their medication or 
induce the nocebo effect: 
“How in-depth do we need to go? There are so many side effects, and we can impose our 
expectations of what patients might experience.” Prescriber 6 (European male) 
“It would be useful, but I think it could potentially scare someone off having a 
medication.” Patient 10 (Māori female) 
“If there was some kind of unintentional bias in the way medicines were talked about and 
explained, you might end up, I don't know, with one of two options sounding much more 
attractive than the other… so I think there could be unintended consequences of not being 
neutral about it.” Patient 1 (Māori female) 
The form of the tool was debated by participants. Doctors mainly discussed access from their 
perspective, access directly integrated into their electronic health record system being 
heavily preferred over a separate add-on website. Most patients thought some kind of app 
or secure website, such as accessing information via their patient portal, would be most 
useful and provide independent patient access. (In NZ, patient portals currently allow 
patients variable access into their own general practice records, depending on what their 
practice has chosen. Access ranges from minimal – booking appointments online and 
checking blood results, to open notes - where patients can see all parts of their record). 
Older patients stated they would not be able to access information if it was a technology-
based tool. This barrier was recognised by most participants: 
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“Maybe just the people who are not good with technology might struggle quite a lot.” 
Patient 8 (European female) 
 
4.7.3. Theme 3 – “Just to be greeted with ‘Kia ora!’” [Collective Action] 
Collective Action is underpinned by the concept of relational integration, which explores the 
effect of the intervention on human relationships, especially the effects on power and 
trust.236,247 Although relationships were not a particular focus of the interview questions, this 
theme was discussed in detail by all participants. They recognised that the action of 
establishing a relationship between patient and prescriber is required before any meaningful 
use of a prescribing tool or shared decision-making can take place. 
Patients were asked what features would enhance the tool and its use for them. Use of 
Māori and Pacific languages was seen as important for enhancing engagement and 
understanding both within the tool and when communicating with the clinician. Whānau are 
important contributors to decision making, therefore opportunities for including whānau 
need to be incorporated into decision making processes when using the tool: 
“Just to be greeted with ‘Kia ora!’ Little things like that make a big difference, I think when 
engaging with a clinician.” Patient 4 (Māori male) 
“Some people don't understand English. But having that written in their own language 
and they read it and understand it… I know some seniors that depend on their children or 
grandchildren to tell them and describe how to take the medicine or when to take the 
medicine. So I reckon that is really important.” Patient 14 (Pasifika female) 
“I think it's just important to include whānau in decision making. That's really important, 
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which I think is not just cultural, it just should be done anyway. A collaborative approach.” 
Patient 4 (Māori male) 
Patients wanted clinicians to use culturally safe practices and to acknowledge that people of 
different cultures may not feel comfortable attending general practice. The power imbalance 
between patients and clinicians was thought to be exacerbated by traditionally deferential 
attitudes towards clinicians, especially if they were of a different gender to the patient. 
These factors can obstruct discussions of medication risk and shared decision-making, 
particularly in the time-limited setting of a medical consultation: 
“I think there's lots of different cultural things about going to the doctor and Māori really 
feel a lot of whakamā [shyness/embarrassment] when talking about some stuff or 
depending on the doctor they get.” Patient 1 (Māori female) 
“Sometimes in a way embarrassed to talk to the doctor. Our culture is a respect. Yeah. It's 
a culture is a respect to talk to the doctor, especially the woman talk to the man, the 
doctor, man doctor.” Patient 13 (Pasifika female) 
“When, as a traditional Pasifika person, you're told, ‘This is what's going to happen. You're 
going to get this. And I know, because I'm the doctor, and I'm telling you that this 
medication will help whatever, your lumbago or hypertension or whatever it is.’ All you 
say as a traditional Pasifika person, ‘Yes, doctor. Yes, yes.’ As soon as you walk into that 
room, as soon as you walk through that door, the stethoscope or the persona of the 
person, or whatever they're wearing, takes away your right of questioning, of 
understanding.” Patient 12 (Pasifika male) 
Trust was acknowledged by both clinicians and patients as an important contributor to 
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shared decision-making. While patient-centered care encourages patients to play an active 
role in their healthcare, the traditional approach of relying on the doctor’s opinion is still an 
important factor in decision making: 
“They trust us as their doctors… I can spend a lot of time discussing the pros and cons and 
they end up saying, ‘Well what would you do, what do you advise?’” Prescriber 3 
(European male) 
“I tend to rely on my GP, I've got quite a high degree of trust for them to be able to 
manage that that risk for me.” Patient 2 (Māori male) 
“We've got a really great relationship. So I feel that he has got my best interest in mind 
when he prescribes something to me.” Patient 10 (Māori female) 
A tool that provided clinicians with tailored risk information and promoted communication 
of that information in a culturally safe and respectful way, could enhance the doctor-patient 
relationship by facilitating shared decision-making. One patient thought the tool could 
potentially redress some of the power imbalance: 
“It might be a model that would shift to having to patients having more power, I suppose 
than, rather than traditional is going to the doctor because you've got a sore throat and 
you come out with a prescription… I always think it's good when people personally have 
more power over what they need for themselves.” Patient 5 (European female) 
4.8. Discussion 
This research was conducted to determine what participants think about a proposed 
electronic prescribing, decision-support and communication tool. Doctors and patients 
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prospectively evaluated a theoretical tool in order to refine the design. The main findings are 
broadly consistent with existing research. 
In theme 1 (NPT = Coherence) patients and doctors understood the underlying premises of 
the proposed tool, particularly the tension between benefits and risks of prescribing. Few 
patient participants felt they had a good understanding of their medications, as has been 
found previously.248,249 Patients were able to clearly describe examples of both poor and 
excellent risk communication. An important finding is that patients preferred full disclosure 
of medication risks in a manner that they can understand. In contrast, doctors felt they give 
an adequate amount of information about medication and risk, based on their personal 
assessment of their patients, which may well reflect their own biases and exacerbate 
inequity.250 These findings are consistent with previous research exploring patients’ and 
doctors’ attitudes towards information sharing.251-255 As has been found elsewhere, doctors 
in our study typically found it difficult to communicate risk.256-258   
Participants actively evaluated the tool in theme 2 (NPT = Cognitive Participation), offering 
many suggestions as to how the tool could best suit their needs. Clinicians described existing 
ineffective or unworkable tools as models to avoid. They would accept a tool as proposed 
only if it was useful and was not perceived to cause additional work at the time of the initial 
clinical encounter, (although if properly implemented the tool has potential to reduce their 
workload through the prevention of harms requiring further clinical review). Their 
statements echoed the vast body of literature outlining failed e-tools and alert 
fatigue.137,138,259,260 It is critical software developers ensure the benefits of using any tool 
outweigh the clinical disruption associated with its use.129 Also consistent with existing 
research, patients want reputable medicines information that they can access on their own 
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terms and in their own time.248,251,261,262 Patients and clinicians were concerned there was a 
potential for the tool to generate negative health outcomes mainly as a result of the nocebo 
effecte; extant literature demonstrates both that these concerns have been shared by 
others,251 and the validity of both nocebo and placebo effectsf.263,264 It is difficult to 
differentiate between a nocebo effect, and patients accurately identifying adverse effects 
they have been warned about. Concerns were also raised about technology being a barrier 
for some patients, which is a known problem.265,266 
In theme 3 (NPT = Collective Action) Patients and doctors stressed the pre-eminence of 
establishing culturally safe relationships. Cultural safety is recognised as an independent 
requirement for achieving health equity.186,267 Participants emphasised the importance of 
communication, particularly the use of Māori and Pacific languages to facilitate 
understanding both in clinical settings and in the proposed tool. This is congruent with 
known strategies to improve cross-cultural communication, such as clinician training and 
enhanced use of interpreter services240,268 Trust remains a bedrock of the doctor-patient 
relationship; without shared power this approach does not promote shared decision-
making.269 Patients want to play an active part in decision-making about their health, while 
clinicians felt there was a wider range of patient responses – some patients have no interest 
in shared decision-making. The literature appears to support both perspectives.252,270-272 
The fourth NPT concept of Reflexive Monitoring,243 which ascertains the impact of a tool, 
was considered less relevant to this prospective evaluation of a potential tool. Patients and 
                                                          
e Nocebo effect – a negative treatment outcome that occurs because the patient believes the treatment will 
cause harm (Latin, nocebo = to harm) 
f Placebo effect – a positive treatment outcome that occurs because the patient believes the treatment will be 
beneficial. (Latin, placebo = to please) In clinical trials “the placebo” refers to an inert medication used to test 
the efficacy of another medication. Placebo/nocebo effects can arise from any medical treatment.  
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GPs were asked to imagine the potential system-wide effects of the tool, as well as the 
intended and unintended consequences that might arise from its use. Participants found 
these questions difficult to answer, therefore there was little relevant data pertaining to this 
concept. 
4.8.1. Strengths and limitations 
This study successfully determined what participants think about a proposed risk 
assessment and communication tool, and interprets this through the lens of NPT. This 
prospective assessment of the tool will be used to refine the proposed tool to ensure it 
meets the requirements of prescriber and patient end-users. This study lays the groundwork 
for future analysis of the tool as it progresses through development and testing phases. 
Future analyses will be able to focus on more practical elements of NPT review. Ultimately, 
it is hoped that use of the proposed tool will support patient understanding of their risk of 
harm from medication, facilitate shared decision-making, and improve the quality of 
informed consent, while not increasing health inequity. This research was designed to 
inform the development of a risk assessment and communication tool in NZ, therefore the 
findings may not be generalisable beyond this scope. 
Participants were all volunteers, and may not represent typical patients and doctors. Due to 
recruitment via Facebook, it is not known how many people chose not to participate. Patient 
participants were highly engaged in their healthcare; all patient participants wanted more 
information about their medications and participating in shared decision- making. 
Conversely, prescriber participants reported a far wider range of patient interest in active 
participation in their healthcare. Similarly, prescriber participants were those who were 
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interested in quality improvement and healthcare technology, and might not represent 
typical clinicians. 
Satisfactory ethnic diversity was obtained for patients, however each ethnicity group is not 
comparable in terms of education and background; NZ European patients were mainly 
unemployed or students, Māori patients in this study were typically highly educated, while 
the Pasifika patients were predominantly immigrants to NZ who spoke English as a second 
language. Patients therefore were not fully representative of their ethnic group, and this 
may limit the extent to which their views and experiences reflect the full range of views and 
experiences within their ethnic group. For example, traditional deferential attitudes towards 
doctors were discussed by Pasifika participants, but these attitudes are not universal 
amongst Pasifika peoples, particularly younger people and those born in NZ. Ethnic diversity 
among doctors was not intentionally sought and was consequently limited. Of the nine 
doctors only two were Māori, and there were no Pasifika doctors. 
NPT was used as a framework for developing the questions and as a sensitising device 
developing the codes and themes (Figure 4-1). NPT was useful in this context, however our 
research findings suggest the emphasis of this framework could be rearranged slightly to 
augment the construct of Coherence. Theme 1 strongly suggests personal or whānau 
experience is a critical factor in understanding medication harms for patients, and to a lesser 
degree for doctors. The lived experiences that participants bring to the sense-making work 
of establishing coherence is not explicitly recognised within the construct of Coherence as it 
is currently defined. 
Participants were united in highlighting the primacy of relationships in the context of 
healthcare provision and use of any prescribing and communication tool. Relational 
115  
Integration is included within NPT construct of Collective Action, but is only ranked second of 
the four elements that make up this construct. In earlier iterations of NPT, Relational 
Integration and the other three elements now contributing to the construct of Collective 
Action formed the entire Normalisation Process model.273 It may be that when 
implementation of a patient-facing intervention is planned using NPT, the area of relational 
integration requires more emphasis. 
4.8.2. Implications 
Given Aotearoa New Zealand’s current high levels of inequity based on ethnicity and 
socioeconomic status, it is vital to consider and pre-emptively address the potential of any 
new intervention to worsen inequity.36,274 In general terms, “upstream” actions that focus on 
equity from a health policy or systems perspective, such as improving access by reducing co-
payments for healthcare, have a far greater impact on equity than “downstream” 
interventions, such as education of individuals, or the use of a tool like that proposed.274,275 
However co-designing interventions tailored for the needs of different groups can reduce 
barriers to receiving healthcare and has the potential to reduce inequities arising from use of 
technological interventions.266,276 It is likely that a multidimensional approach is required to 
reduce health inequities, founded on culturally safe and trustworthy relationships.277 
Targeted strategies to increase technology use can go some way to bridge the digital divide, 
such as public provision of computers and internet access, while family and clinician support 
can encourage older patients to use technology.261,266 
4.8.3. Conclusion 
Patients and doctors provided different perspectives when evaluating a proposed risk 
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assessment and communication tool. Patient participants were keen to take an active part in 
their health and participate in shared decision making about their healthcare, whereas 
doctors described a wider range of interest in patient participation. NPT was a useful 
theoretical framework to conduct this evaluation and identify both requirements for the tool 
and features to avoid. This co-design research identified ideas for the proposed tool which 
had not been previously considered, such as providing patients with access to information 
about their medicines independently of their doctor. Overall patient and doctor participants 
supported the development of the proposed risk assessment and communication tool, but 
recognised successful use of the tool requires culturally safe and trustworthy doctor-patient 
relationships. Use of Māori and Pacific languages in the proposed tool may enhance 
engagement and understanding. 
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4.8.4. List of abbreviations 
GP – General Practitioner 
HRC – Health Research Council of New Zealand 
NPT – Normalisation Process Theory 
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4.10. Chapter Summary 
 
This chapter explored what patients and prescribers would like in a decision support and 
communication tool. Patients and general practitioners were interviewed about their views 
on the theoretical tool. Their responses were interpreted using an implementation science 
perspective, in the form of Normalisation Process Theory. Participants supported the 
concept of the tool overall, and made specific suggestions as to how it would be most useful 
for patients and clinicians. The results of this study were used to inform the development of 
a targeted patient information package on non-steroidal anti-inflammatory drugs (NSAIDs). 




Chapter 5 Feasibility of using an information package to 
reduce patients’ risk of renal damage 
5.1. Preface 
This work in this chapter was informed by the findings of the previous chapters. Medication 
prescribed in NZ general practice harms patients, at an incidence of 73.9 harms per 1000 
patient-years (Chapter 2). Clinician alerts have potential to prevent harm, but rely on 
clinician action (Chapter 3). Patients want relevant information about their medication 
from a trusted source, but clinicians lack time to fully inform patients about their 
medication (Chapter 4). Therefore, we wanted to develop a solution that meets the needs 
of high risk patients and test whether it was feasible to use in a research setting. We chose 
to develop an information package for patients, which they can access independent of their 
clinician. It consists of a PDF document (Figure 5-2), and an online learning exercise 
(https://www.healthnavigator.org.nz/medicines/n/nsaids-learning-activity/ ). The 
information package is designed for patients at risk of renal damage from their 
medications. It warns patients who are taking an antihypertensive plus a diuretic against 
taking anti-inflammatories. 
5.1.1. Chapter Aim 
A full randomized controlled trial is planned post-PhD to test whether this information 
changes patients’ self-reported behavior. This chapter aims to explore the feasibility of 
providing patients with a tailored information package, and to determine whether there are 
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any obstacles to successfully undertaking the full trial. 
The following chapter contains two parts: 
1. The feasibility trial protocol, which is presented as a published original manuscript titled 
“Using an Information Package to Reduce Patients’ Risk of Renal Damage: Protocol for a 
Randomized Feasibility Trial.” It was published in JMIR Research Protocols in 2021: 
Leitch S, Smith A, Zeng J, Stokes T. Using an Information Package to Reduce Patients' 
Risk of Renal Damage: Protocol for a Randomized Feasibility Trial. JMIR Res Protoc. 
2021;10(4):e29161. doi: 10.2196/29161. 
2. The feasibility trial results. 
American spelling has been used throughout this chapter, to maintain consistency with the 
published article. 
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PART 1: Avoiding the “triple whammy”: study protocol for a randomized feasibility 
trial to pilot the use of an information package to reduce patients’ risk of renal 
damage. 
Sharon Leitch, MBChB, PhD candidate, sharon.leitch@otago.ac.nz, Senior Lecturer, 
Department of General Practice and Rural Health, Otago Medical School – Dunedin Campus, 
University of Otago, Corresponding author 
Alesha Smith, MSc, PhD, alesha.smith@otago.ac.nz, Associate Professor, School of 
Pharmacy, University of Otago 
Jiaxu Zeng, BSc (hons), PhD, jimmy.zeng@otago.ac.nz, Senior Lecturer, Department of 
Preventive and Social Medicine, Otago Medical School – Dunedin Campus, University of 
Otago 
Tim Stokes, MBChB, PhD, tim.stokes@otago.ac.nz, Professor, Department of General 
Practice and Rural Health, Otago Medical School – Dunedin Campus, University of Otago 
5.2 Abstract 
5.2.1. Background 
Non-steroidal anti-inflammatory drugs (NSAIDs) are a common cause of renal damage, 
especially when taken together with angiotensin-converting enzyme inhibitors (ACE-i) or 
angiotensin II receptor blockers (ARBs) plus a diuretic – a combination known as the “triple 
whammy.” New Zealand patients are at high risk of the “triple whammy” because they can 
easily purchase NSAIDs without a prescription and in non-pharmacy retail settings (e.g., the 
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supermarket), there is no legal requirement to include patient information sheets with 
medication, and direct-to-consumer drug advertising is permitted. A patient information 
package has been developed for those at greatest risk of the “triple whammy,” consisting 
of a printable PDF and an interactive online learning activity. This information package aims 
to inform patients about their elevated risk of harm from NSAIDS, and discourage use of 
NSAIDs. A randomized control trial was planned to assess the effect of the information 
package. 
5.2.2. Objective 
This study aims to pilot the trial procedures for recruiting patients, providing patient 
information online and to assess the acceptability of the patient information package. 
5.2.3. Methods 
A two-armed randomized feasibility trial will be undertaken in Northland, New Zealand. We 
will recruit 50 patients who are at least 18 years old from those who have signed up to 
receive email alerts through their general practice. Patients eligible for this study have 
been prescribed an ACE-i or ARB, plus a diuretic in the past 3 months. They will be 
randomly allocated to 2 study arms. The intervention arm will receive access to an 
information package plus usual care; the control arm will receive usual care alone. Online 
surveys will be used to assess NSAID knowledge and NSAID use at baseline and after two 
weeks for both arms. The intervention arm will also evaluate the information package in an 
additional survey based on Normalisation Process Theory (NPT) concepts. We will report 
the number and proportion of participants who are eligible and consent to participate in 
the trial. Response and drop-out rates will be reported for each trial arm. 
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The numbers of patients who interact with the education package will be reported together 
with the patient evaluation of it. 
5.2.4. Results 
Funding has been obtained from the Health Research Council of New Zealand (HRC 18- 
031). The University of Otago Human Research Ethics Committee (H21/016) has approved 
this trial. Consultation has been undertaken with The Ngāi Tahu research consultation 
committee. The trial commenced on 1 April 2021. 
5.2.5. Conclusions 
This feasibility trial will test the study processes prior to commencing a randomized 
controlled trial and will determine the acceptability of the patient information package. We 
anticipate this work will provide useful information for other researchers attempting 
similar work. 
5.2.6. Trial Registration 
ANZCTR (Australian New Zealand Clinical Trial Registry): ACTRN12621000574842 
5.2.7. Keywords 
“triple whammy”; medication safety; patient education; general practice; NSAID; digital 
intervention; primary care 
5.3. Introduction 
Non-steroidal anti-inflammatory drugs (NSAIDs) are a common cause of renal damage.278  
The risk of renal injury dramatically increases when NSAIDs are taken together with 
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angiotensin-converting enzyme inhibitors (ACE-i) or angiotensin II receptor blockers (ARBs) 
plus a diuretic279 – this is known as the “triple whammy” combination. Despite this issue 
being well known and publicized heavily to prescribers in recent years, coprescribing of 
these medications is still common in New Zealand; 2017 data suggests more than 26,500 
patients were prescribed these medications concurrently, with the majority of these patients 
aged over 65 years.280,281 
While prescribers should be well aware of the dangers of combining NSAIDs with other 
medications that alter renal perfusion, patients may not be.282-284 The true extent of 
simultaneous use of these medications is unknown. Nonprescription use of NSAIDs may be 
high in New Zealand. This is due to the easy availability of NSAIDs for patients to purchase 
without a prescription and in non-pharmacy retail settings (e.g., the supermarket), no legal 
requirement to include patient information sheets with medication, and direct-to-consumer 
drug advertising.262 Given these issues, it is important to maximize the opportunities to 
advise patients about the potential risks of taking anti-inflammatories as part of the “triple 
whammy.” 
Existing information for patients is generic and not generally considered fit-for- purpose.262 
Tailoring medication information for patients may improve the quality and usefulness of 
information, as well as improve patient knowledge.285,286 However, examples of personalized 
medication information are rare.287 Most patients consider doctors to be their main source 
of health information. Patients want to be able to share that information with their whānau 
(family) as well as health professionals,255,288 but doctors do not always provide patients with 
that information.248,289 Doctors find communicating risk information difficult,256,258 and 
communicating potential risks of NSAIDs may be incomplete.290 Time, low health literacy 
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levels, and lack of patient interest have been suggested as additional barriers to 
communication.288 
Providing information directly to patients may help address some of those issues; however, 
information must be provided at an appropriate health literacy level. New Zealanders 
typically have low levels of health literacy – over half of all adults surveyed had skills 
“insufficient to cope with the health literacy demands they typically face.”159 When the 
health literacy study results were broken down by ethnicity, 75-80% of Māori (the 
indigenous people of Aotearoa New Zealand) and 90% of Pasifika (people living in New 
Zealand who migrated from or have ancestry in the Pacific Islands), had low health literacy 
levels.159 Health literacy has been identified as a cause of health disparities,157 and decision 
support tools can help address deficits in health literacy.158,291 Self-efficacy, a patient’s belief 
in their ability to undertake and successfully complete a task, is another factor highly 
associated with optimal medication use.292,293 
Most medication information for patients is in leaflet form, with patient information 
resources becoming increasingly available online. Patients search for high-quality, 
reputable information, but find it hard to judge the quality of the information they find 
online.288 A few studies have examined novel modalities of delivering health information to 
patients, but there is room for further research to evaluate the efficacy of alternative 
media modalities.294,295 
Conporto Health Event Detection & Mitigation (Conporto) is a software package that 
detects whether general practice patients are at risk of harm from their prescribed 
medications.147 The current system operates in real-time to detect if there is a risk of harm 
from pre-specified conditions, for example, if methotrexate is prescribed without a co-
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prescription for folic acid or if allopurinol is prescribed at a dose of >200mg/day to a 
patient with chronic renal insufficiency. Clinicians are informed of each alert and then 
decide whether to take action or inform patients. Conporto has developed the capacity to 
contact patients directly via text and email, with patient consent. This patient contact is 
triggered when a patient requests a prescription from their general practice, and is 
currently used to inform patients that their prescription is ready for collection. This 
function could also be used to provide patients with more information about their 
medications. 
We have developed a printable information sheet and an online learning activity for 
patients. Patients, general practitioners, pharmacists, and a patient education provider 
have contributed to the development of these resources, which aim to inform patients 
about their elevated risk of harm from NSAIDs, and discourage them from using over-the-
counter NSAIDs. A randomized controlled trial (RCT) was proposed to examine the effect of 
giving at-risk patients this information directly, without needing their health care 
practitioners to provide it. This trial aims to assess the impact of providing an information 
package about avoiding anti-inflammatory medicines to patients at risk of renal damage 
from the “triple whammy,” in particular, the impact on anti-inflammatory knowledge and 
self-reported behavior. However, we have a number of concerns that we need to address 
before carrying out the full RCT. 
First, it is unknown if our recruitment methods will be successful in enrolling a 
representative sample of the target population. Second, a low response rate of online 
surveys is a common concern. Having a better understanding of the survey response rate 
will help us determine the number of participants needed for the full trial. Third, while we 
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have developed the information package with some patient input, it has not been formally 
evaluated by patients. Fourth, we don’t know whether the survey questions are 
appropriate to assess the impact of the intervention. Therefore, we plan to conduct this 
randomized feasibility trial to assess the feasibility of the intervention, pilot the 
recruitment methods and the use of surveys for assessing the impact of the intervention. 
The results of this feasibility trial will help refine our methods prior to commencing a 
definitive RCT. 
5.4. Aims 
The primary aim of this study is to assess the feasibility of conducting a RCT. The RCT will 
investigate the effect of providing a patient information package about NSAIDs to patients at 
increased risk of renal damage because of their medications. The feasibility trial will 
elucidate any issues which could impair our capacity to answer the aims of the full trial. 
The feasibility trial aims to (1) pilot the procedures for recruiting patients and providing 
patient information online to assess the number of eligible participants and the recruitment 
rate, assess the characteristics of participants who are enrolling in the trial, identify any 
technical challenges for patients assessing information online, and assess the drop-out rate 
in each group; (2) assess the acceptability of the patient information package to assess if 
patients trust and understand the information provided and think it is relevant to them; and 
(3) pilot the use of the survey for assessing the effects of providing patients information 
about the risk of NSAIDS to obtain preliminary data of the survey responses to help sample 
size calculation in the full trial, assess the response rates of the surveys, and assess the 
suitability of survey questions to measure the impact of the intervention. 
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5.5. Method 
This will be a two-armed randomized feasibility trial. The trial will be conducted according to 
the steps outlined in Figure 5-1. 
 
5.5.1. Recruitment 
Conporto is used by general practices across New Zealand. Patients attending general 
practices using Conporto in the Northland region will be eligible to participate in the 
randomized feasibility trial. Northland was chosen as Conporto is used widely in the region 
and it has a high proportion of Māori patients. Northland is a subtropical region in New 
Zealand, with a population of 179,000. Compared to the rest of New Zealand, Northland is 
more rural, is poorer, and has a higher proportion of people of Māori ethnicity.296 
Recruitment will be undertaken at the individual level. We aim to recruit 50 patients (25 
patients in each trial arm), to pilot the use of the surveys. Participants will be allocated a 
unique study identification number to preserve anonymity. 
Patients will be identified as having increased risk of harm from NSAIDs from their current 
prescriptions. Patients prescribed at least 2 of the 3 “triple whammy” medications (i.e., an 
ACE-i or ARB plus a diuretic) will be identified by Conporto. Patients will be eligible to 
Figure 5-1 Flow chart of study protocol 
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participate in this study if they were prescribed these medications concurrently in the past 
three months, are over 18 years old, and if they have signed up to receive Conporto’s email 
messages. Box 5.1 describes participant inclusion and exclusion criteria. All eligible patients 
will be invited to participate in the study via email from Conporto. 
Box 5.1: Participant eligibility criteria 
Inclusion criteria 
 Age 18 years or older 
 Angiotensin-converting enzyme inhibitor (ACE-i) or angiotensin II receptor 
blockers (ARB) + diuretic in the past 3 months 
 Signed up to receive Conporto alerts 
 
Exclusion criteria 
 Fails to complete enrollment 
5.5.2. Randomization and blinding 
Following recruitment to the study, patients will be automatically randomized 1:1 to either 
the control or intervention group within each practice. Patients will not be advised which 
group they are allocated to. Stata software will be used to generate the randomization 
sequence, which will be allocated using REDCap (Research Electronic Data Capture) 
software. REDCap software will also be used to administer all the surveys. REDCap is a 
secure web-based survey tool suitable for data requiring high security storage (i.e. patient 
data). Non-respondents at each stage will be emailed 2 further invitations to participate, at 
1-day intervals. 
5.5.3 Baseline assessment 
The study invitation email will contain a link to the baseline assessment (Appendix 3). The 
first page of the assessment contains a consent form approved by the University of Otago 
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Human Ethics Committee. Once the consent form is completed, the rest of the form opens 
automatically to request demographic information, information about current medications 
and NSAID use, a validated single-item health literacy assessment,297 a validated 4-item 
medicine use and self-efficacy questionnaire,292 a validated NSAID knowledge 
assessment,298 and a self-report of NSAID use in the preceding fortnight. 
5.5.4 Study Intervention 
Within 24 hours of completing the baseline assessment, intervention group patients will be 
emailed a link to a webpage containing a fully accessible, online, interactive learning activity 
and a downloadable PDF (Figure 5-2).299 Patient information about avoiding anti-
inflammatories and online interactive learning activity have been developed by SL in 
conjunction with the Health Navigator editorial board, their pharmacist, and the Health 
Navigator patient panel in an iterative process. The webpage is hosted by Health Navigator 
New Zealand, a non-profit initiative that provides curated health information overseen by 
the Health Navigator Charitable Trust. Both the control and the intervention group will 
receive usual general practice care from their own primary care team during the trial. After 
the trial is completed, control group patients will also be sent an email with a link to the 
information package, so all patients in the study eventually have access to that resource. 
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5.5.5 Follow-up assessment 
All patients will be sent a follow-up survey after 2 weeks which repeats 2 survey items from 
the baseline assessment: the validated NSAID knowledge assessment298 and the self- report 
of NSAID use in the preceding fortnight. 
Patients in the intervention arm will also complete an additional survey (Appendix 3) to 
evaluate the information package. This evaluation survey is based on Normalisation Process 
Theory concepts (NPT).242 NPT has been successfully used in the assessment and 
implementation of multiple patient-facing complex health interventions236,237,300 and to 
evaluate other primary care initiatives aiming to reduce kidney injury.301,302 
5.5.6. Measures 
We will report the number and percentage of patients who are eligible to participate in the 
trial, and those who consent to participate. For participants in each of the study arms, we 
will report the response and drop-out rates for each of the surveys. The number of patients 
who open the information package will also be recorded via the website analytic data from 
the Health Navigator website. The numbers of patients who interact with the education 
package will be reported, together with the patient evaluation of it. NSAID knowledge scores 
and self-reports of NSAID use will be measured at baseline and 2-week follow-up. 
5.5.7. Statistical analysis 
Descriptive analyses will be carried out to summarize the characteristics of the participants 
in each study arm. Preliminary data will be obtained for the NSAID knowledge scores and 
self-reported NSAID use at baseline and follow-up to guide sample size calculation for the 
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full trial. If numbers allow, linear mixed models will be used to compare the changes in the 
mean score on the NSAID knowledge questionnaire and self- reported NSAID use between 
the 2 arms. 
5.6. Results 
Funding has been obtained from the Health Research Council of New Zealand (HRC 18- 031). 
The University of Otago Human Research Ethics Committee (H21/016) has approved this 
trial. Consultation has been undertaken with The Ngāi Tahu research consultation 
committee. The trial commenced on 1 April 2021. 
The expected outcomes include that we will determine the uptake, acceptability, and self-
reported effects of providing patients with information about the risk of NSAIDs via a 
webpage; determine the feasibility of conducting this research via online survey, and these 
data will be used to apply for further research funding; and publications and conference 
presentation about trial results 
5.7. Discussion 
This feasibility trial will help us determine whether it is practical to conduct a nationwide 
RCT. It will help refine the information package. Additionally, it may provide preliminary data 
to help understand whether providing information directly to patients increases their 
knowledge or changes their behavior. 
5.7.1. Strengths and limitations 
This trial will evaluate the entire implementation process, testing trial processes and the 
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acceptability of the intervention. The results of this feasibility trial will ensure best use of 
limited health research funding for any future similar studies. Publication of this work will 
help other researchers considering conducing similar patient-focused research. 
Language, education, and technology can be barriers to health literacy.229 The main 
limitation of this research is that patients with the greatest barriers to health literacy are 
likely to experience those same barriers in accessing the proposed intervention and 
participating in this research project. The research project and proposed intervention were 
developed only in English due to financial constraints. If this intervention is successful in 
English on full testing, it is hoped funding will be made available to translate the 
intervention into different languages (e.g. Māori, Samoan and Tongan in the first instance). 
A potential risk of this work is that patients experience anxiety or distress when they realize 
they are at increased risk of harm from medication. This risk is mitigated by the ubiquitous 
nature of health information readily available to patients, and the repeated 
encouragement for participants to discuss their concerns with their healthcare providers. 
5.7.2. Comparison with Prior Work 
Only a handful of feasibility trial protocols have been published to date in the field of 
primary care medication safety. Feasibility studies focus on testing and evaluating the study 
processes to assess “can it work?”, while pilot studies focus on outcomes to assess the 
effectiveness of the intervention, or “does the intervention show promise?”303 Feasibility 
studies are particularly important for complex interventions, which risk of being undermined 
by problems that could be otherwise sorted at an exploratory stage, such as the target 
population failing to engage with the study or intervention.304 Testing the feasibility of a 
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project improves the chance of success of a larger trial, thus ensuring better use of funding 
and reducing the risk of harms arising from the intervention or study processes.304 
5.8. Conclusion 
This feasibility trial protocol describes our plan to test trial processes prior to commencing a 
nationwide randomized control trial. It will provide important information about the 
acceptability of the patient information package. We anticipate this work will offer a useful 
model for other researchers attempting similar work. 
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Figure 5-3 Should I take ibuprofen? 
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PART 2: Randomized Feasibility Trial Results 
  
The protocol was followed without any amendments. As planned, all eligible patients 
attending general practices using Conporto in the Northland region were invited to 
participate in the randomized feasibility trial – in total 177 patients were eligible to 





Figure 5-4 Recruitment and randomization flow-chart 
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The 177 Northland patients aged 18 years and older who met the eligibility criteria for the 
study were sent a total of three email invitations over the course of 10 days from 
Conporto. All 20 patients who consented to participate completed the baseline assessment 
and were randomized 1:1 into either the intervention group or the control group as per the 
protocol (Figure 5-4). The intervention group were emailed a link to the information 
package (https://www.healthnavigator.org.nz/medicines/n/nsaids-learning-activity/), and 
all patients were sent a follow-up assessment via email 14 days after completing the 
baseline assessment as planned. Participants were sent three reminder emails, at 24 hour 
intervals to complete the follow-up assessment. Only one participant did not complete the 
follow-up assessment, from the control group. 
5.10. Variables 
Anonymized demographic data for the eligible Northland population was extracted from 
the general practice records. Socioeconomic deprivation is calculated using geographical 
meshblock data of residential address (NZDep13)195 and is automatically populated with 
the general practice data. Participant demographic details were self-recorded by 
participants, but meshblock data was not collected as it is based on residential address and 
collecting that data would have been a privacy issue. Instead, educational levels were 
recorded by participants as a coarse marker of socioeconomic deprivation and literacy. 
Ethnicity is self-reported in New Zealand; prioritized ethnicity was used.174 Knowledge 
scores were assessed by summation of the total correct answers in the knowledge quiz, to 
give a score out of a maximum of 7 points. 
Participants characteristics are reported with the mean and standard deviation (SD) for 
140  
continuous variables; the number and percentage are given for categorical variables by 
treatment arms. All analyses were performed in Stata 15.1.196 
5.11. Results 
Eleven percent of the eligible population were recruited to participate in this study 
(20/177), and nearly all participants completed the follow-up knowledge survey (19/20, 
95.0%) (Figure 5-4). Potential participants were carefully screened prior to recruitment to 
ensure they were all eligible to participate based on their prescribed medications in the 
past three months. In spite of this, two patients’ self-report of current medications did not 
include all the pre-requisite medication. We elected to include the data from those 
patients in the study results. Both patients were randomized to the control group. 
Compared to the patients eligible to participate, the study patients were slightly older, with 
a higher proportion of females and less ethnic diversity (Table 5-1). Eligible patients tended 
to be from areas of high deprivation, with 57% in NZDep13 quintiles 4 and 5 (101/177). We 
were not able to obtain the addresses and therefore the NZDep13 results for the recruited 
patients, but instead requested their education level. Sixty percent of the study population 
had university education (12/20). 
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Table 5-1 Characteristics of eligible patients compared with recruited patients 
 Eligible patients n=177 Recruited patients n=20 
Age 65.7 (SD 11.8) 69.0 (SD 8.3) 
Age range 29-94 years 54-89 years 
Gender Female 89 (50.3) 13 (65.0) 
Ethnicity    
NZ European 107 (60.4) 16 (80.0) 
Māori 47 (26.6) 4 (20.0) 
Pasifika 1 (0.6) 0 
Asian 3 (1.7) 0 
Other 19 (10.7) 0 
NZDep13 (Missing n=5)   
1 (least deprived) 14 (8.2) n/a* 
2 22 (12.9) n/a 
3 29 (17.0) n/a 
4 48 (28.1) n/a 
5 (most deprived) 53 (31.0) n/a 
Education   
High school n/a** 8 (40.0) 
University n/a 12 (60.0) 
*NZDep13 information not collected for recruited patients 
** Education levels unknown for eligible population 
 
Table 5-2 compares the baseline characteristics of participants randomized to intervention 
and control groups. The two groups were roughly equivalent in terms of age, gender, 
ethnicity, and education. Health literacy and self-efficacy scores had a wider distribution, 
with lower scores in the intervention group than in the control group. There was a similar 
distribution of preferences of sources of medication information in each group between 
healthcare providers and online information. 
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Table 5-2 Comparison of baseline characteristics of participants randomized to intervention 
and control groups 
 Intervention n=8  Control n=12  
Age 66.6 years SD 7.6 70.6 years SD 8.7 
Age range 54-77 years 59-89 years 
Gender Female 6 (75.0) 7 (58.3) 
Ethnicity 
NZ European 6 (75.0) 10 (83.3) 
Māori 2 (25.0) 2 (16.7) 
Education 
Highschool 3 (37.5) 5 (41.7) 
University 5 (62.5) 7 (58.3) 
Single Item Self-Literacy assessment 297  
How often do you need to have someone help you when you read instructions, 
pamphlets, or other written material from your doctor or pharmacy? 
Never 5 (62.5) 11 (91.7) 
Rarely 2 (25.0) 1 (8.3) 
Sometimes 1 (12.5) 0 
Medication Use and Self-Efficacy 292 
It is easy for me to ask my doctor about my medicine 
Agree/strongly agree 8 (100) 12 (100) 
Disagree/strongly disagree 0 0 
It is easy for me to understand my doctors instructions for  my medicine 
Agree/strongly agree 8 (100) 11 (91.7) 
Disagree/strongly disagree 0 1 (8.3) 
It is easy for me to understand instructions on medicine bottles 
Agree/strongly agree 7 (87.5) 12 (100) 
Disagree/strongly disagree 1 (12.5) 0 
It is easy for me to get all the information I need about my medicine 
Agree/strongly agree 7 (87.5) 11 (91.7) 
Disagree/strongly disagree 1 (12.5) 1 (8.3) 
Medication Information Preferences 
I prefer receiving medication from my doctor, pharmacist or other health provider 
Agree/strongly agree 7 (87.5) 11 (91.7) 
Disagree/strongly disagree 1 (12.5) 1 (8.3) 
I prefer finding information about my medicines online 
Agree/strongly agree 6 (75.0) 5 (41.7) 
Disagree/strongly disagree 2 (25.0) 7 (58.3) 
 
5.11.1 Information package evaluation 
Only 50% (4/8) patients randomized to the intervention group reported reading the 
information sheet and completed the online learning module, but the information package 
evaluation was fully completed by at least six participants (6/8, 75.0%). One person 
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commented that they could not download the PDF, but no other technical issues were 
reported. All evaluations were included in the results. 
Evaluation of the information package is outlined in Table 5-3. Scores could range from 0 
(strongly agree) to 100 (strongly disagree), so scores less than 50 suggest agreement, and 
scores greater than 50 suggest disagreement. Participants generally agreed that they 
understood why they were sent the information about anti- inflammatory medicines 
(mean 31.9, SD 33.7), although question 1 had the most divergent scores. 
The first evaluation question (I understand why I was sent the information about anti- 
inflammatory medicines) had the most divergent scores, however Questions 2 (the 
information made me worried about my medicines), 3 (the information helped me learn 
about anti-inflammatory medicines) and 4 (the information made me aware of my risk from 
anti-inflammatory medicines), yielded equivocal results, with scores around 50 (i.e., neither 
agree nor disagree). Participants generally felt the information didn’t help facilitate 
communication with their healthcare provider or family/whānau (questions 5 and 6). They 
generally found the information sheet simple to understand; the learning module was easy 
and didn’t take too long (questions 7-9). Participants found the online learning module was 
a more effective learning tool than the information sheet (question 10). 
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Table 5-3 Information package evaluation 
Question Mean (SD)* 
1. I understand why I was sent the information about anti-
inflammatory medicines (n=7) 
31.9 (33.7) Range 0-98 
2. The information made me worried about my medicines 
(n=7) 
52.9 (28.9) Range 18-90 
3. The information helped me learn about anti-inflammatory 
medicines (n=7) 
50.7 (26.5) Range 17-77 
4. The information made me aware of my risk from  
anti-inflammatory medicines (n=7) 
45.4 (23.8) Range 14-88 
5. The information helped me to talk to my healthcare   
provider about my medicines (n=7) 
54.7 (25.7) Range 27-90 
6. The information helped me talk to my family/whānau   
about  my medicines (n=7) 
64.7 (15.1) Range 50-87 
7. The printable information sheet was confusing (n=7) 64.4 (15.5) Range 46-88 
8. The online learning module was difficult (n=7) 56 (10.3) Range 50-72 
9. The online learning module took too long (n=7) 58.6 (12.4) Range 50-81 
10. The online module helped me learn more than the  
information sheet (n=6) 
42.0 (12.5) Range 23-50 
*Scores could range from 0 (strongly agree) to 100 (strongly disagree) 
 
5.11.2. Preliminary results – knowledge scores and self-reported action 
Knowledge scores remained relatively static for both groups (Table 5-4). Around one quarter 
of patients reported NSAID use in the preceding fortnight at both baseline and follow-up, 
and all users obtained their NSAIDs with a prescription from their healthcare provider. NSAID 
use frequency ranged from “less than once a week” to “every day”. Around a third of 
participants at baseline and follow up intended to take action after completing the survey, 
such as to talk to their healthcare provider or to reduce/stop NSAIDs. 
145  
 
Table 5-4 NSAID knowledge, use, and self-reported action 
 Intervention 
n=8 baseline & follow-up 
Control 
n=12 baseline (11 follow-up) 
NSAID knowledge 
Baseline  mean 4.3 (SD 0.8) range 3-5 mean 4.0 (SD 0.4) range 3-5 
Follow-up  mean 4.3 (SD 0.5) range 4-5 mean 4.5 (SD 1.4) range 3-7 
NSAID use in the past fortnight = yes 
Baseline use 2 (25.0%) 3 (25.0%) 
Follow-up 2 (25.0) 3 (27.3) 
Self-reported action = yes 
Talk to healthcare 
provider 
  
Baseline  1 (12.5) 1 (9.1) 
Follow-up 2 (25.0) 1 (9.1) 
Reduce/stop NSAIDS   
Baseline  2 (25.0) 2 (18.2) 
Follow-up 1 (12.5) 1 (9.1) 
Continue NSAIDS   
Baseline  0 1 (9.1) 
Follow-up 0 2 (18.2) 
None of the above   
Baseline  5 (62.5) 8 (72.7) 
Follow-up 5 (62.5) 7 (63.6) 
 
5.12. Discussion 
This feasibility study demonstrated that email from a known provider of health information 
was a successful recruitment method. Eleven percent of eligible patients were recruited. 
Recruited participants had a higher proportion of females than the eligible population, 
were less culturally diverse, and probably were less socio- economically deprived based on 
the high proportion with university education. 60% of the study population had a university 
education, compared to only 9.6% of people living in Northland (2018 Census).296 Retention 
between baseline and follow-up assessments was excellent, with only one person dropping 
out of the study. However, half of the patients randomized to receive the information 
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package reported they did not engage with the material. 
The survey was successfully piloted; participants were able to complete the survey 
questions, and the survey questions were understandable and suitable for measuring 
patient knowledge. The effect of the intervention appears to be small, but these figures will 
be used to conduct the sample size calculation for the full trial. 
5.12.1. Strengths and Limitations 
Eleven percent of eligible patients were recruited for this study. This recruitment rate is 
similar to what Conporto has observed in other email campaigns,305 but it is far higher than 
in recent published literature for studies using patient portal and email messaging. One 
study recruiting patients at risk of falls only had an enrolment rate of 0.17%,306 a study 
looking at healthy lifestyle and body weight had an enrolment rate of 2.9%,307 while a gout 
study reported a response rate of 4% to patient portal messaging.308 We worked with 
Conporto Health to contact eligible patients by email. Patients attended practices that used 
Conporto Health services, and had already consented to receive other health- related 
information via email from the same service, some activated by the patient using their 
patient portal. (For example, a patient requesting a repeat prescription via their patient 
portal would receive an automatically generated email from Conporto Health once the e-
prescription had been sent to their pharmacy.) It is likely patient familiarity and trust of 
Conporto Health emails led to higher recruitment rates than observed in the literature. 
We anticipated that this study might not recruit patients with low health literacy who 
would potentially most benefit from the intervention.309 This was confirmed with 
substantial differences between study participants and the eligible population in terms of 
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gender, ethnicity, and socio-economic deprivation. People with lower health literacy levels 
may struggle to understand informed consent documents, resulting in anxiety and 
reluctance to participate in clinical trials.310 People with lower education levels and those 
who are more socioeconomically deprived are less likely to use technology to access health 
information, while women and younger people are more likely to do so.266,311 This is 
consistent with the participant demographics in this study. Recruitment of a representative 
cohort may require the use of a variety of methods to reach under-represented groups.308 
However, recruitment of an unrepresentative sample will not affect the results of the full 
randomized controlled trial. 
The information package was developed in conjunction with a patient panel and health- 
providers, but we also wanted research participants to complete a formal evaluation of the 
package. Only 7 participants completed the information package evaluation. We are unable 
to complete the formal evaluation of the information package as planned in the study 
protocol.309 Usability studies assess design factors that affect the user experience of 
operating and navigating an application for an intended purpose.312 In usability studies of 
technological interventions, a sample group of approximately 5-20 patients may be 
considered sufficient to evaluate the intervention.313-315 Other feasibility and pilot studies 
testing e-health technologies associated with medication have had similar low numbers. 
One medication information pilot study had only 11 participants,316 one study looking at 
medication information in the elderly had 16 participants,317 and one usability and 
feasibility study aiming to reduce unsafe medication use had only 17 patients.315 In 
retrospect, it would have been beneficial to get all participants to evaluate the information 
package, not just the intervention arm. In the full trial, participants will also be asked to 
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evaluate the information package as that data is lacking in our current understanding of 
the tool. 
5.12.2. Comparison with the Literature 
eHealth interventions, such as this information package, are cheap to develop and deliver, 
and are an easily scalable method of informing targeted patients about their medications. 
Printed material, software and other eHealth technologies have been effective in 
promoting health education in the community, among patients of all ages.318,319 Knowledge 
and skill acquisition from multimedia education is superior to usual care (ad hoc education 
provided as part of normal clinical care) and no education.318 Online programmes have 
been successful in medication education, promoting decision-making and supporting 
patient self-efficacy.319,320 Education interventions that target over-the-counter 
medications have also improved safe medication use and medication self-efficacy 
scores.320,321 Other similar studies that have also informed patients directly (rather than via 
their clinicians) have been successful in promoting shared-decision making and making 
safer medication choices.322,323 
Our preliminary results suggest that our information package will be similarly beneficial, 
although a full trial is needed to fully evaluate the learning potential of this intervention. It 
is unknown whether providing this information package will promote patient discussion 
with healthcare providers, improve shared-decision making about medications, or reduce 
use of NSAIDs in high-risk patients. However, as discussed in Chapter 4, patients want 
access to high-quality medical information independent of their healthcare providers.288 
Targeting patients rather than healthcare providers is an underutilized and under-
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researched method for promoting medication safety.315,324 Coordinating educational 
campaigns for patients and clinicians may increase the efficacy of both.315 
5.12.3. Conclusion 
This randomized feasibility trial demonstrated that this research method is feasible for the 
purposes of recruiting patients and testing the effects of providing this targeted 
information package. Preliminary findings suggest the patients most likely to benefit from 
the intervention are less likely to participate in this type of research. A full randomized 
controlled trial is planned to formally test the effects of the targeted information package. 
Should the full trial demonstrate the information package is useful, further research will be 
needed to determine how to best disseminate it to patients at greatest risk. 
5.13. Chapter Summary 
This chapter describes the protocol and results from a randomized feasibility trial exploring 
the workability of providing patients with a targeted information package. The methods of 
recruitment and information provision were feasible. The impact of providing the 
information package needs to be fully tested in a randomized controlled trial, which is to 
be conducted after the conclusion of this PhD.
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Chapter 6 Discussion 
 
6.1. Preface 
This chapter provides a summary of the whole thesis and a discussion of the salient points. 
The chapter commences with a discussion of the complexity of medication-related harm, 
seeing it as a “wicked problem.” The major results from each of the four studies are 
presented, followed by a general discussion of the strengths and limitations of the methods 
used in this thesis. Three main issues are compared with the literature. Firstly, the 
importance of the patient perspective is highlighted in defining harm and developing 
solutions. Second, consideration is given to applying a systems perspective to improving 
patient safety. Finally, the inevitability of patient harm is debated. The contribution of this 
thesis to patient safety literature is discussed. The implications of this work, together with 
unanswered research questions, are outlined. 
6.2. Introduction 
Medication-related harm is a complex problem. Simple problems can be clearly defined and 
are relatively easy to solve, such as mathematics and chess problems. In contrast, complex 
problems are ill-defined and lack obvious solutions. Medication-related harm is a complex 
problem which could be regarded as a “wicked problem.”325 Box 6-1 describes the key 
characteristics of a wicked problem. 
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Medication-related harm has all the above 
characteristics:  
1. Defining medication-related harm is difficult, 
as lamented by patient safety experts and 
discussed further below. 
2. It is impossible to know how much 
medication-related harm has been averted 
through any one solution. 
3. Solutions are not value-free. Success depends 
on how the intervention or harm is valued, 
which in turn depends on the societal or individual 
context. For example, low NZ immunisation rates 
were partly attributed to culturally dissonant 
1. Wicked problems are hard to define 
2. It is hard to know when the problem is solved 
3. Solutions are judged by interests and values; there are no correct solutions 
4. The solutions cannot be tested easily 
5. Every attempt to solve the problem is important 
6. It is not possible to describe all potential solutions 
7. Each problem is essentially unique 
8. Each problem can be considered a symptom of another problem 
9. Explanation of discrepancies determines the way the problem will be resolved 
10. The problem solver has no right to be wrong 
Figure 6-1. Immunisation material 
developed without Māori 
consultation 
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imaging in promotional material – the wise old owl of European lore is a harbinger of 
death in Māori legends (Figure 6-1).  
4. Solutions can be tested, but there are many variable factors in each test which are 
difficult to take into account. 
5. Getting it wrong even once can have serious consequences for a patient and their 
whānau. 
6. There are innumerable potential solutions to the problem of medication-related harm. 
7. Patients have individual risk-profiles, which vary through their life-course and in 
different states of health. 
8. One problem leads to another. For example, a patient with angina is prescribed regular 
aspirin to prevent a myocardial infarction. This causes a little gastrointestinal bleeding. 
They also experience increased indigestion, so are prescribed omeprazole, which 
reduces B12 absorption. The patient gradually becomes anaemic resulting in blood 
tests, iron and B12 therapy, and potentially a colonoscopy or gastroscopy. Each 
investigation and treatment carries risk of additional harm. 
9. Explanation of discrepancies determines the way the problem will be resolved. If a 
medication-related harm is defined in terms of prescriber error, the solution will be to 
provide prescribers with more education. If it is attributed to the medication, this may 
result in restriction in use of that medication. Alternatively, it may result in public 
outcry calling for systems change, as evidenced by the public response to six deaths 
potentially caused by a change in the brand of the anti-epileptic medication 
lamotrigine available in New Zealand.326 
10. The problem solver has no right to be wrong. Medical culture contributes to unrealistic 
expectations of perfection and infallibility.327 Compulsory medical indemnity 
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insurance suggests NZ patients and society expect health care providers to be right – 
if not all the time, at least most of the time.328 Until the Crimes Act was amended in 
1997, New Zealand clinicians could be held criminally liable if their patient died as a 
result of even minor acts of negligence. (The amendment brought NZ law in line with 
other similar countries. Now criminal law is applied only if the clinician’s actions are 
judged a major departure from a normal standard of care.329)  
 
The “wicked problem” of medication-related harm can seem insurmountable, but is worth 
grappling with.330 People seek medical care when they need help. Harming patients when 
they seek health care is morally wrong, costly, and detrimental to patients and clinicians 
alike.31,331 “The harm to patients resulting from medical errors at the most vulnerable 
moments of their lives is a profoundly intimate experience for everyone involved. Clinicians 
and staff are also deeply affected when they are involved in an adverse event and frequently 
suffer shame, guilt, fear, and long-lasting depression.”332 Reducing harm from medication 
use in general practice is an important and worthwhile goal that requires creative thinking, 
adequate funding and sustained effort to achieve. 
This thesis aimed to identify problems associated with medication use and then to explore 
strategies to improve medication safety in New Zealand general practice. Four studies were 
undertaken to address those aims. The first two studies identified factors that are associated 
with problems with medication use, by analysing data from two general practice record 
review studies. Study 1 estimated the incidence of medication-related harm in New Zealand 
general practice using data from the Safety, Harms and Risk Reduction Project (SHARP) 
(Chapter 2). Study 2 explored whether clinician action differs across ethnicity groups using 
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data from the Conporto Health proof-of-concept study (Chapter 3). The second half of the 
thesis considered strategies to improve medication safety. Interviews with patients and 
prescribers in Study 3 investigated what they would like from a medication decision support 
and communication tool (Chapter 4). Study 4 used knowledge gained from the preceding 
three studies to develop a tailored information package on avoiding NSAIDs for patients at 
risk of renal damage (Chapter 5). It further evaluated the feasibility of conducting a 
randomised controlled trial to assess potential benefits of the information package in 
improving knowledge of NSAIDs and reducing self-reported NSAID use in patients at risk of 
renal damage. 
6.3. Summary of principal findings 
6.3.1. Study 1: Medication-related harm arising from prescribing in NZ general practice 
Data from a large retrospective review of general practice records (from 2011-2013 
inclusive) were analysed to identify and describe the incidence of medication-related harm 
arising from prescribing in New Zealand general practice. The incidence rate of all 
medication-related harms was 73.9 harms per 1000 patient-years; for preventable or 
potentially preventable medication-related harms the incidence was 15.6 per 1000 patient-
years. The majority of harms were minor (1390/1762, 78.9%), but one in five harms were 
moderate or severe (373/1762, 21.2%); three patients died. Eighteen study patients were 
hospitalised, equating to a hospitalisation rate of 1.1 per 1000 patient- years. Greater age, 
number of consultations, and number of medications were associated with higher risk of 
medication-related harm. Cardiovascular medications, antineoplastic and 
immunomodulatory agents, and anticoagulants caused most harm by frequency and 
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severity. 
6.3.2. Study 2: Evaluation of equity in use of an automated clinician alert system 
An automated GP alert system was found to be effective in reducing the risk of patient harm, 
but concerns were raised about whether there were ethnic inequities in steps taken to 
mitigate harm. The persistence of significant health disparities experienced by Māori and 
Pasifika is extensively documented. Data from a retrospective review of alerts and the 
corresponding general practice patient records were evaluated to see whether Māori and 
Pasifika patients were more or less likely to have action taken. No difference was found in 
the odds of having action taken among ethnic groups after adjusting for potential 
confounders, however, the estimated odds for Māori and Pasifika patients having action 
taken were lower than for European patients (Māori OR 0.88, 95%CI 0.63-1.22; Pasifika OR 
0.88, 95%CI 0.52-1.49). Females had significantly lower odds than males of having action 
taken (OR 0.76, 95%CI 0.59-0.96). 
6.3.3. Study 3: Patient and prescriber perspectives on a decision support and 
communication tool 
An extended decision support system was proposed to both alert clinicians and patients 
about elevated risk situations. Patients and GPs were interviewed about this proposed tool 
to see what their priorities and preferences were. Patients want as much information as 
possible about their medications and risk, but doctors find it difficult to communicate that 
information to their patients. Participants were cautiously optimistic about a prescribing 
decision support tool, but worried about potential harm arising from its use. Participants 
identified requirements for the tool and features to avoid. For example, both doctors and 
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patients wanted a reputable tool that had been formally endorsed, that was intuitive to use 
and available on different platforms; conversely a tool that was slow, expensive or difficult 
to use should be avoided. The success of any patient safety tool is dependent on culturally 
safe and trustworthy doctor-patient relationships. 
6.3.4. Study 4: A feasibility trial of an information package to reduce patients’ risk of 
renal damage 
Improving the quality of patient medication information is crucial to improve patient 
understanding about their medications and any greater risk from those medications. A 
feasibility study was undertaken to determine the practicality of the study processes, with a 
focus on evaluating recruitment strategies, acceptability and suitability of the intervention. 
The targeted population were patients at greater risk of renal damage from non-steroidal 
anti-inflammatory drugs (NSAIDs). The intervention was an information package advising 
them of that risk. Recruitment was by email to patients attending clinics using the Conporto 
Health alert system. I77 eligible patients were identified from the dataset and were invited 
to participate in the feasibility trial. Eleven percent of the eligible population agreed to 
participate (20/177), and most participants completed the follow-up survey (19/20, 95.0%). 
Participants reported few technical issues accessing the information package and found it 
simple to understand. The online learning module was regarded a more effective learning 
tool than the information sheet. NSAID knowledge scores remained relatively static, but 
approximately one third of participants reported they intended to discuss their NSAID use 
with their healthcare provider. This feasibility trial demonstrated patients are willing to 
participate in a study via email recruitment, and engage with an interactive learning activity 
online. The effect of the intervention appears to be small, but the results obtained in this 
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feasibility trial will be used to conduct the sample size calculation for the full trial. 
6.4. Strengths and limitations of the chosen methods 
Laboratory data, clinical trials, and trigger tools provide quantitative data for orderly 
analysis, but fail to account for the daily chaos of busy general practice clinics in their 
communities.333 A strength of this thesis is that much of the work is based on real-world 
data. Real-world data are derived from multiple sources, such as claims data and electronic 
health records, and can be linked for more in-depth analysis.334 Using these data for research 
purposes offers potential for cost-effective and timely research into medication use, quality 
and safety, and they are routinely used for post-market adverse event monitoring.335-337 
Routinely collected data were pragmatically used in this thesis to investigate medication 
safety in New Zealand general practice; Study 1 used data collected for the purposes of 
providing patient care, while Study 2 used data collected by a commercial organisation 
(Conporto Health) for their proof-of-concept trial. 
The record review method, as used in Studies 1 and 2, is the gold standard method of 
patient safety research.51 The main limitation of this method is that harms may go 
undocumented, as the content of medical records is mostly determined by the clinician 
entering the data. In addition, record reviewers struggle to agree on the presence of harm, 
harm preventability and severity, as evidenced by low-to-moderate inter-rater reliability 
scores across the literature.51 More consistent data recording in electronic health records is 
required before these data could be routinely used for medication safety research and 
healthcare quality improvement.338,339 
Trigger tools are used to expedite systematic and standardised record review studies.43 
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Future refinement of trigger tools and improved coding practices (e.g., using the 
Systematised Nomenclature of Medicine Clinical Terminology, SNOMED CT) may provide an 
acceptable standard for detecting and monitoring known harms.51,340 Companies like 
Conporto Health use a trigger tool approach to automatically screen electronic records and 
prospectively alert clinicians to patients at higher risk of harm. Using data obtained with this 
type of technology for research is an obvious next step, and was demonstrated in Study 2. 
One of the overriding themes of this work has been a lack of shared definition for patient 
safety terms. Despite a substantial body of work aiming to classify and define these terms 
over the past two decades, there remains a multiplicity of definitions, hindering patient 
safety research.23,24,26,176,341 Similarly, our capacity to compare findings from different studies 
and examine the precision of harm estimates is hindered by a lack of agreed definitions for 
harm, harm severity, and harm preventability.342 Medication error, adverse drug event, 
critical incident and never-event describe an event but not the outcome. Only some events 
result in patient harm. This thesis has focused on patient harm. 
Medication-related harm was regarded from the patient perspective, a recommended 
approach which is discussed in the section below. However, one of the contentious elements 
of considering harm from a patient perspective was the inclusion of financial costs and 
opportunity costs associated with medication-related harm. It is hard to find these elements 
of harm discussed in patient safety literature, but they are a major problem for patients. 
Thirty-four percent of New Zealanders aged 15-44 years report the most common barriers to 
seeking medical help to be GP appointment cost and the cost of taking time off work. 343 
Stakeholder engagement in health care, research, policy and governance marks an 
important transition from traditional paternalistic care to personalised patient-centered 
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medicine.245,344 Patient engagement is recognised as having a wide range of beneficial 
outcomes, including improved health literacy, clinical decision making, self-care and self-
management, and patient safety.345 Valuing the opinion of all stakeholders - patients as well 
as clinicians - led to the interviews conducted in Study 3. Data from those interviews 
contributed to the material developed in Study 4. 
One of the main limitations of pursuing technical interventions, even low-tech interventions 
such as information provision in Study 4, is that the people who would most benefit from the 
intervention are often unable to access it due to technological barriers, low English literacy, 
and low health literacy. Older patients interviewed in Study 3 did not typically use 
technology such as computers or smart phones, preferring paper-based resources. Our 
intervention contained a printable information sheet, but it requires motivation, hardware, 
and a small amount of technical knowledge to print it off. Stakeholders also recommended 
developing the resources in different languages, especially Pasifika languages. We lacked the 
resources to undertake the necessary translation and consultation work. This is an area for 
future attention. 
6.5. Comparison with the literature 
6.5.1. Patient harm – collateral damage of healthcare in a complex system? 
Patient harm may be considered an inevitable consequence of humans administering 
advanced socio-technical interventions in a highly complex system to people who are often 
physiologically compromised, and who are sometimes desperately unwell.346 Indeed, many 
patient safety terms are qualified by the concept of “acceptable minimum” harm.347 
“Patient safety is the absence of preventable harm to a patient during the process of 
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healthcare and reduction of risk of unnecessary harm associated with healthcare to an 
acceptable minimum. An acceptable minimum refers to the collective notions of given 
current knowledge, resources available and the context in which care was delivered weighed 
against the risk of non-treatment or other treatment. Therefore, it is the minimum 
prerequisite for high-quality care.”348 This approach is consistent with the risk management 
concept of keeping risk “as low as reasonably practicable” or ALARP, and “so far as is 
reasonably practicable” or SFAIRP.349 
These pragmatic considerations must be kept in balance with the sometimes devastating 
effects of medication-related harm. Writing off the trauma of a medication-related harm as 
some kind of “acceptable” collateral damage in the provision of healthcare is likely to be 
unpalatable to patients and families who have experienced severe harm. Accepting a 
narrative of inevitable patient harm is defeatist and demotivating for efforts to understand 
and improve medication safety.330 In Study 1 the majority of medication-related harms 
were deemed not preventable; importantly, about one in five harms was judged potentially 
preventable or preventable. These potentially preventable harms are where we must 
concentrate our attention and energy. Further research on the SHARP dataset is planned to 
explore the nature of the medication-related harms considered preventable or potentially 
preventable, and determine whether there are any particular demographic characteristics 
associated with a greater risk of experiencing those harms. Preventable patient harm is 
caused by multiple factors, but predominantly by health systems and clinicians working 
within those systems.30,330 A systems approach is likely to provide the best opportunity to 
identify targets for in order to effect meaningful change.129 
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6.5.2. Patient perspective 
Just as patient-centered health care is considered an essential domain of health 
quality,350,351 including the patient perspective is an important element in patient safety 
research.352,351 Ignoring stakeholders can result in developing inappropriate or harmful 
interventions, as in the immunisation owl example at the start of this chapter. Māori 
consultation radically altered the immunisation 
promotional material presented earlier (Figure 6-
1), as seen in Figure 6-2. The new poster depicts 
the three baskets of knowledge (which the god 
Tāne stole from the heavens to help mankind), 
and a rainbow (representing power from the 
gods). Māori immunisation rates still lag other 
ethnicities, but have improved over time.353,354 
Similarly, building from a shared understanding 
with patients of the problems and potential 
solutions for medication-related harm increases 
the likelihood of success for each intervention. 
Considering health care safety from the patient 
perspective has been recommended as a key 
method of promoting transformational change of the health system.332,355 Best practices for 
patient involvement have not yet been established, but encouraging and empowering 
patients or their family members to speak up if something doesn’t seem right is one 
strategy widely recommended to improve medication safety.115,245,332,356. Improved patient 
Figure 6-2 Immunisation poster 
developed with Māori consultation 
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access to medical advice is another method of improving patient safety. Increasing use of 
patient portals, email, telephone and video consultations are already improving healthcare 
accessibility, and may help reduce or mitigate medication-related harm.357,358 Patients and 
clinicians have been willing to explore the use of mobile apps for reporting medication risk 
and providing advice in research settings.340,359 Key recommendations for patient 
involvement are summarised in Box 6-2. 
Box 6-2 Summary of key recommendations from Safety is Personal: partnering with patients 
and families for the safest care332 
Target group Recommendation 
Policy makers  Involve patients in policy-making 
 Use safety metrics that foster accountability and 
transparency 
 Engage patients in setting and implementing the research 
agenda 
Health system leaders  Involve patients and families in organisational 
activities  
 Train staff to be effective partners with patients 
and families 
 Partner with patient advocacy groups and organisations 
to increase public awareness and engagement 
Clinicians and staff  Provide patients and families with the information, 
training and tools they need to manage their health 
 Engage patients as equal partners in safety improvements 
 Support patients and families when things go wrong 
Patients, families, 
the public 
 Ask questions about care, understand medicines and care 
plans 
 Repeat back instructions and information to clinicians 
 Bring a friend/family member to appointments  
 Understand who is in charge of their care 
 
The first two groups, policy makers and health system leaders, have the capacity to influence 
patient safety from a systems perspective. This thesis has focused on the last two groups in 
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Box 6-2 – clinicians and patients. As per WHO recommendations, it has tried to “empower 
patients, families and their carers to become actively involved and engaged in treatment or 
care decisions, ask questions, spot errors and effectively manage their medications,” by 
putting “mechanisms in place, including the use of tools and technologies, to enhance patient 
awareness and knowledge about medicines and medication use process, and patients’ role in 
managing their own medications safely.”115 
6.5.3. Systems perspective to improve patient safety 
A systems approach to patient safety underpins the work of this thesis. The concepts of 
human factors/ergonomics (HFE) and the Systems Engineering Initiative for Patient Safety 
(SEIPS) model were introduced in Chapter 1. Implementation science is related to systems 
theory, but is particularly concerned with the best method to embed evidence-based 
practice into routine care.130 Normalisation Process Theory (NPT) is one such theory, which 
was used in Study 3 to prospectively evaluate a proposed risk assessment and decision 
support tool. NPT can help researchers anticipate implementation issues while developing a 
complex intervention and its evaluation.235-237,242 Healthcare tools, such as decision support 
or alert systems, will only work if they are embedded into and do not impede workflow, as 
was reiterated by healthcare providers in Study 3. 
Of course the scope for a systems perspective approach extends far beyond the 
implementation of an information package, (such as that proposed in Study 4). Systems 
thinking considers multiple facets of a problem, including cultural pressures, the law, 
organisational factors, individual behaviour, physical ergonomics and physical devices.123,124 
A systems approach to reduce the harm from consumption of over-the-counter (OTC) 
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medicationsh can be illustrated in the following examples of access to OTC Non-Steroidal 
Anti-Inflammatory Drugs (NSAIDs) and paracetamol. As discussed in Study 4, use of NSAIDs 
can be harmful for patients at risk of renal damage due to their other medications. 
Paracetamol access has been debated recently in New Zealand, following a student’s 
accidental death from paracetamol overdose.360,361 A HFE approach can help understand the 
drivers which influence individuals choosing to purchase and consume OTC analgesia such as 
NSAIDs and paracetamol, as described below. 
Current societal pressures indirectly encourage use of analgesia by valuing wellness and pain 
avoidance. Capitalist economies reward the “productivity” associated with employment 
(although largely ignore unpaid work362), therefore, being well enough to work is vital. 
Employees may feel pressure to attend work even when unwell.363 Our society is built 
around the concepts of comfort and convenience – pain and suffering are seen as adverse 
events which should be prevented or alleviated.364,365 The law determines that small-volume 
packets of paracetamol and ibuprofen tablets are general sales medicines – they are 
available for purchase in pharmacies and other retail outlets. Larger packs and different 
formulations of these medications are available as pharmacy-only medicines or restricted 
medicines.366 Individual behaviour is the other factor which is most likely to determine 
whether a person will take OTC medications or not. Addressing these factors to reduce OTC 
medication use is a complex exercise. Some economists have attempted to change the way 
society values work.362 Encouraging safe work practices and culture may address 
                                                          
h OTC medications are available for purchase by the public without a prescription. They are classified into 
three main groups by availability: 
 Restricted medicines (pharmacist-only medicines - available for purchase only after speaking 
to a pharmacist)
 Pharmacy-only medicines (can only be sold in pharmacies)
 General sales medicines (available from pharmacies and other retail outlets) 
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presenteeism. Health professionals are some of the worst culprits in attending work while 
sick; targeted professional development programmes may help clinicians both recognise 
when they are unwell and give themselves permission to take time off.363 Perhaps a simpler 
approach is to amend the law to further restrict the availability of these medications. 
However, such action may result in inadvertent harm, such as increased cost due to 
administration of compliance measures at a pharmacy, or inequity if people are unable to 
purchase these medications without a prescription, resulting in needless suffering. 
 
In short, healthcare systems are deeply complex. Addressing healthcare safety within the 
context of a healthcare system goes well beyond the application of any one simple check-list 
or tool, but instead requires understanding of the daily compromises that are made between 
healthcare safety and efficiency.121,367 NZ lacks a systems approach to medication use and 
safety.368 Examples include inequitable use of antibiotics, failure to prescribe anti-gout 
medications for those who need it, and poor access to medication due to cost.368 Cultural 
misalignment means Māori patients seldom achieve medicines optimisation.368,369 Working 
within the existing health system is necessary, but sometimes the system is so dysfunctional 
that a complete overhaul is considered necessary. 
 
6.5.4. New Zealand health system reforms 
A major review was undertaken to ascertain the state of the NZ health and disability system 
during 2018-2020.190 The review found the system was overly complex and fragmented. It 
articulated a host of unsatisfactory outcomes, particularly in relation to existing health 
inequities for Māori, Pasifika, people with more socio-economic deprivation, people with 
disabilities, and people living in rural towns.190 It found the health system has failed to 
169  
honour the Treaty of Waitangi by not supporting self-governance and self-determination for 
Māori healthcare.368  
As a result, the NZ government announced major restructuring of the health system in April 
2021.370 The 20 district health boards responsible for funding and providing healthcare in 
each region will be replaced with a single agency, Health NZ. A Māori Health Authority will 
be established to ensure health policy and strategy supports Māori health, and the Māori 
Health Authority will commission Health NZ for healthcare services for Māori communities. 
The changes aim to reduce complexity and strengthen primary care. The proposed changes 
address major issues discussed in this thesis, including the need for improved equity, explicit 
partnership with Māori, person and whānau-centered care (where people have control over 
the management of their own health), and provision of continuously improving high-quality 
care.370 
New Zealand is familiar with health system change; sequential major restructuring over the 
past four decades has been disruptive and expensive, with little benefit perceived at the 
healthcare coal-face.187,371,372 Whether the proposed restructuring of the health and disability 
system achieves its laudable aims remains to be seen. Whatever the outcome, patient safety 
within the system remains of paramount importance. 
6.6. Contribution to the literature 
Each of the four studies described in this thesis has contributed to the patient safety corpus. 
Study 1 assessed medication harm arising from prescribing in New Zealand general practice, 
as observed in general practice records. The Safety, Harms and Risk Reduction Project 
(SHARP) is the largest general practice record review study undertaken in New Zealand to 
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date. This study builds on the evidence base about the risk posed by medication in the real 
world. Findings can be used to inform decision-making in general practice and to target 
patient safety initiatives towards patients at higher risk of harm. 
Study 2 re-evaluated data from an automated alert system to see if there were differences in 
clinician action depending on the ethnicity of the patient. Despite the importance New 
Zealand places on equity, there appears to be scant literature evaluating health care 
interventions and tools by ethnicity. This work has added to the body of knowledge on this 
topic and provides unique insight into New Zealand practice. 
Study 3 prospectively evaluated a proposed risk assessment and communication tool by 
interviewing patients and clinicians using Normalisation Process Theory (NPT). The work 
considered the themes of safe prescribing, medical autonomy and cultural safety in the 
setting of New Zealand general practice. This work is useful for researchers developing tools 
intended for use by patients and clinicians, particularly in NZ and similar societies. 
Study 4 explored whether providing patients directly with targeted medicines information 
via an email and internet was feasible. Few randomised feasibility trial protocols have been 
published, therefore this publication should assist other researchers planning their own 
feasibility studies. Our preliminary results found this method of targeting patients rather 
than clinicians for information provision was feasible. 
6.7. Implications for approaches to patient safety and future research 
This thesis has addressed medication safety in New Zealand general practice. Implications 
arising from this study may be considered in the following categories; health systems and 
health leadership, clinicians and healthcare staff, and patients and whānau, as broadly 
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described in Box 6-2 above. 
6.7.1. Health systems and health leadership 
The health system reforms present an opportunity to address medication safety from a 
national perspective. Centralisation of health funding and commissioning, together with 
standardisation of the health information technology used nationwide, should enhance the 
country’s capacity to routinely audit and continuously improve medication safety. 
Further research is required to corroborate the extent of harm arising from general practice 
as found in Study 1. It is not feasible to use extensive record review studies for routine safety 
monitoring, but this work provides a baseline epidemiology of harm which could be used to 
set audit parameters and ongoing priorities for medication safety research in New Zealand 
general practice. 
Enhanced connectivity and compatibility of eHealth records,190 should improve medication 
reconciliation and knowledge of patient alerts during patient transfers between care 
settings. More specific actions to improve patient safety could be also taken, such as a 
national roll-out of targeted alerts, (e.g., Conporto Health EDM, which resulted in clinician 
action in Study 2), or requiring prescribing software to prevent inadvertent concurrent 
prescribing of contraindicated medication (such as the “triple whammy”). 
The establishment of the Māori Health Authority presents a novel opportunity for health 
policy and health service commissioning to be influenced with a clear equity and partnership 
mandate. Study 2 found evidence of inequity in clinician action by ethnicity and gender; the 
Māori Health Authority could advocate for increased cultural safety and bias recognition 
training for health care workers. As discussed by patients and clinicians in Study 3, improved 
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access to healthcare and medications could help address New Zealand’s high levels of 
inequity based on ethnicity and socioeconomic deprivation, and improving public access to 
technology could improve patient access to health information. This thesis has attempted to 
consider and pre-emptively address the potential of a new intervention to worsen inequity. 
Health equity requires repeated evaluation to measure the impact of health interventions 
and ensure new interventions are designed to reduce, or at least not exacerbate, existing 
inequities. It is within the Māori Health Authority’s remit to advocate for further research in 
this area. 
6.7.2. Clinicians and healthcare staff 
Clinicians are extremely motivated to provide high-quality patient care.327,328 Study 2 found 
targeted alert systems can help general practitioners dealing with increasing patient 
complexity by identifying patients at greatest risk of experiencing medication-related harm, 
and take mitigating actions to reduce the risk of patient harm. Clinicians could request 
wider use of such a system, which has the potential to reduce medication- related harm in 
general practice. 
Addressing clinician biases may improve the equitability of health care provision,267 as 
discussed in Studies 2 and 3. Clinicians are already required to do regular cultural safety 
training as part of their maintenance of professional standards activities. Specifically 
training clinicians to recognise their own biases and speak up against racism and sexism 
may help reduce inequities based on those characteristics.267 Further research is required 
to determine whether this type of training reduces health inequities. Patient and clinician 
perspectives are required to develop workable solutions to the pervasive problem of 
medication-related harm. 
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6.7.3. Patients and whānau 
Patient empowerment is an important strategy recommended to improve medication 
safety.332,345 Improving access to medical information can help inform patients and their 
whānau, and improve their capacity to engage in dialogue about treatment options and 
advocate for themselves and their families in healthcare encounters.318-320 Information 
packages, such as that tested in Study 4, are relatively simple to develop and cheap to 
deliver. Our study showed providing medication information directly to patients at risk of 
renal damage was feasible, but a full randomised controlled trial is required to determine 
whether this information package can change knowledge or behaviour. The information was 
provided in English only; another study could examine whether presenting information in 
Māori and Pasifika languages enhances engagement and understanding. Further testing of 
the information package will determine its effectiveness; if successful, then the method 
described in Study 4 is easily scalable. 
6.8. Conclusion 
This thesis builds on the evidence base about the risk posed by medication in the real world 
by examining aspects of medication-related harm in New Zealand general practice. 
Medication-related harm in general practice is common – but most harm is minor and not 
preventable. Clinicians typically take action on alerts arising from a general practice 
electronic alert system, but possibly take less action for women and Māori and Pasifika 
patients. Patients and doctors felt the most important aspect of healthcare is culturally safe 
and trustworthy doctor-patient relationships. Patients want to take an active part in their 
health; independent access to reliable information is a critical element in being able to 
participate in shared decision-making. This thesis has proposed a solution that may help 
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improve patient capacity in shared decision-making by delivering medication-risk 
information directly to patients. Further investigation will determine whether that 
information improves knowledge or changes behaviour. Solving the “wicked” problem of 
medication-related harm requires intentional health policy and leadership, unbiased 





She asked me if she took one pill for her heart and one pill for her 
hips and one pill for her chest and one pill for her blood how come 
they would all know which part of her body they should go to. 
 
I explained to her that active metabolites in each pharmaceutical would adopt a 
spatial configuration leading to an exact interface with receptor molecules on 
the cellular surfaces of the target structures involved. 
 
She told me not to bullshit her. 
 
I told her that each pill had a different shape and that each part of her body had a 
different shape and that her pills could only work when both these shapes could 
fit together. 
 
She said I had no right to talk about the shape of her body. 
 
I said that each pill was a key and that her body was a thousand locks. 
 
She said she wasn’t going to swallow that. 
 I told her that they worked by magic. 
She asked me why I didn’t say that in the first place. 
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Appendix 1. COREQ checklist 
Additional information for patient and prescriber perspectives on a decision support and 
communication tool, as per the consolidated criteria for reporting qualitative research 
(COREQ) checklist 
Domain 1: Research Team and reflexivity 
Personal Characteristics 
1. Interviewer/facilitator; 2. 
Credentials; 3. Occupation; 
4. Gender; Experience and 
Training 
SL conducted all the interviews. SL is a general 
practitioner with 12 years of clinical experience and 5 
years of health research experience. This work was 
completed as part of her PhD, supervised by TS and AS. 
SC is a research advisor on this project. 
 
TS is an experienced researcher and general practitioner 
who has led and collaborated on externally funded (≈ 
NZ$7.8 million) health service delivery implementation 
research (UK & NZ) using both quantitative and 
qualitative methods. His research expertise in general 
practice and in quality improvement research is 
fundamental to this project.  
AS is an experienced investigator in the field of clinical 
pharmacy, focusing on quality use of medicines and 
Pharmacoepidemiology. She has experience developing 
and implementing trials of electronic decision support 
tools.  
SC is an experienced Māori health researcher and 
general practitioner. She helped plan the data 
collection, and provided cultural insights into the data 
analysis.  
 
All researchers were employed by the University of 
Otago. SL is a Clinical Research Training Fellow, TS is a 
Professor, AS is a Senior Research Fellow, and SC is an 
Associate Professor. 
 
Relationship with participants 
6. Relationships established; 7. 
Participant knowledge of the 
interviewer; 8. Interviewer 
characteristics 
Collegial relationships were well established with the 
local Dunedin prescribers prior to the commencement 
of the study, who were personally invited to participate 
by SL. Invitation was made either face-to-face or via 
email. Several of the participants recruited via Facebook 
page “GPs for GPs” were also known to SL.  
Patients recruited for the study were unknown to SL. 
They were recruited via Facebook and Facebook 




SL was identified to all participants as a GP who was 
conducting research for her PhD research. SL has had 
extensive communication skills training through her 
undergraduate, postgraduate and vocational training. 
She has 18 years’ experience working as a clinician, 12 
years of those working as a GP.  
Doman 2: study design 
Theoretical framework 
9. Methodological orientation 
and theory; 
The methodology of this paper is outlined in detail 
within the paper. It draws strongly on Implementation 
Science theory, particularly Normalisation Process 
Theory (NPT).  
Participant selection 
10. Sampling; 11. Method of 
approach; 12; Sample Size; 13. 
Non-Participation 
A purposive sampling approach was taken for 
recruitment of both prescribers and patients. Initially 
Dunedin GPs were invited to participate in the study. 
This resulted in 5 face-to-face interviews with Dunedin-
based prescribers. Subsequent prescribers were 
recruited on a closed Facebook page for New Zealand 
GPs, “GPs for GPs”. Five people, four men and one 
woman expressed an interest in participating in the 
study, with the four men all participating in either phone 
or Zoom interviews.  
 
Patients of different ethnicities were sought for this 
project in an attempt to increase the diversity of the 
views. A Māori-owned company in Dunedin was 
approached for research participants, resulting in three 
interviews with Māori patients. Participants were then 
sought via a post on the “Dunedin News” Facebook 
page. This was an extremely effective method of 
recruitment, and a further two Māori patients, five NZ 
European patients, and one Pasifika patient were 
recruited. Pacific Trust Otago were then approached for 
recruitment. The Trust holds a weekly meeting for their 
elders, which includes exercise (provided by a 
physiotherapy student), food, a sing-along, and an 
occasional educational talk. SL gave an educational talk 
on medication safety at this meeting and recruited 
another four Pasifika patients. SL had no relationship 
with any patients prior to the study interview, apart 
from the Pacific Trust group as described.  
 
All participants received information about the study 
and signed a consent form approved by the University of 




The study team anticipated that we would not need any 
more than 15 patient or GP interviews to reach data 
saturation in each group. SC suggested the ethnicity split 
5 European/5 Māori/5 Pasifika as that would help us 
gain an understanding of the perspectives of different 
ethnicities.  
 
Due to recruitment via Facebook, it is not known how 
many people chose not to participate. 
Setting 
14. Setting of data collection; 
15. Presence of non-
participants; 16. Description of 
sample 
Dunedin-based prescriber interviews occurred face-to-
face, in either the prescriber’s office, at the University of 
Otago, or in a café.  
All patients were Dunedin-based to allow face-to-face 
interviews. These took place in the patients’ home, their 
workplace or at the University of Otago. Non-
participants were not present during the interviews.  
Participants self-identified their personal characteristics, 
including age and ethnicity  
Data collection 
17. Interview guide; 18. 
Repeat interviews; 19. 
Audio/visual recording; 20. 
Field notes; 21. Duration; 22. 
Data saturation; 23. 
Transcripts returned 
SL developed the interview guide following the NPT 
structure. This was reviewed by TS and AS, and refined 
through practice interviews. No repeat interviews 
occurred, but two prescriber participants sent additional 
material to SL via email following their interview. All but 
one of the interviews were recorded, due to a failure of 
the recording equipment on one occasion. Extensive 
field notes were taken during that interview and were 
written up immediately afterwards. Each interview 
lasted from 30-90 minutes. Interviews were either 
transcribed by SL or sent to rev.com for transcription, 
and all transcripts were closely reviewed and revised by 
SL to ensure they were as accurate as possible. 
Participants did not have the opportunity to review 
transcripts.  
 
Although the sample size was planned as executed, data 
saturation was observed within the last few interviews 
in each group, with no new ideas being discussed by 
participants. 
Domain 3. Analysis and findings 
Data analysis 
24. Number of data coders; 25. 
Description of the coding tree; 
Derivation of themes; 27. 
Software; 28. Participant 
checking 
SL developed the coding structure and coded all data 
using NVIVO qualitative data management software.374  
Coding was reviewed in depth by TS. Codes were 
clustered into themes derived from the NPT framework 
and focussed on the development of the proposed tool.  
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Participants were not involved at the data analysis 
stage.   
Reporting 
29. Quotations presented; 30. 
Data and findings consistent; 
31. Clarity of major themes; 
32. Clarity of minor themes 
Quotations were extracted from the transcripts to 
illustrate the major and minor themes. These were 
checked during analysis to ensure they were not taken 
out of context of the interview, and consistently and 
accurately represented the participants’ views.  
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Appendix 2. Interview Topic Guide  
For patient and prescriber perspectives on a decision support and communication tool 
Interview Topic Guide for Prescribers 
Before we begin, do you have any further questions (about the consent process/study)?  
Could you tell me a bit about yourself and your practice setting?  
How long have you been at this practice?  
How long have you worked as a GP (and in NZ if applicable)?  
Have you completed any extra qualifications on top of your medical degree?  
What is your list size? What is your role in the practice (partner/associate/locum)?  
What PMS does your practice use?  
What prompts you to consider assessing a patient’s risk from their medication?  
How do you currently assess patients’ risk of medication harm?  
What tools do you use? 
Do you have support in this area from a pharmacist/secondary care?  
How confident do you feel explaining medication risk to patients? 
What encourages/discourages you to discuss risk with patients? 
How open do you feel your patients are to discussing medication risk? 
When would you focus on medication risks and when would you focus on the benefits? 
Why? 
Do you use any resources to help explain concepts of risk to patients? What are they? 
Risk scenarios:  
High risk patient: elderly female, eGFR 20 mL/min, 10 long term medications, presents with 
increasing SOB likely due to deterioration of known congestive heart failure.  
High risk medication: Methotrexate/Insulin/Warfarin 
High risk condition: Psychosis/rheumatoid arthritis/cancer 
What do you understand by the term shared decision making?  
How do you feel about shared decision making in your clinical practice? 
How do you promote shared decision making? 
How open do you feel your patients are to shared decision making? 
Have you ever had any training in promoting shared decision making with patients? 
Can you describe a case (anonymously) where a patient has experienced problems from 
their medication that were potentially preventable? 
What stands out for you in this case that was different from other patients?  
What were the factors contributing to medication harm?  
What were the factors contributing to patient safety?  
You mentioned XXX as working well, do you think this could be supported in other 
cases?  
You mentioned XXX as working poorly, how do you think this could be changed? 
Do you think the proposed MedKōrero tool, to assess risk and communicate that risk to patients, 
will promote shared decision making? 
What kind of impact would a tool like this have in your clinical setting?  
Would it be helpful to your day-to-day work?  
What would promote its use?  
What would be a barrier to its use? 
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What would be the top priorities for a patient safety tool like MedKōrero? 
High risk patients? 
High risk medications? 
High risk conditions? 
Can you think of potential system-wide effects of using this tool? 
What would be the intended and unintended consequences 
If you could make a recommendation/suggestion to improve patient safety in primary 
care in relation to medication use, what would it be?  
Explore patient factors in relation to these recommendations for larger implications  
Can you think of anything else I should ask? 
Is there anything else I should ask other prescribers? 
 
Interview Topic Guide for Patients 
Before we begin, do you have any further questions (about the consent process/study)?  
Could you tell me a bit about yourself and your experiences with medicine?  
How old are you? Ethnicity? 
Do you take medicine every day?  
When was the last time you were prescribed medicine?  
Do you help someone else regularly with their medication?  
What does harm from medicine mean to you? What does risk from medicine harm mean? 
Can you give me an example?  
Synonyms of risk: danger, peril, possibility, hazard, menace, threat 
When do you think it’s important to know about your risk from medication?  
High-risk vs low-risk medications/conditions? 
Treatment vs prevention? 
Personal perception of risk (high risk patient)? 
Do you think it’s important to discuss medication risk with your GP?  
What encourages/discourages you to discuss risk with your GP? 
How open do you feel your GP is to discussing medication risk? 
When would you focus on medication risks and when would you focus on the benefits? 
Why? 
Have you ever been given information about medication risk? What was it? Was it helpful? 
Risk scenarios:  
High risk patient: elderly relative who is frail and on 10 long term medications.  
High risk medication: Methotrexate/Insulin/Warfarin 
High risk condition: Psychosis/rheumatoid arthritis/cancer 
What do you understand by the term shared decision making?  
Can you recall a time when you felt like you and your doctor made treatment decisions 
about your health care together? 
How do you feel about shared decision making about your health care? 
How open do you feel your doctor is to shared decision making? 
Can you describe a time when you or someone close to you experienced problems from 
their medication? 
What were the factors contributing to the medication harm?  
What were the factors contributing to patient safety?  
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You mentioned XXX as working well, do you think this could be supported for other 
people? 
You mentioned XXX as working poorly, how do you think this could be improved? 
Do you think the proposed MedKōrero tool, to assess risk and improve communication about that 
risk, will help you/your whanau make decisions about treatment? 
Do you think it would promote shared decision making? 
What kind of impact would a tool like this have for you/your whanau when you are 
deciding on a treatment option?  
What would promote its use?  
What would be a barrier to its use? 
What do you think should be the top priorities for a patient safety tool like MedKōrero? 
High risk patients? 
High risk medications? 
High risk conditions? 
Can you think of potential system-wide effects of using this tool? 
What would be the intended and unintended consequences 
If you could make a recommendation/suggestion to improve patient safety in primary 
care in relation to medication use, what would it be?  
Explore patient factors in relation to these recommendations for larger implications  
Can you think of anything else I should ask you? 
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